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Ovine herpesvirus 2 (OvHV-2) is a gamma herpesvirus and is the causative agent of 
lymphoproliferative disease – sheep-associated malignant catarrhal fever in 
susceptible ruminants, including cattle. Sheep become persistently infected but do 
not show apparent clinical infection. MCF is characterized by marked T cell 
hyperplasia and proliferation of unrestricted cytotoxic large granular lymphocytes 
(LGLs) which leads to necrosis of infiltrated tissues and generally causes death of the 
host. Little is known about the underlying molecular basis of MCF pathogenesis or 
what controls the differences in clinical outcome of infection in two closely-related 
host species.  
MicroRNAs (miRNAs) constitute a large family of small, ~22nt, noncoding RNA 
molecules that regulate gene expression by targeting messenger RNAs post-
transcriptianally in eukaryotes and viruses. Herpesvirus encoded miRNAs have been 
shown to play a role in regulating viral and cellular processes  including cell cycle 
and may have a role in pathogenesis. OvHV-2 has also been found to encode for at 
least 46 OvHV-2 miRNAs in an immortalized bovine LGL cell line. 23 of these 
miRNAs have also been validated by northern blot analysis and RT qPCR.  It was 
hypothesised that these OvHV-2 miRNAs may regulate viral and cellular genes 
expression and may play a role in MCF pathogenesis. The aim of this project was to 
determine if OvHV-2 miRNAs have functional targets within viral and host cell 
genes. 
Bio-informatic analysis has predicted several targets for these OvHV2 miRNAs in 
the 5’ and 3’ UTRs of several virus genes. Luciferase inhibition assay confirmed that 
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out of 13 selected predicted targets, three (two targets ORF73 and one within 
ORF50) were positive and functional. A fourth predicted target was also found 
functional (ORF20), but its functionality could not be confirmed by knocking out the 
target site. A newly developed technique Crosslinking, Ligation And Sequencing of 
Hybrids (CLASH) was also used to identify miRNAs bound targets within cattle and 
sheep genome. High throughput sequencing and analysis of the hybrid data revealed 
many target genes. Four of those targeted genes, were validated by luciferase 
inhibition assays and three were found to be targeted by OvHV-2 miRNAs.  
This study gives the first evidence of viral miRNAs bound to their targets in cattle 
and sheep cells, by a highly sensitive technique-CLASH and provides a tool for 





Malignant catarrhal fever (MCF) is a fatal disease of cattle and deer caused by infection with the virus 
ovine herpesvirus 2 (OvHV-2). Sheep are infected soon after birth, carry the infection for life but 
never show signs of any disease. If cattle catch this virus from sheep they develop MCF and usually 
die. This disease is economically important not only in the UK but also in Sub-Saharan Africa and 
other areas of the developing world where it places a major burden on food production. In sheep the 
virus infects, and then lies dormant for the life of the animal, in cells of the immune system, these 
cells continue to function normally. In cattle the same type of cell is infected but they change such that 
they now become aggressive and attack and kill other cells in the body, resulting in disease and death. 
A   major question in understanding how OvHV-2 causes disease is: why, given that sheep and cattle 
are closely related species, do sheep survive and cattle die? Herpesviruses normally only infect one 
species and have co-existed and evolved with that species for millions of years. A previous study in 
the group identified molecules, termed microRNAs (miRNAs), produced by the virus that have the 
potential to control the way the infected immune cell functions. miRNAs work by affecting how much 
of a particular protein is produced in a cell and they do this by binding very specifically with the 
mRNA (“blueprint”) for this protein and targeting it for destruction. The hypothesis is that the virus 
miRNAs have evolved to work in sheep immune cells and allow the virus to colonise these cells and 
survive long term.  In order to investigate this hypothesis it is necessary to identify the viral and 
cellular proteins targeted by these miRNAs, this formed the basis of this thesis. Herpesviruses can 
either grow in a cell and produce new virus or remain dormant for long periods of time. I first showed 
that virus miRNAs can affect the production of three virus proteins , important in controlling whether 
the virus is dormant or growing. The control of this step may differ in sheep in cattle and may 
influence disease. I then investigated  which cellular mRNAs (and so proteins) are targeted by virus 
miRNAs in sheep and cattle.  I used a novel method which allows the purification of miRNAs bound 
to their target mRNAs. The mRNAs are then analysed and the protein they produce identified. This 
complex technique identified a number of cellular mRNAs (proteins) which are potentially targeted by 
the virus miRNAs.  Using bioinformatics I analysed which targeted proteins would be predicted to 
play a role in disease and went show that two of these were in fact targeted by the virus miRNAs.   
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Herpesviruses are widely distributed in nature. Most animal species have been shown 
to be infected with at least one, and sometimes several distinct, herpesviruses (Pellet 
and Roizman, 2007, McGeoch and Davison, 1999). The number of the herpesviruses 
that have been isolated exceeds 200 (Pellet and Roizman, 2007). Despite this 
knowledge, the majority of potential animal hosts for herpesviruses have so far not 
been investigated (Wibbelt et al., 2007). Herpesviruses have co-evolved with their 
hosts for millions of years. This notion is supported by the understanding that they 
have diversified from a common ancestor, in a manner mediating co-speciation of 
herpesviruses with host species, through species-specific latent infections (Umene 
and Sakaoka, 1999, Fossum et al., 2009). 
Herpesviruses share a number of biological properties including shared expression of 
a large number of enzymes involved in nucleic acid metabolism (e.g. thymidine 
kinase), DNA synthesis (e.g. DNA helicase/primase) and processing of proteins (e.g. 
protein kinase). Herpesvirus genomic synthesis and the assembly of capsids occurs in 
the nucleus. All known herpesviruses are able to establish and maintain a latent state 
in their host. In the infected cell, the viral genome is present in an episomal and 
circular form during latency and only a small subset of viral genes is expressed 
(Pellet and Roizman, 2007). Latent virus is able to reactivate following cellular 
stress, and resumes viral replication and new infectious virion production. 
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1.1.1 Herpesvirus structure 
A typical herpesvirus particle consists of a core containing genomic linear double 
stranded DNA which is wrapped in an icosahedral capsid of T=16 symmetry and has 
an approximate diameter of 100 to 110 nanaometres (nm) (Figure 1.1). The viral 
capsid is surrounded by a loosely organised protein structure termed the tegument. 
The tegument contains many viral proteins which play important roles in initiating 
host cell infection, regulating viral gene expression, assisting transport of viral 
proteins across the nuclear membrane and controlling the packaging of viral DNA 
(Penkert and Kalejta, 2011, Yu et al., 2011). 
A lipid bilayer envelope derived from patches of altered host cellular membrane, 
surrounds the tegument. The viral envelope also contains embedded virally encoded 
glycoproteins which vary in number and relative amount, for example herpes 
simplex virus-1 (HSV-1) encodes at least 11 glycoproteins (Roizman and Knipe, 
2001). The size of the virion increases from 120nm to approximately 300nm after the 
inclusion of the tegument and envelope (Roizman & Pellett., 2001). 
 





Figure 1.1: A typical herpesvirus virion 
A. Diagrammatical representation showing the major structural components 
(image adapted from http://viralzone.expasy.org/all_by_species/526.html) 
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1.1.2 Herpesvirus genome 
Herpesvirus genomes vary in length from 120 to 250 kilobase pairs (kb) and encode 
between 70-220 open reading frames (ORFs) (Roizmann et al., 1992, Cha et al., 
1996) although recent characterization of clinical human cytomegalovirus (HCMV) 
strain suggests that the viral genome has 252 ORFs that may encode potential 
proteins (Murphy et al., 2003). The current estimate is that 43 ORFs are core genes 
and are conserved throughout the herpesvirus family. The core genes include capsid 
proteins, tegument proteins and components involved in DNA replication (McGeoch 
and Davison, 1999). The remaining ORFs are unique and vary between sub-families 
(alpha, beta & gamma) species and genus. In addition to protein coding regions, 
there are several regions within herpesvirus genomes which either do not encode for 
any protein or encode non-coding RNAs (Stevens., 1981, Hart et al., 2009). 
Furthermore microRNAs (miRNA) have also been identified in most of the 
herpesviruses (Cai et al., 2006b, Grey et al., 2005, Levy et al., 2012, Pfeffer et al., 
2004). miRNAs will be discussed in greater detail in Section 1.4. 
Herpesvirus genomes contain internal and terminal repetitive (reiterated) sequences 
through extensive regions. The genome length can vary depending on the copy 
number of these repeat sequences. Herpesviruses are grouped into six categories A – 
F, on the basis of the presence and location of reiterations of terminal sequences 
greater than 100 base pairs (bp) (Pellet and Roizman). A diagrammatic 
representation of the sequence arrangements of each group is shown in Figure 1.2.  
In the viruses in group A (e.g channel catfish herpesvirus) a large sequence from one 
terminus is directly repeated at the other terminus of the genome. These regions are 
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named as left terminal repeat (LTR) and right terminal repeat (RTR). In group B 
viruses (e.g herpesvirus saimiri (HVS), the genomes possess a variable number of 
directly repeated sequences at either of the termini. The grouping of Group C virus 
(e.g Epstein-Barr virus (EBV) genomes is similar to that of group B with the 
exception that the direct repeat sequences are fewer in number in comparison with 
group B. Additionally group C unique genome sequences are further divided by other 
directly repeated, though unrelated, genome sequences of more than 100 bp. In the 
group D virus genomes (e.g varicella-zoster virus (VZV), the unique sequences are 
grouped into unique long (UL) and unique short (US) regions. In this group, the 
repeat sequence present on one terminus is also present in an inverted orientation 
internally. The US domain is flanked by those inverted repeat sequences. The 
genomes of group E viruses (e.g herpes simplex virus (HSV) and human 
cytomegalovirus (HCMV) are also divided into UL and US domains. However, the 
difference is the presence of its own inverted repeat sequence on the flanks of each 
domain. These sequences are called RL (long or large) and RS (short or small) 
repeat. Quite similar to US domains of group D viruses, in the viruses of group E, 
UL and US domains can invert to each other resulting in four possible isomers. The 
genomes of group F (e.g tupaia herpesvirus) do not contain any repeat sequences 








Figure 1.2: Schematic diagram depicting the sequence arrangement of six 
classes (A-F) of viral genome of herpesvirus family.  
The genomes A, B, C, D, E and F are exemplified by the channel catfish herpesvirus, 
herpesvirus siamiri, Epstein-Barr virus, varicella zoster virus, herpes simplex viruses, 
and tupaia herpesvirus, respectively. The relative orientations of repeat sequences are 
indicated with arrows.  The genomes of group A viruses contain a large sequence 
from one terminus directly repeated at the other terminus.  The genomes of group B 
viruses contain a variable number of directly repeated sequences at both termini.  
The genomes of group C viruses contain both terminal repeats and other unrelated 
repeat sequences that subdivide the unique sequence. The unique regions of the 
genomes of group D viruses are divided into two segments separated by an inverted 
repeat of the terminal region from the short (US) segment. The unique regions of the 
genomes of group E viruses are similarly divided with inverted repeats flanking both 
the long UL and US regions. On one terminus there are n copies of sequence ‘a’ next 
to a larger sequence designated as ‘RL’. The other terminus has one directly repeated 
‘a’ sequence next to a sequence designated as ‘RS’. The terminal repeat ‘RLa’ and 
‘RSa’ sequences are inserted in an inverted orientation.  Terminal reiterations in the 
genome of group F have not been described. (Figure adapted from Roizman et al., 
1992).  
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 Herpesvirus classification 1.2
The members of Herpesviridae family are divided into three sub families: 
Alphaherpesvirinae, Betaherpesvirinae and Gammaherpesvirinae. Herpesvirus 
classification is based on; biological properties, DNA sequence homology, 
similarities in the genome sequence arrangements and relatedness of important viral 
proteins (Roizman & Pellett., 2001). 
1.2.1 Alphaherpesviruses 
Alphaherpesviruses have a broad host range, efficient and short reproductive cycles 
and establish latency primarily but not exclusively, in sensory neuronal cells 
(Roizman & Pellett., 2001). This sub-family is divided in four genera: Simplexvirus 
(including HSV-1), Varicellovirus (including VZV), Mardivirus (including Marek’s 
disease virus (MDV) and Iltovirus (including infectious laryngotracheitis virus). 
HSV-1 (human herpesvirus 1, HHV-1) and HSV-2 (human herpesvirus 2, HHV-2) 
were the first of the human herpesviruses to be discovered and are among the most 
intensively investigated of all viruses (Roizman & Knipe., 2001; Hunt., 2011). HSV 
generally causes genital or oral infections which can result in a wide range of clinical 
conditions, from mild cutaneous lesions to fatal encephalitis. Primary infection of 
HSV is generally asymptomatic. After transmission through the epithelial mucosa of 
mouth or genitals, virus establishes latency in the sensory ganglia which are 
innervating the site of infection. Reactivation of the virus may occur as a result of 
stress. Symptoms related to HSV reactivation (typically cold sores) include small, 
grouped vesicles or blisters on the epithelial surfaces which then pustulate, ulcerate 
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and later form a crust. Vesicles are filled with newly produced infectious virions. 
HSV-1 can also cause more severe clinical symptoms including vision loss, serious 
complications of atopic eczema, erythema multiforme, Stevens-Johnson syndrome, 
neurological impairment and death in neonates (Ferrante et al., 2000) 
Varicella Zoster virus (VZV, human herpesvirus 3) is another widespread, human 
pathogen. It is efficiently transmissible, usually during childhood, through skin to 
skin contact and inhalation of infected droplets. VZV causes chicken pox (varicella) 
which is characterized by the appearance of widespread skin lesions (Arvin, 1996, 
Asano et al., 1990, Ito et al., 2001). VZV establishes latency in sensory ganglia and 
its reactivation remains limited, generally once in a lifetime resulting in a localized 
vesicular rash (herpes zoster). Reactivation can be frequent in immune suppressed 
systems. VZV can also cause serious infections such as pneumonia, liver failure, 
varicella encephalitis, cerebellar ataxia and thrombocytopenia in immunosuppressed 
individuals (Rawson et al., 2001). 
Marek’s disease virus (MDV or gallid herpesvirus 2) is a member of Mardivirus 
genus and is the cause of Marek’s Disease (MD). In poultry, MDV initially infects B 
lymphocytes although latency is established in CD4+ T cells (Mwangi et al., 2011). 
It was reclassified as an alphaherpesvirus due to its sequence homology and gene 
organization as against its classic classification as a gammaherpesvirus (Buckmaster 
et al., 1988, Roizmann et al., 1992).  It is highly contagious and has identical early 
stages of replication to other members of the Alphaherpesvirinae (Schumacher et al., 
2005). MDV does not release detectable free enveloped virus into the supernatant of 
cultured cells (Calnek et al., 1970, Tischer et al., 2005)  




Unlike alphaherpesviruses, betaherpesviruses have a restricted host range and a long 
reproduction cycle. Betaherpesvirus infection progresses slowly in cell culture and 
the infected cells become enlarged rather than lyse (Roizmann et al., 1992). Latent 
infection is established predominantly in monocytes or macrophages. The viruses in 
this sub-family are subdivided into 4 genera (Cytomegalovirus, Muromegalovirus, 
Roseolovirus, and Proboscivirus) comprising 14 species (AJ et al., 2009, Davison et 
al., 2009). 
Human Cytomegalovirus HCMV (human herpesvirus 5 or HHV-5) is a pathogen in 
immunocompromised individuals. Primary infection typically starts with replication 
of the virus in the mucosal epithelium as a result of direct contact with infectious 
secretions from an infected individual. Primary infection is generally asymptomatic 
but occasionally can lead to the development of prolonged fever and mild hepatitis 
(similar to gammaherpesvirus EBV mononucleosis) (Crough and Khanna, 2009). In 
a natural infection, HCMV establishes latency in monocytes, macrophages and their 
progenitors while reactivation may occur with shedding of the virus from mucosal 
sites (Mocarski, 2004). Severe clinical conditions of HCMV virus are usually only 
observed in neonates and immunosuppressed individuals. Congenital HCMV 
infection can result in jaundice, purpura, hepatosplenomegaly, microcephaly and 
sensorineural hearing loss in neonates (Pass et al., 2006). HCMV more rarely 
presents with multisystem manifestations, in immunocompetent individuals, with 
symptoms ranging from fever, rash, anemia and thrombocytopenia to retinitis, 
encephalitis, pneumonitis, hepatitis and pancreatitis  (Rafailidis et al., 2008). Organ 
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and stem cell transplantation may involve complications including HCMV infection 
leading to fatal pneumonitis (Gandhi et al., 2003, Green et al., 2012). 
1.2.3 Gammaherpesviruses 
The members of the sub family Gammaherpesvirinae have a limited host range.  The 
experimental host range of the gammaherpesviruses is limited to the family or order 
to which the natural host belongs (Roizman & Pellett., 2001). Gammaherpesviruses 
replicate in lymphoblastoid cells and some also cause lytic infections in epithelioid 
and fibroblastic cells, in vitro. Unlike alpha- and betaherpesviruses, 
gammahepesviruses establish and maintain latency in either T or B lymphocytes 
(Ackermann, 2006).  In addition to the genes conserved between herpesviruses, each 
gammaherpesvirus also contains a set of unique genes which are usually located at 
the terminal regions of the genome and which are important for viral pathogenesis.   
In addition, gammaherpesviruses have more cellular homologue genes than the 
members of the other two sub-families. The viruses in this sub-family are sub 
divided into 4 genera (Lymphocryptovirus, Rhadinovirus, Macavirus, and 
Percavirus) comprising 34 species (AJ et al., 2009, Davison et al., 2009) 
EBV is the most studied virus in the genus Lymphocryptovirus. EBV is found in the 
vast majority of adults worldwide.  EBV is a strictly human pathogen and in most 
cases transmitted through saliva (Ascherio and Munger, 2010). Primary infection 
occurs usually in infants and has an asymptomatic course. In contrast, in adolescents 
it leads to infectious mononucleosis (IM), a lymphoproliferative disease 
characterised by lymphadenopathy, tonsillitis, pharyngolaryngitis and skin eruptions 
(Henle et al., 1968). Primary infection occurs in epithelial cells of the oropharynx 
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and after replication at the infected site latency is established by targeting the naïve B 
cells in such a manner that the immune response of the host is not activated (Babcock 
et al., 1998, Thompson and Kurzrock, 2004).  EBV has also been linked to numerous 
lymphomas in immunodeficient individuals; Burkitt’s lymphoma (BL), Hodgkin 
lymphoma (HD), nasopharyngeal carcinoma (NPC) and post-transplant 
lymphoproliferative disease (PTLD) (Henle and Henle, 1970, Haque et al., 1996). 
Immunocompetent individuals may develop EBV associated cancers due to the host 
genetic background/ contributing environmental factors in the growth of EBV, in 
certain geographical locations. 
Human herpesvirus 8 (HHV-8, Kaposi’s sarcoma-associated herpesvirus (KSHV) is 
a Rhadinovirus and humans are the only known hosts of the virus. There are 
currently three proliferative diseases associated with KSHV infection; Kaposi’s 
sarcoma (KS) (a tumor of endothelial cells origin), primary effusion lymphoma 
(PEL) (a B-cell lymphoma) and multicentric Castleman’s disease (MCD) (B-cell 
lymphoproliferative disorder). These lymphomas are most frequently identified in 
immunosuppressed individuals, particularly patients with acquired 
immunodeficiency syndrome (AIDS) (Chang et al., 1994, Moore and Chang, 2001). 
KSHV transmission occurs mostly through saliva. The principal site of KSHV lytic 
replication is the oropharynx, most likely in B cells of tonsillar or other pharyngeal 
lymphoid tissue (Duus et al., 2004). Latency is established in B-cells and in latent 
infection the linear viral genome circularizes in the nucleus and is maintained as an 
episome autonomously there. Because most viral genes are not expressed, viral gene 
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expression is sharply restricted in latency and there is no cytotoxicity and no virus 
particles are produced (Ganem, 2010). 
Murine gammaherpesvirus 68 (MHV-68) or murid herpesvirus 4 (MHV-4) is another 
member of the genus Rhadinovirus. MHV-68 was originally isolated from the bank 
vole (Cletrinomys glariolus) in Slovakia (Blaskovic et al., 1980). MHV-68 appears 
to be widespread among rodent populations and MHV-68 infection of laboratory 
mice also represents an amenable model system for investigating gammaherpesvirus 
pathogenesis (Simas and Efstathiou, 1998). Transmission of MHV-68 occurs through 
the intranasal route. Lytic infection occurs in the alveolar epithelial cells in the lungs 
followed by virus dissemination and latent infection of B lymphocytes as well as 
macrophages (Sunil-Chandra et al., 1992). Latently infected B lymphocytes reside 
and maintain latency in spleen. Initially, those cells undergo expansion which results 
in splenomegaly, followed by an infectious mononucleosis-like syndrome, and 
lymphoproliferative disease (Sunil-Chandra et al., 1992, Nash et al., 2001, Flano et 
al., 2002). 
Herpesvirus saimiri (HVS) a T lymphotropic virus, is the classical prototype of the 
genus Rhadinoviruses. The natural host for HVS is squirrel monkeys (saimiri 
sciureus) and these are found to be persistently infected with this virus. Squirrel 
monkeys are usually infected by HVS via saliva within the first two years of life 
(Melendez et al., 1968). HVS is apathogenic in its natural host, but causes acute 
peripheral T cell lymphomas in other monkey species after experimental infection 
(Fickenscher and Fleckenstein, 2001). Certain strains of HVS e.g C488 have the 
ability to transform human T-lymphocytes to continuous growth without the need of 
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re-stimulation by an antigen or a mitogen, providing for the first time a means of 
human T-lymphocyte immortalization in cell culture (Fleckenstein and Ensser, 
2004). 
Ovine herpesvirus 2 (OvHV-2) and Alcelaphine herpesvirus 1 (AlHV-1) are 
members of genus Macavirus. Both viruses have been shown to cause a fatal 
lymphoproliferative disease (malignant catarrhal fever (MCF) in cloven-hoofed 
animals (Russell et al., 2009, O'Toole and Li, 2014) and will be discussed in detail in 
Section 1.4. 
 Herpesvirus life cycle 1.3
The life cycle of herpesviruses is divided into two different stages in the host; the 
lytic stage and the latent stage. The lytic stage involves virus replication and release 
of infectious virus particles from the infected cell. In the latent stage, virus genome 
persists in the infected cell as an episome with very little virus gene expression and 
no infectious progeny is produced. The latent virus is able to reactivate following a 
number of stimuli including cellular stress, UV, immunosuppression or tissue 
damage and resumes viral replication and new infectious virion production. 
 Attachment and entry 1.3.1
Viral entry into the host cell is first step in the typical lifecycle of the herpesviruses. 
Most of the herpesviruses enter into the host cell by fusion but some also use the 
endocytic pathway for viral entry (Nicola et al., 2003, Nicola and Straus, 2004). The 
glycoproteins present in the viral envelope interact with the target molecules present 
on the host cell membrane and allow the entry of viral capsid and tegument proteins 
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into the host cell cytoplasm. The process of HSV virion attachment involves the 
interaction of five glycoproteins (gB, gC, gD, gH-gL heterodimer) with the surface 
of host cells (Akhtar and Shukla, 2009). Initial interactions occur between gC and gB 
(to a lesser extent) with the glycosaminoglycan (GAG) molecules present on the host 
cell membrane. This interaction brings the cellular and viral membranes into close 
apposition. Heparin sulphate proteoglycan is the predominant GAG molecule 
involved in this interaction (Shieh et al., 1992) though other molecules like 
chondroitin sulphate can also be used in its absence. After initial attachment to the 
cell membrane, the process of penetration begins which depends on the host cell type 
and mode of entry (Campadelli-Fiume et al., 2007). Viral entry may require fusion of 
the virion envelope with the plasma membrane or with the membrane of an 
intracellular vesicle (Clement et al., 2006). In HSV, gD interacts with one of several 
specific cell membrane receptors; nectin-1, nectin-2 herpesvirus entry mediator 
(HVEM) or 3-O sulfated heparin sulphate (3-O HS) (Spear, 2004, Shukla et al., 
1999). The binding of gD to one of its cognate receptors induces conformational 
changes in gD that cause the formation of a multi-glycoprotein complex involving 
gB, gD, gH-gL (Atanasiu et al., 2007, Subramanian and Geraghty, 2007). Nectins 
(Warner et al., 1998, Geraghty et al., 1998) and 3-O HS (Shukla et al., 1999) have a 
wide tissue distribution and can mediate entry of all HSV-1 strains tested. Soluble 
forms of gD and its receptors can trigger fusion of HSV with the host cell membrane 
which indicates that the interaction of gD with its receptors has a role in the 
attachment and fusion for entry of HSV (Tsvitov et al., 2007). 
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EBV interacts with the B lymphocytes through the interaction of EBV envelope 
glycoprotein gp350/220 with the cellular complement receptor type 2 (CR2 or CD21) 
(Carel et al., 1990, Connolly et al., 2011, Fingeroth et al., 1984). K8.1 of KSHV and 
gp150 of MHV-68, are thought to be the homologues of gp350/220 and carry out the 
initial attachment of these viruses (Stewart et al., 2004, Sun et al., 1999). It has also 
been shown that a complex of three glycoproteins gp85 (homologue of gH), gp25 
(homologue of gL) and gp42 are essential for virus penetration into host cells. 
Attachment of EBV to host cells is not sufficient to trigger fusion; instead a complex 
formed of gp25-gp42-gp85 (three-part complex) mediates the interaction by binding 
gp42 to the human leukocyte antigen class II (HLA class II) on target B cells (Li et 
al., 1997), whereas entry into epithelial cells which lack HLA class II, requires a 
glycoprotein complex without gp42 (two-part complex) (Borza and Hutt-Fletcher, 
2002). To accommodate infection of both epithelial and B cells EBV virions carry 
both two and three part complexes and the ratio of the two on the virus particle also 
influences the cell tropism of the virus (Shannon-Lowe et al., 2006). Deletion of 
gp42 or addition of gp42 can produce virus that can infect only epithelial cells or 
only B lymphocytes respectively (Borza and Hutt-Fletcher, 2002). 
The HSV and EBV receptor-binding activities described above can trigger fusion but 
are not sufficient for the completion of this process. To initiate the core fusion 
machinery, a glycoprotein complex in HSV (gB and gH-gL) and EBV (gB and gp85-
gp25) is required (Haddad and Hutt-Fletcher, 1989, Miller and Hutt-Fletcher, 1988). 
gB is a conserved herpesvirus fusion protein and has been shown to have a key role 
in virus attachment to host cells and fusion of the envelope with the host cell 
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membrane (Backovic and Jardetzky, 2011, Heldwein et al., 2006). Viral fusion 
proteins are thought to be inserted into the host cell membrane and undergo large 
conformational changes by refolding, which draw viral and host cell together 
(Connolly et al., 2011). As a result a fusion pore is formed that allows mixing of the 
cytoplasmic contents with viral contents. This step delivers the viral tegument and 
nucleocapsid into the cytoplasm (Akhtar and Shukla, 2009). Fusion at the plasma 
membrane is a pH-independent process (Spear, 2004) whereas low pH is required for 
HSV-1 entry through an endocytic route for certain cell types (Nicola et al., 2003, 
Nicola and Straus, 2004). EBV also uses endocytosis to enter into the normal B cells 
(Miller and Hutt-Fletcher, 1992). The low pH of the endosome effects major 
conformational changes in the fusion proteins and leads to the fusion of the HSV-1 
envelope with the plasma membrane of the vesicle releasing the nucleocapsid and 
tegument into the host cell cytoplasm (Stampfer et al., 2010). In HSV-1, dissociation 
of the outer tegument from the nucleocapsid occurs during entry into the cytoplasm 
and is mediated by UL13 (viral tegument protein) through phosphorylation (Kelly et 
al., 2009). Inner tegument proteins; UL36 and UL37 remain associated with the 
capsid and are transported along with the nucleocapsid to the nucleus. UL36 assists 
in the transfer of the viral genome into the nucleus through the nuclear pore (Kelly et 
al., 2009, Sodeik et al., 1997). Upon entry into nucleus the genome circularizes 




Chapter 1  Introduction 
18 
 
 Lytic replication 1.3.2
Transcription of herpesviruses genes occurs via a highly regulated expression 
cascade (Honess and Roizman, 1975). Soon after HSV infection (about 2 to 4 hours 
post-infection) the viral immediate early (IE) genes (also referred to as alpha or α) 
are expressed. The peak expression of the next set of genes; early (E) genes (also 
referred to as beta or β) occurs between about 4 to 8 hours post-infection. The third 
set of genes are late (L) genes (also referred to as gamma or γ), whose peak 
expression occurs between about 7-15 hours post-infection (Alwine et al., 1974, 
Boehmer and Lehman, 1997, Honess and Roizman, 1975). 
The transcription of IE genes does not require de novo protein synthesis (Moriuchi et 
al., 1993). VP16 a HSV-1 tegument protein plays a key role in promoting the 
expression of IE genes. VP16 is synthesized during the late phase of HSV-1 
replication and is packaged into the tegument during virion assembly. During 
infection of host cells, this protein is released and stimulates transcription of HSV-1 
IE genes (Batterson and Roizman, 1983). It acts in complex with the cellular 
proteins; Octamer binding protein Oct-1 (Oct-1) and host cell factor-1 (HCF-1) to 
activate RNA polymerase II-dependent transcription from the viral IE genes (ICP0, 
ICP4, ICP22, ICP27 and ICP47) promoters through their TAATGARAT motifs 
(Gerster and Roeder, 1988, Grondin and DeLuca, 2000, Kristie et al., 1989, Xiao and 
Capone, 1990). It has been reported that HCF-1 carries VP16 to the nucleus where 
the VP16-HCF-1 complex binds to Oct-1 bound to IE genes promoters leading to the 
transcription of the IE genes to initiate the viral gene cascade (Roizman & Knipe., 
2001). 
Chapter 1  Introduction 
19 
 
In EBV, the proteins encoded by IE genes BZLF-1 (Zta) and BRLF-1 (replication 
and transcription activator (Rta) have been shown to play key roles in inducing lytic 
gene expression (Westphal et al., 1999). In B cells, the expression of BZLF-1 and in 
epithelial cells, the expression of BZLF-1 or BRLF-1 is sufficient to trigger induction 
of EBV lytic infection (Hardwick et al., 1988, Rooney et al., 1989, Wen et al., 2007, 
Zalani et al., 1996). The Rta protein is analogous to other gammaherpesvirus 
transactivators; ORF50 of HVS, KSHV and MHV-68 (Lukac et al., 1999, 
Whitehouse et al., 1997) which are also capable of driving lytic replication in latently 
infected cells (Gradoville et al., 2000, Goodwin et al., 2001, Wu et al., 2000a). EBV 
Rta, has been shown to activate its own expression as well as the transcription of a 
number of viral IE genes including other transactivators such as Zta and BMLF-1 
also referred as Mta. In the gammaherpesviruses, Mta and its homologues encoded 
by ORF57 are capable of both post-transcriptional activation and repression of a 
number of viral genes and the shuttling of intronless viral mRNAs (Chen et al., 2002, 
Goodwin et al., 2000, Whitehouse et al., 1998, Williams et al., 2005). KSHV ORF50 
and HVS ORF50a have also been shown to induce ORF57 gene expression (Lukac et 
al., 1999, Nicholas et al., 1991, Walters et al., 2005, Whitehouse et al., 1997). 
The products of IE genes initiate the transcription of E genes. Many E genes are 
involved in viral DNA replication such as DNA polymerase (e.g EBV BALF-5, 
OvHV-2 ORF9), ss-DNA binding proteins (e.g EBV BALF-2), ribonucleotide 
reductase (e.g EBV BORF-2 and BORF-1, OvHV-2 ORF60 and ORF61) and 
thymidine kinase (e.g EBV: BXLF-1, OvHV-2 ORF21) (Roizman and Knipe, 2001). 
The products of some of the E genes cluster at the origin of replication of viral 
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genome. It has been proposed that herpesvirus DNA synthesis is initiated by a theta 
mechanism and at some point and by an as yet undefined 
mechanism, theta replication switches to the rolling circle mode, which is the 
predominant mode of herpesvirus DNA replication (Lehman and Boehmer, 1999) 
and results in the formation of long head to tail concatamers of viral genomic DNA 
being produced (Ben-Porat et al., 1976). 
Newly synthesized viral DNA genomes are used as templates for L gene 
transcription, and the late mRNAs produce viral structural proteins necessary for the 
assembly of progeny virions inside the nucleus (Johnson and Baines, 2011). 
Cleavage and packaging of concatemeric DNA occurs in newly formed capsids. It is 
a tightly coupled process in which the cleavage of the genome concatemers occurs at 
the terminus of one unit length as they are packaged into the capsid (Boehmer and 
Lehman, 1997). Before the insertion of viral DNA, a protein scaffold is formed to 
support the capsid.  EBV BDRF1 acts as a scaffold on which other late structural 
capsid proteins BCLF1, BFRF3, BORF1 and BDLF1 form a spherical procapsid 
(Henson et al., 2009). BVRF2 cleaves the BDRF1 scaffolding as the newly 
replicated viral DNA is packed inside, resulting in the formation of a mature 
icosahedral nucleocapsid (Dasgupta and Wilson, 1999, Paulus et al., 2010). 
The completed nucleocapsids are released from the nucleus through a two stage 
enveloping process. The first envelope is made through budding at the inner nuclear 
membrane into the perinuclear space. De-envelopement of the first envelope occurs 
by fusion with the outer nuclear membrane (Mettenleiter, 2002) and de-enveloped 
nucleocapsids are delivered to the cytoplasm for association with tegument proteins. 
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The second envelope is acquired during rebudding into the trans-Golgi network. The 
newly formed virions are then transported to the cell surface and are released by 
exocytosis (Kelly et al., 2009, Mettenleiter, 2002). 
In HSV-1, two of the herpesvirus conserved proteins UL31 and UL34 are involved in 
embedding the nucleocapsid into the inner nuclear surface. The UL13 protein is 
involved in the destabilization of the nuclear surface for the entrance of the 
nucleocapsid into the perinuclear space. In the Golgi, the proteins UL36 and UL37 
have been shown to make the first layer of the tegument and proteins UL11, UL16, 
and UL21 make the outer tegument layer (Johnson and Baines, 2011, Mettenleiter et 
al., 2013). 
In EBV gB is thought to have a role in the initial envelopement of the nucleocapsid 
due to higher levels of gB being present in the nuclear membrane of cells producing 
virus than in the mature enveloped virions (Kelly et al., 2009). In addition, gB also 
plays a role in nuclear egress (Herrold et al., 1996).  EBV gH and gp350/220 are 
found in the Golgi and on the plasma membrane of infected cells. gp350/220 is the 
most abundant virus protein in the lytically infected cell membrane and virus 
envelope, whereas only a small amount of the protein accumulates in the infected 
cell nuclear membrane. It is thought that during the re-envelopment process at the 
plasma membrane level, the virus receives envelope rich in gp350/220 (Gong and 
Kieff, 1990). Mature progeny virions reach to the surface by vesicular movement 
through the Golgi apparatus and are released into the extracellular space by 
exocytosis. 
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 Herpesvirus latency 1.3.3
In latency, the virus enters a state where there is limited gene expression and no 
replication occurs (Ackermann, 2006). In this stage of the herpesvirus life cycle the 
nucleosomes become relatively more stable and dense (Nevels et al., 2011, Paulus et 
al., 2010). The expression of genes during latency varies considerably among 
herpesviruses. Consistent with the previous section, in this section the strategies of 
HSV-1 and EBV will be discussed. 
The latency associated transcripts (LATs) are the only viral transcripts which are 
detected frequently in HSV-1 latency (Stevens, 1987, Nicoll et al., 2012). No protein 
product has been attributed to the LAT gene. LAT is complementary to an α gene, 
ICP0 and overlaps the ICP0 transcript and it has been suggested that LAT inhibits 
ICP0 expression by an antisense mechanism (Gordon et al., 1988, Jones, 2003, Perng 
and Jones, 2010, Wagner et al., 1988). There have been various reports regarding the 
role of LAT expression in the establishment of latency or reactivation of virus from 
latency (Leib et al., 1989, Bergstrom and Lycke, 1990, Hill et al., 1990, Nicoll et al., 
2012, Trousdale et al., 1991, Thompson and Sawtell, 1997). Ahmad et al reported 
that 2.0-kb region of the LAT intron and the exon 1 region of the LAT were 
important in protection from apoptosis (Ahmed et al., 2002). LAT inhibits apoptosis 
and maintains latency by promoting the survival of infected neurons (Perng et al., 
2000, Perng et al., 2002) possibly by down-regulation of the transcripts of α genes 
involved in lytic replication such as ICP0 (Chen et al., 1997, Garber et al., 1997). It 
has also been shown that repression of lytic gene expression during latency was 
achieved by HSV encoded miRNAs in latently infected cells (Jurak et al., 2010, 
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Tang et al., 2009, Tang et al., 2008, Umbach et al., 2008, Umbach et al., 2010). LAT 
region encodes for more than 50% of HSV-1 miRNAs which are expressed 
abundantly during latency (Jurak et al., 2010, Cui et al., 2006, Sun and Li, 2012). In 
transient transfection assays, HSV-1 LAT region encoded miRNA, miR-H2, can 
repress expression of ICP0 (Umbach et al., 2008) (Section 1.5.6.1).  
In gammaherpesviruses homologues of EBV EBNA-1 or KSHV LANA are 
considered to play a key role in the maintenance of latency.  During latency as many 
as eleven EBV genes are expressed; six EBV nuclear antigens (EBNA1, EBNA2, 
EBNA3A, EBNA3B, EBNA3C and EBNALP), three latent membrane proteins 
(LMP1, 2A and 2B); transcripts from the BamHIA region (BART) of the viral 
genome and small, non-polyadenylated, non-coding RNAs, EBER1 and EBER2 
(Rickinson and Kieff, 2001, Young and Rickinson, 2004).  It has been shown that 
there are three types of latency (I, II, III) that can occur in EBV virus on the basis of 
viral transcripts present (Rowe et al., 1992, Thorley-Lawson and Babcock, 1999).  
By using different transcription programs latent EBV genomes can multiply in 
dividing memory cells (latency type I), induce B-cell differentiation (latency type II) 
and activate naïve B cells (latency type III) (Odumade et al., 2011). Latency type I is 
seen in Burkitt’s lymphoma and during this EBNA-1 viral transcripts, BARTs, 
EBER1 and EBER2 are found. Activation of a Qp promoter initiates the transcription 
of EBNA-1 and it is the only virus protein expressed in type I latency. Latency type 
II can be seen in Hodgkin’s lymphoma, T cell lymphomas and nasopharyngeal 
carcinoma. In latency type II, LMP-1, LMP-2A and LMP-2B along with other 
latency I associated viral transcripts are expressed. Activation of one or more LMP 
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promoters leads to the expression of LMPs. LMP-1 has been shown to have a role in 
preventing apoptosis by inducing the expression of bcl-2 (Kaye et al., 1993), while 
LMP-2A and LMP-2B proteins inhibit the B cell activation required for lytic 
replication (Longnecker, 2000). In addition to the viral transcripts expressed in 
latency type II, latency type III cells express five more EBNA transcripts: EBNA2, 
EBNA3A, EBNA3B, EBNA3C and EBNALP. They perform various functions in 
both up and down regulation of viral gene expression.  This state of EBV latency has 
been seen in cultured human EBV infected B cells and cells derived from B cell 
lymphomas. It has been reported that EBV encoded miRNAs played important role 
EBV latency. Three of the EBV miRNAs which flank the BHRF1 ORF are found 
exclusively in B cells with latency III. Remaining EBV miRNAs are located within 
the introns of the BART region and are consequently called the BART miRNAs and 
are located in two clusters. Yang et al reported that miR-BHRF1 and miR-BART 
families were expressed differentially in a tissue- and latency type-dependent 
manner. In NPC tissues and the EBV-positive cell line C666-1, 10% of all the 
detected miRNAs were expressed from the BART region, suggesting that these 
miRNAs have important roles in maintaining latent EBV infections and in driving 
NPC tumorigenesis. In addition, EBV miRNA-based clustering analysis clearly 
distinguished between the three distinct EBV latency types (Yang et al., 2013).   
Latently infected B cells can occasionally be stimulated to reactivate and produce 
new virions, which can infect new B cells and epithelial cells (Odumade et al., 
2011). The precise stimuli which trigger the reactivation in vivo is not clearly 
understood. The presumption is that the reactivation occurs as a result of B cells 
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response to foreign or unrelated infections because in B-cell lines, B-cell receptor 
stimulation can trigger reactivation (Amon and Farrell, 2005, Odumade et al., 2011). 
 Malignant Catarrhal Fever 1.4
 Occurrence and significance 1.4.1
Malignant catarrhal fever (MCF) is a sporadic, mostly fatal disease of cattle and 
other cloven-hoofed species including deer, water buffalo, bison and swine (Loken et 
al., 1998, Martucciello et al., 2006, Reid et al., 1984, Schultheiss et al., 2000).  MCF 
is characterised by acute lymphoproliferation and marked necrosis in susceptible 
species. MCF is mainly caused by one of the two gammaherpesviruses from genus 
Macavirus; ovine herpesvirus 2 (OvHV-2) and alcelaphine herpesvirus 1 (AlHV-1). 
OvHV-2 is naturally present in sheep and causes sheep associated MCF (SA-MCF) 
while AlHV-l is naturally present in wildebeest and causes wildebeest associated 
MCF (WA-MCF). These viruses do not produce any clinical disease in their natural 
hosts but cause MCF in susceptible species some of which are closely 
phylogenetically related to the reservoir hosts (Bridgen and Reid, 1991, Plowright et 
al., 1960). In susceptible species MCF is traditionally regarded as a disease with a 
short clinical course, low morbidity and high case fatality rate, though there have 
been some cases where recovery and chronic disease was observed (O'Toole et al., 
1997). 
MCF was first discovered in 1923 in Africa in cattle that were in close contact with 
wildebeest herds and in 1930 in Europe in cattle that were kept in intimate contact 
with apparently healthy sheep (Mushi and Rurangirwa, 1981), referring to (Mettam, 
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1924). WA-MCF has also been reported in Eastern and Southern Africa where 
wildebeest are found (Plowright, 1965a, Bedelian et al., 2007, Straver and van 
Bekkum, 1979). WA-MCF has also been identified as a problem in zoological parks 
and game farms where wildebeest are kept (Meteyer et al., 1989, Whitaker et al., 
2007). SA-MCF was initially observed in Europe however it is found worldwide 
wherever sheep or cattle or other MCF susceptible species are kept together (Russell 
et al., 2009). SA-MCF has been reported in Europe (Collery and Foley, 1996, 
Desmecht et al., 1999, Frolich et al., 1998, Yus et al., 1999), America (Reid and 
Robinson, 1987), Africa (Rossiter, 1981), the Middle East (Abu Elzein et al., 2003), 
and Southeast Asia (Wiyono et al., 1994). 
Several members of the order Artiodactyla are highly susceptible to MCF including 
species classified within the subfamily Bovinae e.g cattle, water buffalo and bison 
(Dettwiler et al., 2011, Li et al., 2006, Martucciello et al., 2006, Reid et al., 1984, 
Schultheiss et al., 2000). The members of family Cervidae e.g deer, reindeer and 
moose have also been shown to be susceptible hosts (Crawford et al., 2002, Denholm 
and Westbury, 1982, Li et al., 1999, Neimanis et al., 2009, Reid et al., 1979). Pigs 
(family Suidae) are also among the affected species (Albini et al., 2003, Alcaraz et 
al., 2009, Loken et al., 1998). 
 MCF viruses 1.4.2
The MCF virus (MCFV) group include ten members which belongs to the genus 
macavirus of the Gammaherpesvirinae; AlHV-1, OvHV-2, AlHV-2 caprine 
herpesvirus 2 (CpHV-2) (naturally infects goat), Ibex-MCFV (naturally infects 
Nubian ibex), hippotragine herpesvirus 1 (HipHV-1) (naturally infects roan 
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antelopes), Muskox-MCFV (naturally infects musk ox), Aoudad-MCFV (naturally 
infects aoudad) and MCFV-WTD causing the classic MCF in white-tailed deer (may 
infect domestic goats naturally) (O'Toole and Li, 2014, Davison et al., 2009, Russell 
et al., 2009, Li et al., 2000, Li et al., 2005, Li et al., 2014). 
 AlHV-1 and OvHV-2 1.4.2.1
AlHV-1 and OvHV-2 are the two best characterized causative agents of MCF 
(Russell et al., 2009). 
Primary infection caused by AlHV-1 is asymptomatic in its natural host (blue 
wildebeests) and most wildebeest calves before three months of age are infected with 
the virus and excrete the virus in their nasal and lachrymal secretions. Perinatal 
calves are thought to be the main source of AlHV-1, however wildebeest cows may 
also excrete virus in late pregnancy or when in stress (Plowright, 1967, Mushi, 1980, 
Rweyemamu et al., 1974). 
OvHV-2, the causative agent of SA-MCF is closely related to AlHV-1. Sera from 
adult sheep showed cross reactivity to AlHV-1 however sheep sera were not virus 
neutralizing (Rossiter, 1981). It has also been shown that sera from cattle infected 
with non-WA-MCF (NWA-MCF) could cross react with AlHV-1 but not neutralize 
it (Rossiter, 1983). These studies suggested that virus associated with sheep was 
antigenically related to AlHV-1 (Rossiter, 1981, Rossiter, 1983, Reid et al., 1989b). 
Attempts to culture the virus in vitro from tissues of SA-MCF affected animals, have 
not been successful. However, it is possible to derive lymphoblastoid cell lines 
(LCL) from the tissues of SA-MCF affected animals (Reid et al., 1989a, Reid et al., 
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1983). These cell lines were found to contain viral DNA with homology to AlHV-1 
(Bridgen and Reid, 1991) and this finding led to the proposal that SA-MCF was 
caused by a herpesvirus and named as ovine herpesvirus-2 (OvHV-2). In 1993, a 
polymerase chain reaction (PCR) test was developed using OvHV-2 DNA isolated 
from OvHV-2 infected LCL (Baxter et al., 1993). This test has subsequently been 
used for the diagnosis of SA-MCF and for the presence of OvHV-2 in natural host 
and in the cases of suspected SA-MCF in susceptible species (Baxter et al., 1993, Li 
et al., 1995, Loken et al., 1998, Muller-Doblies et al., 1998). The genomes of AlHV-
1 and OvHV-2 have been sequenced and compared (Dewals et al., 2006, Ensser et 
al., 1997, Hart et al., 2007). The sequencing of the OvHV-2 genome from a large 
granular lymphocyte (LGL) cell line derived from a SA-MCF affected cow has 
shown that its genome is co-linear with the other rhadinoviruses (Hart et al., 2007). It 
is also somewhat similar to AlHV-1 genome and shows 40-90% of similarities across 
the genome including the majority of unique ORFs (Hart et al., 2007, Ensser et al., 
1997). 
 Clinical forms of MCF 1.4.3
MCF-susceptible species are considered as dead-end hosts. This disease is 
characterized by the sudden onset of fever as well as ocular and nasal discharge, 
corneal opacity, generalized lymphadenopathy, lymphoid cell infiltration, 
degenerative lesions in the mucosa of the upper respiratory tract and the 
gastrointestinal tract (Russell et al., 2009, Li et al., 2014, O'Toole and Li, 2014). The 
natural incubation period for cattle is generally 2 to 10 weeks but can be as long as 9 
months (Plowright, 1990). In an outbreak following exposure of cattle to sheep in an 
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enclosed space, the mean number of days between apparent exposure and death due 
to MCF was 71 with a range of between 46 to 139 days (Moore et al., 2010). The 
disease course is three times shorter when cattle are inoculated with infected blood 
from acutely infected animals (Pierson et al., 1979). 
There can be five overlapping clinical forms of MCF; head and eye form,  peracute, 
alimentary, neurological, and cutaneous (Russell et al., 2009, O'Toole and Li, 2014). 
The head and eye form of the disease is the most common and characteristic. In this 
form symptoms are predominantly seen in head and neck regions of the animal.  
Discharge from eyes and nose is a classic feature of this form (Figure 1.3). Other 
signs include fever, inappetence, lesions from buccal cavity and muzzle, diarrhoea 
and depression. Due to the lesions in the buccal cavity slight to marked drooling can 
be observed.  Initially the nasal discharge is serous but may progress to 
mucopurulent and purulent. Mucopurulent discharge from ocular mucosa is also 
common. Ocular swelling, corneal opacity, photophobia, enlargement of lymph 
nodes in the head and neck region, hyperventilation, and/or death are the additional 
presentations which can be seen in affected animals (Costa et al., 2009). 
Peracute MCF is the most severe form of the disease. It is characterised by pyrexia, 
depression, diarrhoea, dysentery, occasional oral and nasal mucosa inflammation and 
death within 24-72 hours (Smith, 2002). Severe hemorrhagic gastroenteritis is 
prominent in all affected animals. 
Intestinal MCF is similar to the peracute form. Pyrexia, diarrhoea, hyperaemia of oral 
and nasal mucosa with accompanying discharges, and lymphadenopathy is 
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descriptive of this form. The symptoms become more prominent with the progress in 
the disease which leads to death of the animal within 4-9 days. 
Cutaneous MCF is rare and appears more often in wild ruminants than in cattle. 
Cutaneous lesions may present in the form of circular alopecia that secreted clear 
yellow exudates in the regions sometimes at the base of the horns, the dewclaws and 
the interdigital space (David et al., 2005). 
Neurological MCF is also a rare form of the disease. Nervous signs such as 
hyperaesthesia, incoordination, head shaking and pressing, nystagmus and muscle 
tremors may be present in the absence of other clinical signs or as part of a broader 
more characteristic syndrome (OIE, 2013). 
 Gross pathology 1.4.4
Widespread post-mortem (PM) lesions can be recognized in MCF affected cases 
however the severity of PM findings can vary between animals. PM lesions include 
extensive inflammation, ulcerations and petechial haemorrhages of the systemic 
mucosal membranes, necrotic lesions of mucosa and enlarged lymph nodes (Metzler, 
1991, Russell et al., 2009). Peracute MCF fatalities show lesser lesions other than 
hemorrhagic enterocolitis, whereas animals which died of the head and eye form can 
present lesions in several tissues and organs including liver, brain, joints, kidneys and 
urinary and respiratory tracts.  
Lesions in the upper respiratory track involve hyperaemia of the nasal passage, nasal 
turbinates, larynx and trachea with the presence of mucopurulent exudates. Erosions  




Figure 1.3: A cow exhibiting clinical signs of head and eye form malignant 
catarrhal fever. 
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and ulcerations of the pharyngeal and tracheobronchial mucosa are also found 
(Liggitt et al., 1978, O'Toole et al., 2007, Reid et al., 1984, Selman et al., 1974). 
Erosions and haemorrhages are seen throughout the gastrointestinal tract 
predominantly in the oesophagus, tongue and occasionally the forestomachs and 
intestine. In general, lymph nodes are enlarged and oedematous, although the extent 
of lymph node involvement varies within an animal. The liver and spleen are 
congested and enlarged. Ocular lesions consist of synechiae formation where the iris 
adheres to either the cornea (i.e. anterior synechia) or lens (i.e. posterior synechia) 
and fibrosis is seen in the corneal substantia propria. Ulcers causing corneal 
perforations result in the entrapment of the iris in the cornea (O'Toole and Li, 2014). 
Within the urinary tract, hemorrhagic infarcts in the kidney and characteristic 
echymotic haemorrhages of the epithelial lining of the bladder are often present 
(OIE, 2013). 
 Microscopic pathology 1.4.5
The microscopic findings of MCF include epithelial degeneration, vasculitis, 
hyperplasia and necrosis of lymphoid organs as well as mononuclear cell infiltration 
in the affected tissues (Simon et al., 2003, Liggitt et al., 1978, Selman et al., 1974). 
Mostly lymphocytes and lymphoblasts with fewer monocytes and macrophages are 
present in these infiltrates. Lymphocytic infiltration is found as major 
histopathological finding in the affected tissues. Another significant finding is 
epithelial necrosis and sloughing due to the infiltration. These lesions are usually 
found in the oral and nasal mucosa, epithelia of the gastrointestinal tract, biliary 
epithelium, conjunctiva, ducts of endocrine glands, urinary tract, respiratory tract and 
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brain. Vasculitis may also found in the small and medium blood vessels of these 
tissues (Costa et al., 2009, Liggitt and DeMartini, 1980b, Metzler, 1991, Russell et 
al., 2009, Sanford and Little, 1977). Lymph node hyperplasia is characterised by an 
expansion of lymphoblastoid cells in the paracortical region, whereas degenerative 
lesions in the severely affected lymph nodes are generally associated with the 
presence of foci. Interstitial accumulation of lymphoid cells in non-lymphoid organs 
can be found, in particular the renal cortex and periportal areas of the liver. In the 
kidney development of multiple raised white foci of lymphoid cells may be very 
extensive (OIE, 2013). 
 Transmission of AlHV-1 and OvHV-2  1.4.6
The transmission of both AlHV-1 and OvHV-2 from wildebeest calves and lambs, 
respectively, appears to occur by contact or aerosol transmission routes, under 1-year 
of age (Mushi et al., 1981, Russell et al., 2009, Li et al., 1998). Shedding of the virus 
from the natural host is associated with lambing or calving (wildebeest) (Li et al., 
2004).  Under natural conditions, most lambs acquire OvHV-2 by about three months 
of age and produce cell-free infectious virus from oral and nasal secretions, until 6 to 
9 months of age (Collery and Foley, 1996). However, no conclusive evidence has 
been found that viral shedding is increased in dams at parturition (Li et al., 2004). 
There have been reports of transmission over distances of five kilometres between 
lambs and bison without any physical contact (Li et al., 2008). Infected lambs can 
transmit OvHV-2, through nasal secretions to susceptible species without direct 
contact (Moore et al., 2010). Similarly, the oral and nasal discharges by wildebeest 
calves living in a closed area may initiate the transmission (Plowright, 1965b), 
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however, how the infectious virus travel over long physical distances in the open 
without any direct contact is yet to be discovered. The viruses can also be transmitted 
between individuals of the natural hosts and from natural to susceptible species, by 
the horizontal route through liquid discharges from the noses and the eyes of the 
infected lambs/wildebeest calves. It has also been shown that wild boars can transmit 
OvHV-2 through semen to sows which develop MCF at a later stage (Costa et al., 
2010). Susceptible species are dead end hosts and cannot transmit OvHV-2 or AlHV-
1 (Kim et al., 2003, Muller-Doblies et al., 2001). The possible reason for this might 
be that the virus replicates in a cell-associated manner in susceptible species and cell-
free virus, required for transmission, is not produced (Russell et al., 2009). 
Experimental induction of WA-MCF in cattle can be achieved using wildebeest nasal 
secretions containing AlHV-1 or via the transfer of intact blood cells or crude cell 
suspensions derived from the affected tissues of infected animals (Plowright, 1964, 
Plowright, 1965b, Plowright, 1965a). It has recently been shown that SA-MCF can 
be transmitted to bovine calves via nebulizations with OvHV-2 positive nasal 
secretions (Taus et al., 2005, Taus et al., 2006). Transmission of SA-MCF from 
affected to healthy cattle can also be achieved via transfer of large volumes of blood 
or lymph node cell suspensions (Liggitt and DeMartini, 1980b, Liggitt and 
DeMartini, 1980a, Reid et al., 1986), however this is not a natural route.  
 Immunization 1.4.7
Due to short clinical course of the disease, MCF affected animals can die within a 
few days after the presentation of initial symptoms and the treatment is not viable. 
Serological testing has been used as an important diagnostic tool for both natural and 
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susceptible species. AlHV-1 and OvHV-2 are serologically related (Li et al., 1994, 
Loken et al., 2009, O'Toole et al., 1997) and antibodies from carrier sheep and MCF 
affected cattle are able to recognise AlHV-1 antigen (Rossiter, 1981, Rossiter, 1983). 
Due to the lack of an OvHV-2 permissive cell culture system, attenuated AlHV-1 
vaccines were used to try and provide protection against OvHV-2, however all the 
efforts proved unsuccessful (Edington and Plowright, 1980, Plowright et al., 1975).  
Unlike OvHV-2, cell-free attenuated and virulent AlHV-1 can be obtained from 
tissue culture. Recent immunization studies using AlHV-1 demonstrated that 
immunity to MCF can be induced by the use of an attenuated AlHV-1, adjuvant 
containing vaccine, administered by intramuscular injection (Haig et al., 2008, 
Russell et al., 2012). The vaccine protected the cattle from fatal intranasal challenge 
with pathogenic AlHV-1 at both three and six months post-vaccination and high 
titres of virus neutralizing antibodies could be detected in the nasal secretions of the 
protected animals (Haig et al., 2008, Russell et al., 2012).  
Efforts are underway to develop systems which could help in the production of 
OvHV-2 vaccines. In a study in sheep, Li et al described the development of an in 
vivo system that mimics a neutralization test to measure antibody’s ability to block 
OvHV-2 at the entry site. The test was based on the mixing of virus and anti-OvHV-
2 serum before challenge by intranasal nebulization. The sheep who had received the 
OvHV-2 positive showed approximately 1000 fold reduction in infectivity, based on 
delayed seroconversion and delayed detection of viral DNA, compared to the sheep 
that had received OvHV-2 negative serum (Li et al., 2013a). 
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The other reliable control measure for MCF is to keep susceptible species separated 
from potential natural hosts (Traul et al., 2005). A distance of one kilometre is 
regarded as the minimum distance of separation to limit the risk of virus transmission 
(Barnard, 1990). 
 Large granular lymphocyte cell lines 1.4.8
Lymphoblastoid cell lines can be derived from various tissues of MCFV infected 
animals (Cook and Splitter, 1988, Russell et al., 2009). These cells contain electron 
dense granules within their cytoplasm and have the morphology of large granular 
lymphocytes (LGL). The LGLs exhibited indiscriminately cytotoxicity characteristic 
of natural killer cells and can kill various target tissues in a major histocompatibility 
complex (MHC) unrestricted manner (Herberman and Ortaldo, 1981). These cell 
lines can be maintained in vitro, by the addition of exogenous interleukin-2 (IL-2). 
LGL cell lines established from the lymph nodes of OvHV-2 infected cattle have 
been shown to contain OvHV-2 DNA; e.g BJ1004, BJ1044, BJ1104, BJ971 and 
BJ1035 (Schock et al., 1998). These cell lines were unable to transfer disease to 
rabbits, deer and other cattle. Uninfected T lymphocytes proliferated on the exposure 
of concanavalin A (ConA) whereas LGL cell lines were found to be unresponsive to 
ConA stimulated proliferation. Studies on the surface phenotype of the five LGL cell 
lines showed that three (BJ1004, BJ1035 and BJ1104) were CD4+/CD8- T cells, one 
(BJ971) was CD4-/CD8+ T cells and one (BJ1044) was a mixture of CD4+/CD8- and 
CD4-/CD8+ T cells. In addition these cell lines constitutively express; tumour 
necrosis factor-α (TNF-α), interferon- γ (IFN-γ) and IL-10 (Schock et al., 1998). 
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LGL cell lines from OvHV-2 infected cattle had viral genomes that were mainly 
circular in form, which is suggestive of latency (Rosbottom et al., 2002). In another 
study Thonur et al., 2006 showed that these cell lines contained a mixture of circular 
and linear genome configurations, which indicated that LGLs may be comprised of a 
mixture of latently and productively infected cells (Thonur et al., 2006). 
 Proposed model for MCF pathogenesis 1.4.9
OvHV-2 DNA can be detected in most organs as well as in buffy coat cells of cattle 
with MCF. However, demonstration of viral antigen in MCF affected tissues has 
largely been unsuccessful and it has been hypothesized that direct viral cytotoxicity 
is not involved in MCF pathogenesis (Ackermann, 2006). The vasculitis and necrosis 
in a variety of MCF affected tissues is mainly due to the infiltration and 
accumulation of large number of LGLs (Liggitt and DeMartini, 1980a, Muller-
Doblies et al., 2001, Taus et al., 2006). LGLs derived from tissues of MCF infected 
animals showed a variable expression of CD2, CD4 and CD8 (Meier-Trummer et al., 
2010, Schock et al., 1998, Swa et al., 2001). Proliferating LGLs have a natural killer 
cell phenotype, and these cells are activated by cytokines released from other 
lymphocytes and kill other cells in an un-restricted MHC class I, manner (Cook and 
Splitter, 1988).  
Significant, but low, levels of IL-2 have also been detected in lymph nodes of MCF 
affected animals (Meier-Trummer et al., 2009). IL-2 has been shown to play a key 
role in the propagation of T-cells in vitro (Smith and Johnson, 1988). It has been 
reported in various studies that a lack of IL-2 leads to T lymphocytes establishing an 
abnormal growth rate (Sharfe et al., 1997) which might be mediated through 
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interactions of IL-2 with regulatory T-cells (Almeida et al., 2002, Kramer et al., 
1995). The critical role of IL-2 in the development and expansion of regulatory T 
lymphocytes in lymph nodes helps in supressing the autoreactivity and replication of 
T lymphocytes (Nelson, 2004). It is possible that accumulation and autoreactivity of 
the T lymphocytes in MCF-affected animals is due to the low abundance of IL-2 in 
the lymph nodes (Meier-Trummer et al., 2009). 
A mixture of CD8+ cytotoxic γ/δ T cells, CD4+/perforin- αβ T regulatory or helper 
cells, B cells and macrophages has been found in the inflammatory infiltrates from 
MCF infected bison. It has been hypothesized that γ/δ T cells latently infected with 
OvHV-2 might be the cause of necrotic lesions in the vasculature (Nelson et al., 
2010, O'Toole and Li, 2014). It has also been suggested that only a small number of 
OvHV-2 infected lymphocytes are infiltrating in MCF lesions and most of the cells 
are uninfected, multiplying T lymphocytes. This may also suggest that MCF has an 
autoimmune like pathology (Reid et al., 1984, Meier-Trummer et al., 2010, Russell 












MicroRNAs (miRNAs) are small (21-24 nucleotide (nt) in length) non-coding RNAs, 
which are able to regulate gene expression at the post transcriptional level (Bartel, 
2004). The first miRNA; lin-4 (22 nt long) was identified in a nematode; 
Caenorhabditisis elegans (C. elegans) in 1993 by the Ambros and Ruvkun 
laboratories simultaneously (Lee et al., 1993, Wightman et al., 1993). It was found to 
negatively regulate the expression of the lin-14 protein product by targeting 
complementary sites in the 3’ untranslated region (3’UTR) of the lin-14 mRNA via 
an antisense RNA-RNA interaction (Wightman et al., 1991, Wightman et al., 1993). 
Mutation in the lin-4 ORF did not affect its function, suggesting that lin-4 did not 
encode for a protein (Lee et al., 1993). This discovery remained unrealized for 
almost seven years when Reinhart et al, identified a second miRNA; let-7 in C. 
elegans (Reinhart et al., 2000). let-7 was found to interact with the 3’UTRs of lin-41 
and lin57 mRNAs and inhibit their translation (Abrahante et al., 2003, Vella et al., 
2004). These discoveries unveiled a new family of RNAs which later became known 
as microRNAs (miRNAs) (Lee and Ambros, 2001). It has since been shown 
miRNAs are expressed in large numbers and present in a diverse range of different 
species (including algae, arthropods, nematodes, protozoa, vertebrates, plants, and 
viruses) (Bartel, 2004, Lee et al., 2004b, Grundhoff and Sullivan, 2011). The latest 
miRBase release (v20, June 2013), contains 24521 miRNA loci, processed to 
produce 30424 mature miRNAs from 206 species (Kozomara and Griffiths-Jones, 
2014) (http://www.mirbase.org/). The regulatory roles of miRNAs have been 
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identified in various biological processes including cell fate determination, 
proliferation, cell death, immune response and tumorigenesis (Bhatt et al., 2011, 
Dong et al., 2013, Tuddenham and Pfeffer, 2013). 
 miRNA biogenesis 1.5.2
The biogenesis of miRNAs is a multistep process. It involves sequential processing 
and editing of transcribed miRNA genes (Figure 1.4). Then majority of miRNAs are 
derived from large RNA polymerase (pol) II transcripts, while a small proportion of 
miRNAs is derived from pol III transcripts (Lee et al., 2002, Monteys et al., 2010). 
These primary transcripts (pri-miRNAs) are 5’end capped and 3’ end polyadenylated 
and range from hundreds to thousands of nucleotides in length (Cai et al., 2004, 
Aparicio et al., 2006). Pri-miRNAs are transcribed from introns, exons, intergenic 
regions or in an antisense direction of annotated genes (Cai et al., 2004, Kim, 2005, 
Lee et al., 2004a). A single pri-miRNA transcript can either generate monocistronic 
miRNA or polycistronic clusters of miRNAs, under the influence of a single 
promoter or different promoters for individual miRNAs (Cai et al., 2004, Lee et al., 
2002, Song and Wang, 2008). Approximately 40% of human miRNAs are 
cotranscribed as clusters encoding more than one miRNA sequences in a single pri-
miRNA transcript (Altuvia et al., 2005, Hertel et al., 2006). A pri-miRNA contains 
an imperfect double-stranded (ds) stem-loop structure flanked by single-stranded (ss) 
RNA. One arm of the stem-loop structure includes the mature miRNA (Zeng et al., 
2005).  
The stem-loop structure and the flanking region of the pri-miRNAs direct the pri-
miRNAs to a multiprotein complex called the microprocessor complex (Beezhold et 
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al., 2010, Davis-Dusenbery and Hata, 2010, Landthaler et al., 2004, Lee et al., 
2003). The microprocessor complex contains an RNase III enzyme called Drosha 
and its cofactor protein DiGeorge syndrome critical region gene 8 (DGCR8). 
DGCR8 interacts with the stem-loop structure and recruits Drosha, which then 
cleaves the pri-miRNAs precisely at the stem-loop structure and liberates a 60-110 nt 
long RNA product called the precursor miRNA (pre-miRNA) with a 5’ phosphate 
and a 2 nt overhang  at the 3’ end (Kim et al., 2009, Zeng et al., 2005, Zeng and 
Cullen, 2005) (Figure 1.4). The 3’ overhang and adjacent stem of pre-miRNA is 
recognized by a heterodimer made up of Exportin 5 and Ran-GTP cofactor 
(Exportin/Ran complex). The Pre-miRNA interacts with the Exportin/Ran complex 
and is exported from the nucleus into the cytoplasm (Bohnsack et al., 2004, 
Leisegang et al., 2012).  
In the cytoplasm the hydrolysis of Ran-GTP to RanGDP causes the release of the 
pre-miRNA from the Exportin/Ran complex (Wang et al., 2011). The pre-miRNA is 
then taken up by the RISC loading complex (RLC) made up of an RNase III enzyme 
called Dicer, its cofactors; TAR RNA‑binding protein (TRBP) and protein activator 
of PKR (PACT) and the argonaute-2 (Ago-2) protein (Gregory et al., 2005, Haase et 
al., 2005, Lee et al., 2006, MacRae et al., 2008). TRBP and PACT are not absolutely 
required for pre-miRNA processing but they seem to help in stabilizing Dicer, 
recruiting Ago-2 and in RLC formation (Chendrimada et al., 2005, Kok et al., 2007, 
Lee et al., 2006). Once in the RLC, the exported pre-miRNA is recognized by the 
PAZ (piwi-argonaute-zwille) and two RNase III domains (RNase IIIa and RNase 
IIIb) of Dicer (Lingel et al., 2003, MacRae et al., 2007, MacRae and Doudna, 2007, 
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Yan et al., 2003).  Once bound, Dicer cleaves the pre-miRNA at the base of the 
stem-loop, leaving an ~22 nt miRNA duplex with a 5’ phosphate and a 3’ OH with 2 
nt overhang (Zhang et al., 2004). 
Once pre-miRNA has been cleaved by Dicer, the resultant miRNA duplex directly 
interacts with an Ago protein (also called as elF2C2) to generate the effector 
complex; RNA induced silencing complex (RISC) (Gregory et al., 2005, Hutvagner 
and Zamore, 2002, Mourelatos et al., 2002). The Ago family proteins are the key 
effector molecules of RISC (Maniataki et al., 2005) and are composed of PAZ, MID 
and PIWI domains. The PAZ domain recognizes and interacts with the 2 nt overhang 
at 3’ end of the miRNA, whereas the MID domain anchors the 5’ end of the miRNA 
(Lingel et al., 2004, Jinek and Doudna, 2009, Ma et al., 2004).  The PIWI domain 
structure is similar to RNase H and is thought to play a role in cleaving of the target 
mRNA bound to the miRNA (also called slicer activity) (Kim et al., 2009, Ma et al., 
2005, Parker et al., 2005). In mammals four Ago proteins (Ago1-4) are associated 
with the miRNA but among those only Ago2 has been found to have an 
enzymatically competent PIWI domain with slicer activity to cleave the target 
mRNA strand that are perfectly complementary to the mature miRNA (Liu et al., 
2004, Meister et al., 2004). 
After loading onto Ago proteins the miRNA duplex is unwound by helicases. One 
strand of the duplex remains in Ago and acts as a mature miRNA (the guide strand or 
miRNA), whereas the other strand (the passenger stand or miRNA*) is released for 
degradation or to be incorporate into another RISC as another mature miRNA 
(Ghildiyal et al., 2010, Hutvagner and Zamore, 2002, Kim et al., 2009, Okamura et 
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al., 2008). Relative thermodynamic stability of the two strands in the duplex, 
determines which strand is to be selected as the guide strand (Khvorova et al., 2003). 
The strand with the less stable base pairing at the 5’ end is incorporated into RISC 
and becomes the mature miRNA.  If both strands of the duplex are used as mature 
miRNAs with similar frequency then 5p or 3p is added at the end of their names to 
denote which arm of the duplex, the mature sequence comes from (Griffiths-Jones et 
al., 2006). Once the mature miRNA has become associated into RISC, the miRNA is 
used to guide and bind the complex to their complementary target sites located in the 
mRNA transcripts.  
 Mode of action of miRNAs 1.5.3
 miRNA target recognition 1.5.3.1
miRNAs generally regulate gene expression by binding to target mRNAs, at a post 
transcriptional level. Plants show perfect or near perfect complimentarity between 
miRNA and their target mRNA and induce translational repression through 
degradation of their target transcripts (Brodersen et al., 2008) whereas in animals, 
miRNAs generally use a 6-8 nt sequence (seed region) out of ~21 nt of miRNA 
sequence to recognize the target mRNA (Lewis et al., 2003). The miRNAs seed 
region is located at nucleotide position 2-7 or 2-8 at the 5’ end of the mature miRNA 
(Gottwein and Cullen, 2007) and it is this region which is most conserved across 
metazoan miRNAs (Lewis et al., 2005, Lim et al., 2005). The binding of most 
miRNAs includes the 5' seed region however the presence of non-seed interactions 
have also been reported e.g. at the 3’ end of miRNAs and a site in the centre of 
miRNAs (Helwak et al., 2013, Lee et al., 2009, Shin et al., 2010).  




Figure 1.4: Schematic diagram of miRNA biogenesis. 
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Helwak et al mapped human miRNAs and mRNAs interactions using a biochemical 
approach combined with bioinformatic analysis; “Cross linking, Ligation And 
Sequencing of Hybrids (CLASH) and identified that approximately 60% of the 
interactions between the seed region and target sites in mRNAs were non-canonical 
containing bulged and mismatched nucleotides. Eighteen percent of the total 
miRNA-mRNA interactions, in this study, involved the 3′ end of miRNAs, with little 
evidence for 5′ end contact (Helwak et al., 2013). In addition to seed region match, 
base pairing with target mRNA at the 3’end of miRNA is also possible and is called 
supplementary pairing (Grimson et al., 2007). The presence of mismatches or G:U 
pairing (refers to the pairing of a G with a U instead of a C) in the seed region is also 
acceptable, however  target repression can be affected in this type of pairing (Doench 
and Sharp, 2004, Brennecke et al., 2005, Didiano and Hobert, 2006).  
A miRNA can target several mRNAs by hybridizing to the target site/s 
(complementary to the miRNA seed region) located in the 5’UTRs, coding regions 
and/or 3’UTRs leading to translational inhibition or mRNA degradation (Brennecke 
et al., 2005, Grey et al., 2010, Lee et al., 2009, Lytle et al., 2007). miRNA-mediated 
mRNA cleavage, mediated most likely by Ago2 RNase H activity, is based on 
perfect complimentarity between the miRNA and its target mRNA (Bushati and 
Cohen, 2007, Davis et al., 2005, Doench et al., 2003, Hutvagner and Zamore, 2002). 
However an imperfect complementarity between miRNA and its target mRNA might 
lead to the initiation of the other mechanisms of miRNA mediated gene silencing; 
translational repression and mRNA degradation.  
Chapter 1  Introduction 
46 
 
 Translational repression 1.5.3.2
The process of mRNA translation initiates with the recognition of the 5’ cap by 
eukaryotic translation initiation factor (eIF) 4E, along with other eIFs (eIF4G, eIF4A 
and eIF3). This interaction facilitates the recruitment of ribosomes to the 5′ end of 
mRNA and thus initiates translation.  
It has been suggested in various studies that miRNA mediated translational 
repression can occur at the translational initiation stage or at the translational post-
initiation stage (Chekulaeva and Filipowicz, 2009, Filipowicz et al., 2008, 
Huntzinger and Izaurralde, 2011, Hussain, 2012). 
mRNAs whose translation is not dependent on the presence of 5’ cap i.e mRNAs 
containing an internal ribosome entry sites (IRES) and mRNA which has a non- 
functional 5’ cap, have been found to show resistance to miRNA-mediated 
repression (Humphreys et al., 2005, Mathonnet et al., 2007, Meijer et al., 2013, Pillai 
et al., 2005, Wakiyama et al., 2007). These studies suggest that miRNA-mediated 
silencing interferes with eIF4E function or the cap recognition process during the 
initiation of translation. Moreover, evidence also suggests that repression of cap-
dependent translation can be mediated by inhibiting the formation of the mature 
ribosomal complex i.e. by inhibiting the recruitment of the 40S subunit and 80S 
initiation complex formation (Thermann and Hentze, 2007) or by inhibiting the 
joining of the 60S ribosomal subunit with the 40S subunit (Chendrimada et al., 2007, 
Hussain, 2012). In another study, Mathonnet et al, discussed the possibility that 
Ago2, as a part of the RISC, interacts with the 5’cap of the mRNA and interferes 
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with the binding of eIF4E, which leads to the inhibition of translation initiation 
(Mathonnet et al., 2007).  
miRNA-mediated inhibition of translation at the post-initiation stage has also been 
proposed as another mechanism to target mRNAs. It was found that the lin-4 miRNA 
did not change the abundance of the target mRNA lin-14 in polysomal fractions, 
suggesting that translation was initiated normally and that miRNAs might act after 
translational initiation (Olsen and Ambros, 1999). Various other studies also 
supported this mechanism of inhibition and provided evidence that repressed 
mRNAs were associated with actively translating polysomes (Maroney et al., 2006, 
Nottrott et al., 2006, Petersen et al., 2006). miRNAs can also interfere with the 
elongation phase of translation either by causing degradation of the nascent 
polypeptide chain (Nottrott et al., 2006) or by initiating premature ribosome drop-off 
from the target mRNA (Petersen et al., 2006). 
 miRNA mediated degradation of target mRNA 1.5.3.3
Although, previous studies suggested that miRNA mediated silencing results in the 
repression of translation of the target mRNA without changing the mRNA levels 
(Olsen and Ambros, 1999), recent studies have indicated that miRNA-mediated 
translational repression is associated with the destabilization and degradation of the 
target mRNA (Behm-Ansmant et al., 2006b, Eulalio et al., 2009). 
Degradation of target mRNA by an miRNA, requires deadenylation and/or 
5’decapping of the target mRNA (Behm-Ansmant et al., 2006b, Humphreys et al., 
2005). The degradation of the target mRNA is thought to occur in the cytoplasmic P-
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bodies (Eulalio et al., 2007, Liu et al., 2005, Parker and Sheth, 2007). The Ago 
proteins, the poly(A) binding proteins (PABP) and the P-body protein GW182, are 
all involved in the deadenylation of the target mRNA (Braun et al., 2011, Fabian et 
al., 2009, Fabian et al., 2011, Zekri et al., 2009). GW182 protein recruits the 
deadenylase complexes; CCR4-CAF1-NOT1 and PAN2-PAN3 through direct 
interaction with NOT1 and direct or indirect interaction with PAN3 and PABP 
respectively. These interactions are considered important for the deadenylation and 
degradation of the target mRNA in a 3’-to-5’ direction. However, the exact 
mechanisms involved in the recruitment of the deadenylase complex to the RISC and 
subsequent deadenylation of the poly(A) tail are still not well understood (Braun et 
al., 2011, Fabian et al., 2011, Hussain, 2012, Yamashita et al., 2005, Zekri et al., 
2009). 
The next step in miRNA-mediated degradation involves the 5’ decapping of the 
target mRNA by the decapping-complex proteins DCP1 and DCP2 (Rehwinkel et al., 
2005). Knockdown of the decapping-complex proteins has been shown to lead to an 
accumulation of deadenylated mRNAs (Behm-Ansmant et al., 2006a, Eulalio et al., 
2007). A decapped mRNA is then degraded by the exonuclease activity of the major 
cytoplasmic 5’– 3’ exonuclease XRN1 (Cougot et al., 2004, Rehwinkel et al., 2005).  
 miRNA mediated translational activation 1.5.3.4
Several miRNAs have been reported to induce translational activation instead of 
repression under certain conditions or in specific cells (Lin et al., 2011a, Vasudevan 
et al., 2007, Vasudevan, 2012). Translational up-regulation by miRNAs could be 
achieved in two ways; activation by direct action of the miRNA or by the relief of 
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repression where the action of a repressive miRNA is abrogated (Vasudevan, 2012). 
The translation of the CAT1 mRNA is repressed by a liver specific miRNA miR-
122, in the P-bodies in human hepatoma cells. However following amino acid 
starvation the CAT1 mRNA is released from the P-bodies and interacts with the 
polysomes. This process depends on the binding of HuR, an AU rich-element 
binding protein, to the 3’UTR of the CAT1 mRNA and it is this binding that inhibits 
the repression by miR-122 (Bhattacharyya et al., 2006). Another miRNA miR-369-3 
has been shown to target the 3’UTR of TNFα mRNA and repress its translation in 
proliferating cells, however in G1/G0 arrested cells translation of TNFα mRNA has 
been found to be up-regulated. It has been reported that under serum starvation 
conditions miR-369-3 in RISC, bound to TNFα mRNA could recruit the fragile X–
related protein 1 (FXR1) and stimulate mRNA translation (Vasudevan et al., 2007, 
Vasudevan and Steitz, 2007).  Another miRNA, miR-10a which can interact with the 
5′-terminal oligopyrimidine tract (5′-TOP) motif in the 5’UTR of many ribosomal 
proteins’ mRNAs, has also been shown to up-regulate translation of these mRNAs 
under stress conditions or nutrient shortage (Orom et al., 2008).  
 Biological function of miRNAs 1.5.4
miRNAs play important roles in the regulation of most biological processes. The 
biological processes involved include cellular differentiation (Chen et al., 2004), 
proliferation (Pickering et al., 2009), apoptosis (Cimmino et al., 2005), regulation of 
immune response (O'Connell et al., 2010, Rodriguez et al., 2007, Taganov et al., 
2006), embryonic development (Johnston and Hobert, 2003), cell migration (Chen et 
al., 2011), the cell cycle (Petrocca et al., 2008), angiogenesis (Fish et al., 2008), 
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tumorigenesis (Xia et al., 2008a) and virus replication (Zheng et al., 2011). A 
detailed discussion of regulatory roles and functions of miRNAs is not possible in 
this thesis, however, a few examples of the miRNAs involved in the regulation of 
immune system, cellular differentiation, cell proliferation and cell development are 
described as follows.  
Disruption in the expression of miRNAs by interfering with the miRNA processing 
or miRNA processing components, has been shown to cause differentiation and 
developmental defects in variety of cell types (Chen et al., 2004, Esau et al., 2004, 
Makeyev et al., 2007, Luo et al., 2013, Yi et al., 2008). Embryonic stem (ES) cells 
from dicer deficient mouse have been found to be defective in differentiation as well 
as in the generation of miRNAs (Kanellopoulou et al., 2005). Similarly, Ago2 
deficient mice are embryonic lethal and defective in siRNA responses (Liu et al., 
2004). miRNAs miR-124 and miR-9 are considered important in the regulation of 
mammalian neural development. The overexpression and knock down of miR-124 
triggers and prevents neural development respectively (Gao, 2010).  
miRNAs also have been shown to have roles in B and T cell lineage differentiation. 
miR-181a was the first miRNA reported to have a role in B cell differentiation in 
bone marrow. Overexpression of miR-181a facilitated B cell development which 
resulted in a two to threefold elevation of the B cell number and a twofold reduction 
in the circulating T cell number (Chen et al., 2004, de Yebenes et al., 2013).  Recent 
studies have suggested that miR-181a can control the strength of T cell receptor 
(TCR) signaling, during T cell development in the thymus. It has also been suggested 
in that study that increasing miR-181a expression in mature T cells increases their 
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sensitivity to peptide antigen whereas inhibiting miR-181a expression in immature T 
cells reduces sensitivity (Li et al., 2007). It has been reported that two miRNAs miR-
17-92 and miR-34a also play major roles in B cell differentiation and deletion of 
these miRNAs blocks the transition of pro-B cells to pre-B cells, a vital step in the 
development of the B cells (Rao et al., 2010, Ventura et al., 2008). In Dicer deficient 
animals, the expression of two of the predicted targets of miR-17-92; the pro-
apoptotic gene Bim and tumor suppressor PTEN are strongly up-regulated (Koralov 
et al., 2008). miR-34a is up-regulated by p53 and the ectopic expression of miR-34 
induces cell cycle arrest. Furthermore, it has also been reported that the expression of 
miR-34a is altered in various cancers (Hermeking, 2010, Raver-Shapira et al., 2007). 
These pieces of evidence suggest a role for this miRNA in cell cycle regulation.  
Various miRNAs have been found to be important in the regulation of the immune 
system. miR-146a is expressed in various immune cell types including dendritic cells 
(DC), monocytes and macrophages and its expression has been shown to be 
deregulated in various cancers (Montagner et al., 2013, de Yebenes et al., 2013). 
miR-146a and –b were found to be induced after toll-like receptor (TLR) signaling. 
miR-146a has been shown to be a negative regulator of inflammation. Its expression 
is increased by to the response of lipopolysaccahrides (LPS) in monocytes (Taganov 
et al., 2006). It targets and suppresses the expression of two proteins; TNF receptor-
associated factor 6 (TRAF6) and IL-1 receptor-associated kinase 1 (IRAK1) that are 
important in NF-kB activation by mediating TLR and interleukin-1β (IL1-β) 
signaling (Taganov et al., 2006). It has been shown that a chronic inflammatory 
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response developed in miR-146a deficient mice, which lead to B cell malignancies 
(Zhao et al., 2011a).   
miR-155 is the most studied miRNA in mature B cells. Activation of B and T 
lymphocytes leads to the induction of miR-155 which suggests that it might play a 
role in regulation of immune system (Babar et al., 2012, Haasch et al., 2002, Tili et 
al., 2007).  Increased expression of miR-155 has been observed during the DC 
activating and maturation (Turner et al., 2011). miR-155 deficient mice failed to 
activate T cells efficiently and showed defective antigen presentation function in 
these cells which contributed in the overall reduced immune response (Rodriguez et 
al., 2007). miR-155 was however also the first miRNA described as oncogenic (Tam 
and Dahlberg, 2006). The primary transcript of miR-155 is encoded in a non-protein 
coding region, the B cell integration cluster (BIC). Over expression of BIC and miR-
155 has been observed in lymphomas of activated B-cell origin including Hodgkin’s 
lymphoma (Kluiver et al., 2005, van den Berg et al., 2003). Transgenic mice over 
expressing miR-155 develop pre-B cell proliferation and lymphoblastic 
leukemia/high grade lymphomas (Costinean et al., 2006). The functional orthologues 
of miR-155 (MDV-miR-M4 and KSHV-miR-K12-11) have been found in 
herpesviruses (will be discussed in Section 1.5.6.1). 
miRNAs are also involved in the regulation of the host response upon different 
infections. miR-122 has been shown to up-regulate the translation of hepatitis C virus 
(HCV). miR-122 binds to two target sites located in the 5’UTR of HCV RNA. This 
interaction stops the activity of the 5’exonuclease Xrn1, preventing the decay of 
HCV RNA and hence stimulating translation (Li et al., 2013c). It has also been 
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reported that both of the target sites, within the HCV genome, involve extensive base 
pairing outside of the miR-122 seed region and form a stable tertiary complex 
(Mortimer and Doudna, 2013). In contrast, another miRNA miR-101 has been shown 
to suppress HSV-1 replication by targeting the 3’UTR of a mitochondrial ATP 
synthase subunit beta (ATP5B) suggesting that ATP5B might function as a pro-viral 
factor (Zheng et al., 2011). 
 Approaches for miRNAs target identification 1.5.5
Since the discovery of miRNAs, an extensive amount of work has been done on 
miRNA target identification and regulation of those target mRNAs at the 
translational stage. However, to identify and validate miRNA targets to allow 
understanding of the functions of miRNAs, proved to be the most challenging aspect 
of miRNAs studies. Several approaches have been successfully applied for miRNA 
target identification, however, a combination of computational and experimental 
approaches has been found to be the most useful. 
 Bioinformatic approaches 1.5.5.1
A number of computational programs have been developed to identify/predict 
putative miRNA targets. Those programs include miRanda (John et al., 2004), Pictar 
(Lall et al., 2006), TargetScan (Ruby et al., 2007), PITA (Kertesz et al., 2007), 
DIANA-microT (Kiriakidou et al., 2004), rna22 (Miranda et al., 2006) and 
RNAhybrid (Rehmsmeier et al., 2004). These algorithms all work on the basis of 
basic miRNA-mRNA interaction rules i.e sequence complementarity between the 
seed region at the 5’end of the miRNA and the target site in the mRNA, 
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thermodynamic stability of the duplex (miRNA-mRNA) and conservation of the 
target site between orthologous genes (Yu et al;., 2009). All of these algorithms set 
different parameters such as scoring and threshold, to predict or identify the targets 
and makes it difficult to get common sets of target genes by these methods. Most of 
these programs predict target sites within the 3’UTR of mRNA, however many 
studies have shown the presence of putative miRNA target sites within the 5’UTR 
and CDS of the mRNAs (Liu et al., 2013, Thomson et al., 2011, Zhou et al., 2009). 
As discussed above, these algorithms use sequence complementarity to predict the 
targets, due to which a significant proportion of false positive targets are generated 
(Didiano and Hobert, 2006). To overcome this problem, targets predicted by these 
algorithms are generally validated by experimental approaches.  
 Experimental approaches 1.5.5.2
Currently three main experimental approaches have been developed for identification 
of the miRNA targets: whole transcriptome based analysis, biochemical approaches 
such as crosslinking and immunoprecipitation technique (CLIP) of isolated RNAs 
and proteomic analysis. 
Transcriptome analysis 
Transcriptome analysis is based on the measurement of gene expression in cells in 
the presence or absence of specific miRNA.  
Microarray is used to analyse the effect of miRNAs on the transcripts and also to 
compare the global gene expression profile of the test sample vs a control sample 
(Lim et al., 2005). Lim et al used a microarray approach to examine changes in 
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transcript levels upon over expression of miR-124 and miR-1 in Hela cells. 
Approximately 100 genes were found to be significantly down-regulated in each case 
and all genes identified also had target sites complementary to the seed region of 
each miRNA used (Lim et al., 2005).  
Microarrays for the identification of miRNAs targets have limitations; Firstly, it is 
possible that some of the observed changes in gene expression are not produced by 
direct targeting of miRNAs. Secondly, this method cannot detect miRNAs that cause 
minor or no change in the mRNA levels e.g miRNAs that cause translation 
repressions not mRNA degradation. Deep sequencing techniques such as RNA-seq 
can be used as an alternate to microarray. RNA-seq does not require complementary 
probes and is capable of measuring the expressed transcripts accurately, hence 
provides more in depth analysis of the data. It also allows the analysis in species for 
which a full transcript map is not available. 
The targets identified using these methods and bioinformatics approaches (Section 
1.5.6.1) can be validated using luciferase based reporter assay. The dual luciferase 
assay has and continues to be widely used in miRNAs studies. A description of the 
dual luciferase assay is presented in chapter 3 (Section 3.2).  
Biochemical approaches 
These approaches are based on the identification of the direct physical interactions 
between miRNA-mRNA target pairs and the Ago2 protein in the RISC. Purification 
of mRNAs bound to miRNAs can be achieved through immunoprecipitation (IP) of 
Ago2 in the RISC also called a Co-IP or RISC-IP (Beitzinger et al., 2007, Chi et al., 
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2009, Grey et al., 2010). The immunoprecipitated, or “pulled down” mRNAs can 
then be identified through expression profiling approaches such as microarray 
analysis or deep sequencing. However this method has some limitations; the 
interaction between miRNA and mRNA might be disrupted by the multi-step 
experimental conditions used in the Co-IP or RISC-IP approach, low stringency of IP 
might also purify indirect targets and this method can only give information 
regarding the targeted genes but not on the specific interaction sites.  
To overcome these issues an improved method, high throughput sequencing of 
RNAs isolated by UV crosslinking and immunoprecipitation (HITS-CLIP), was 
introduced  (Chi et al., 2009, Zisoulis et al., 2010). This method uses UV irradiation 
which covalently crosslinks the Ago2 protein with the miRNA-mRNA complex with 
which it is in direct contact within the cells (Chi et al., 2009). Crosslinking of 
proteins with nucleic acids is an irreversible process and crosslinked complexes can 
withstand the stringent purification conditions in the CLIP techniques. HITS-CLIP 
has been successfully used to identify cellular targets of KSHV (Haecker et al., 
2012) and EBV (Riley et al., 2012) encoded miRNAs.  
To overcome the problem of low efficiency crosslinking due to the short wavelength 
radiation (254 nm) used in HITS-CLIP, Hafner et al, introduced a new method called 
photoactivable-ribonucleoside-enhanced-CLIP (PAR-CLIP) (Hafner et al., 2010). In 
this technique cells are incubated with a photoactivable nucleoside, 4-thiouridine 
(4SU) to be incorporated into the transcripts in the cells. After that a UV crosslinking 
is performed at 365 nm wavelength and Hafner et al, reported that mRNA recovery 
was 100 to 1000fold better when compared to other CLIP methods using short 
Chapter 1  Introduction 
57 
 
wavelength and without 4SU  (Hafner et al., 2010).  4SU has a preference to bind with 
guanine instead of adenine. During cDNA synthesis 4SU binds to guanine and during 
PCR-amplification these turn thymidine to cytosine respectively in the PCR product, 
that will be deep sequenced. This method also has an advantage of mapping the exact 
crosslinking sites (Corcoran et al., 2011, Hafner et al., 2010, Spitzer et al., 2014). 
Gottwein et al and Skalsky et al successfully used PAR-CLIP to identify the miRNA 
targets in KSHV and EBV respectively (Gottwein et al., 2011, Skalsky et al., 2012) 
Skalsky et al., 2012). Nevertheless HITS-CLIP and PAR-CLIP techniques do not 
provide a definitive target identification.  
Recently a new technique called crosslinking ligation and sequencing of hybrids 
(CLASH) has been developed to overcome the limitation inherent to previous CLIP 
techniques (Helwak et al., 2013). Using CLASH, miRNAs and their targeted 
transcripts can be identified together due to an intramolecular ligation step. An RNA 
ligase is used to covalently link a small proportion of the purified mRNA molecules 
to their targeting miRNAs. This allows the identification of miRNAs linked to their 
target genes and their specific interaction sites through chimeric miRNA-mRNA 
target sequences. The CLASH technique has been shown to be highly specific. 
Sequencing of the chimeric reads also revealed large number of non-canonical 
interactions between miRNAs and target mRNA pairs (Umbach et al., 2010). More 
detail on the CLASH technique is presented in Chapter 4. 
Proteomic approaches 
Proteomic methods are useful to identify miRNAs targets when miRNAs cause very 
little or undetectable changes in the levels of target mRNAs. The difference, in the 
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levels of newly synthesized protein in the presence and absence of specific miRNA 
can be measured using a pulsed stable isotope labelling with aminoacids in cell 
culture (pSILAC) (Baek et al., 2008, Selbach et al., 2008, Vinther et al., 2006). In 
this method different amino acids are labelled with different heavy isotopes in the 
growth medium of cultivated cells, with or without specific miRNAs. Cells are 
harvested, samples pooled, digested and analysed by mass spectrophotometry. The 
ratio of isotopes quantitatively determines the relative expression of protein. Vinther 
et al used pSILAC to examine the targets of miR-1 in Hela cells. A total of 504 
proteins were identified, however 12 of those proteins were repressed after miR-1 
induction, and 6 of the 12 proteins were validated (Vinther et al., 2006).  
 Viral miRNAs 1.5.6
Viruses are well known for controlling the host cell regulatory system for their 
survival and propagation and it was hypothesized that virus encoded miRNAs could 
help viruses to evade the immune response as a result of regulating both cellular 
systems and viral gene expression (Tuddenham and Pfeffer, 2013, Sullivan, 2008). 
Because miRNAs are non-immunogenic and occupy little genomic space, virus 
encoded miRNAs can be a powerful mechanism for viruses to modulate host gene 
expression (Sarnow et al., 2006).  
Viral miRNAs were first identified in EBV, by Pfeffer and co-workers in 2004, after 
small RNA profiling of infected cells. Those viral miRNAs were differentially 
expressed depending on the stage of the viral life cycle (Pfeffer et al., 2004). Since 
that discovery, over 400 viral miRNAs have been identified from genomes of 
different viruses including herpesviruses, polyomaviruses, retroviruses, adenoviruses 
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and Iridoviruses (Cai et al., 2006a, Jurak et al., 2010, Kincaid et al., 2012, Rosewick 
et al., 2013, Pfeffer et al., 2005, Samols et al., 2007). DNA viruses which replicate in 
the nucleus have been shown to encode most of the viral encoded miRNAs. 
Herpesviruses encoded miRNAs represent the majority of viral encoded miRNAs 
identified and herpesviruses also have the highest average number of miRNAs 
encoded per virus i.e typically >10 per genome (Kincaid and Sullivan, 2012). In the 
nucleus, DNA viruses have full access to the miRNA biogenesis initiating machinery 
(Kincaid and Sullivan, 2012, Tuddenham and Pfeffer, 2013). Those viruses which 
replicate in the cytoplasm (e.g Pox, HCV) might not have evolved to encode 
miRNAs possible due to their lack of contact with Drosha (Cullen, 2010). Some 
studies have shown that human immunodeficiency virus type 1 (HIV-1) also encodes 
for miRNAs (Bennasser et al., 2004, Omoto et al., 2004), however more recent 
studies reported that HIV-1 neither encodes for any miRNAs nor represses the RNA 
interference machinery in infected cells (Lin and Cullen, 2007, Pfeffer et al., 2005). 
There is very little reported evidence that RNA viruses might encode miRNAs. 
Kincaid et al showed that a retrovirus; bovine leukemia virus (BLV) clearly encodes 
numerous miRNAs (Kincaid et al., 2012, Rosewick et al., 2013). BLV encodes a 
conserved cluster of miRNAs that are transcribed by RNA polymerase III. The 
transcribed hairpin structures directly serve as Dicer substrates thus avoiding the 
cleavage of its RNA genome and mRNA by Drosha (Kincaid et al., 2012).    
 Herpesviruses encoded miRNAs 1.5.6.1
Herpesviruses encoded miRNAs constitute more than 90% of the viral encoded 
miRNAs so far identified (Grundhoff and Sullivan, 2011, Tuddenham and Pfeffer, 
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2011, Tuddenham et al., 2012). The functions and functional targets of the majority 
of these miRNAs however, remain unknown. A few targets of herpesvirus encoded 
miRNAs have been found to play a role in the regulation of viral and cellular gene 
expression, maintainance of latency, immune evasion and viral pathogenesis (Table 
1.2 and 1.3).  It is out of the scope of this thesis to give a description of all the known 
targets for herpesvirus encoded miRNAs. However, some of the miRNAs which 
have viral targets involve in viral replication and pathogenicity and cellular targets 
involve in immune evasion, apoptosis resistance and support latency, will be 
discussed.  
Viral targets of herpesvirus encoded miRNAs  
It has been reported that miRNA targeting of lytic or IE and late genes to regulate the 
viral life cycle, is used by many of the herpesviruses (Table 1.2). 
HSV-1-miR-H2-3p is antisense to ICP0 and its expression causes a translational 
repression of ICP0 (an immediate early transcriptional activator), which might be 
expected to promote or maintain viral latency (Umbach et al., 2008). HSV-1-miR-H6 
targets the IE transcription factor ICP4 which is required for maximal expression of 
most HSV genes (Umbach et al., 2008, Watson et al., 1980). HSV-2-miR-H2, -H3 
and -H4 have been shown to target ICP0 and ICP34.5 (a viral neurovirulence factor) 
(Tang et al., 2009). ICP34.5 is involved in virus replication and down regulation of 
this viral protein might result in the establishment and maintenance of latency.  
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Table 1.1: Current number of virus encoded miRNAs 
Family Subfamily Virus 





α-Herpesviridae Bovine herpesvirus 1 12 
 Herpes B Virus 15 
 Herpes Simplex Virus 1 27 
 Herpes Simplex Virus 1 24 
 Marek’s disease virus 26 
 Marek’s disease virus type 2 36 
β- Herpesviridae Human cytomegalovirus 26 
 Mouse cytomegalovirus 29 
 
Human herpesvirus 6 
8 
γ- Herpesviridae 
Epstein Barr Virus 
44 




Murine Herpesvirus 68 
28 
 Rhesus lymphocryptovirus 
68 
 
Rhesis monkey rhadinovirus 
11 





 JC polyomavirus 
2 
 Merkel cell polyomavirus 
2 
 









Bovine leukemia virus 
10 
Foot notes: Adapted from miRBase release (v20, June 2013) 
(http://www.mirbase.org/). 
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MDV1-miR-M7-5p, targets two MDV IE genes, ICP4 and ICP27 which suggests 
that this miRNA may play an important role in establishing and maintaining viral 
latency (Strassheim et al., 2012). In addition, MDV also encodes a functional viral 
ortholog (MDV1-miR-M4) of the cellular miRNA miR-155 which targets UL28 and 
UL32 proteins involved in the cleavage and packaging of viral DNA (Muylkens et 
al., 2010). 
HCMV-miR-UL112-1 targets the viral immediate early gene IE72 (also known as 
UL123 or IE1) and can modulate viral replication and can lead to viral latency (Grey 
et al., 2007, Murphy et al., 2008).   
Several studies on KSHV miRNAs reported that the KSHV transactivator 
RTA/ORF50, can be targeted by different miRNAs (miR-K-12-1, miR-K-12-5, miR-
K-12-7, miR-k-12-9*, miR-k-12-9) directly or indirectly (Bellare and Ganem, 2009, 
Lei et al., 2010, Lin et al., 2011b, Lu et al., 2010). EBV-miR-BART2 targets the 
viral DNA polymerase BALF5 and it has been shown that regulation of BALF5 by 
miR-BART2 is important for the correct control of the switch from latent to lytic life 
cycle (Barth et al., 2008). EBV-miRs originating from the BART cluster 1 are 
reported to regulate the expression of the viral LMP1 protein (Lo et al., 2007). LMP1 
is produced during EBV latency and is required to induce cell growth and 
transformation for the development of nasopharygeal carcinoma (NPC) (Izumi et al., 
1997). However, over expression of LMP1 can result in growth inhibition and 
increase apoptosis (Eliopoulos et al., 1996). It is proposed that EBV miRNAs tightly 
regulate LMP1 expression for EBV pathogenesis.  
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Cellular targets of herpesvirus encoded miRNAs 
Herpesvirus miRNAs with known cellular targets may play a significant role in cell 
survival, proliferation and immune evasion, which helps in viral persistence and 
pathogenesis (Table 1.3). HCMV-miR-UL112-1, EBV-miR-BART2-5p and KSHV-
miR-K12-7 have a common target, a NK receptor ligand: major histocompatibility 
complex class I related chain B (MICB) (Nachmani et al., 2009, Stern-Ginossar et 
al., 2007). Binding of one of these miRNAs to the MICB transcripts results in a 
decrease in MICB binding to the natural killer activating receptor (NKG2D) resulting 
in inhibition of NK cell recognition of virally infected cells, suggesting the role of 
these miRNAs is immune evasion (Nachmani et al., 2009, Stern-Ginossar et al., 
2007). HCMV-miR-UL112-1 also targets Bcl-2 associated factor, BclAF1, which is 
a nuclear protein important in apoptosis, transcriptional regulation and export of 
RNA from the nucleus (Sarras et al., 2010). It has been reported that the BclAF1 
protein is also targeted by viral proteins, p71 and UL35 at the start of HCMV 
infection. An increase in the expression of BclAF1 inhibits viral replication and a 
reduction in BclAF1 levels enhances HCMV gene expression. These findings 
suggest that cellular genes important for viral persistence can be targeted by viruses 
using more than one strategy (Lee et al., 2012). HCMV-miR-US25-1 targets a 
number of cellular genes involved in the regulation of the cell cycle and results in the 
arrest of the G1/S phase of the cell cycle (Grey et al., 2010).  
MDV-1 encodes a miRNA, miR-M4 which is an ortholog of cellular miR-155. miR-
155 plays an important role in the lymphocyte differentiation  (Section 1.5.4). Zhao 
et al, found a significant role for miR-M4 in lymphomagenesis in chickens infected 
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with a virulent strain of MDV-1. A miR-M4 deleted virus failed to induce 
lymphomas in the chickens after infection (Zhao et al., 2011b). KSHV-miR-K12-11, 
was also identified as an orthologue of miR-155 and they have nearly identical sets 
of target mRNAs (Skalsky et al., 2007). It has been reported that ectopic expression 
of either miRNA can inhibit BACH-1, a transcriptional repressor. Furthermore the 
mRNA levels of BACH-1 are down regulated in latently infected KSHV-infected 
endothelial cells (An et al., 2006) which might be due to miR-K12-11 targeting. 
miR-K-12-11 and miR-155 have also been found to target CCAAT enhancer binding 
protein β (C/EBPβ) which is a negative regulator of IL-6 and is involved in B cell 
lymphomagenesis (Boss et al., 2011) and Jarid2 which plays an important role 
during embryonic development and cell differentiation and functions as a tumor 
suppressor (Dahlke et al., 2012).  
KSHV-miR-K-12-6-3p targets thrombospondin 1 (THBS1) which encodes a protein 
involved in cell to cell adhesion, and has anti-proliferative and anti-angiogenesesis 
activity. It has been observed that the translation of THSB1 mRNA was inhibited by 
miR-K-12-6-3p (Samols et al., 2007). Lu et al found that KSHV miR-K12-4-5p can 
target the Rbl2 3′ UTR and down regulate Rbl2 protein levels. Rbl2 is a member of 
the Rb family and has global effects on the control of the cell cycle and cellular-
differentiation (Lu et al., 2010). KSHV-miR-12-1 targets a cellular cyclin-dependent 
kinase inhibitor, p21 and strongly attenuates the cell cycle arrest which normally 
occurs in response to p53 activation (Gottwein and Cullen, 2010). KSHV miRNAs; 
miR-K12-10a, K12-9 and K12-5 target TWEAKR, IRAK1 and MYD88 respectively 
and reduce inflammatory-cytokine expression (Abend et al., 2012, Abend et al., 
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2010). EBV-miR-BHRF1-3 have been shown to help immune evasion of the virus by 
targeting CTL chemoattractant CXCL11 leading to a reduction in the recognition of 
EBV infected cells by CTLs (cytotoxic T lymphocytes) (Xia et al., 2008b). As a 
means of protecting cells from apoptosis, EBV-miR-BART5 targets the pro-
apoptotic protein, p53 up-regulated modulator of apoptosis (PUMA) in 
nasopharyngeal carcinoma (Choy et al., 2008).  
 OvHV-2 encoded miRNAs 1.5.7
Like other herpesviruses OvHV-2 also encodes miRNAs (Levy et al., 2012). Using 
high throughput sequencing and bioinformatics, 46 OvHV-2 encoded miRNAs  were 
predicted(Levy PhD thesis, 2012), eight of those were validated by northern 
hybridization as putative miRNAs expressed in the BJ1035 cell line and named as 
ovhv2-miR-1 – miR-8 (Levy et al., 2012).  
The discovery of OvHV-2 miRNAs was the first report of the expression of virally 
encoded miRNAs in the Macavirus genus of the Herpesviridae. OvHV-2 encoded 
miRNAs are located throughout the genome in three clusters, in regions of the 
genome which were not encoded for any protein (Figure 1.5). Cluster 1 is located at 
the left hand end of the OvHV-2 genome and encodes five miRNAs. Cluster 2 and -3 
are located between ORF11 and ORF17/17.5, in a 9.3 kb region of the genome which 
does not encode for any functional protein. Both of these clusters are approximately 
4 kb apart from each other. Cluster 2 and -3 encode twenty seven and three miRNAs 
respectively (Figure 1.5).  
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Since the work described in this thesis was carried out, a further study has validated 
the expression of a total of 35 OvHV-2 encoded miRNAs (Nightingale et al., 2014) 
(Table 1.4). A new nomenclature for OvHV-2 encoded miRNAs was also introduced 
in that study. However I will use the previous nomenclature as described in Table 
1.4. 
 Aims of the study 1.5.8
The identification and validation of viral and cellular targets of OvHV-2 miRNAs is 
an important step in understanding the role of those miRNAs in virus biology. 
Bioinformatic analysis predicts a large number of possible OvHV-2 miRNAs targets 
in host (cattle or sheep) and viral transcripts. Experimental approaches to validate 
selected targets would be a realistic approach. So the overall aim of this thesis work 
was to identify and functionally validate the OvHV-2 miRNAs targets in virus and 
host transcripts. Specifically, we aimed to: 
 Validate the predicted OvHV-2 ORFs as targets of OvHV-2 miRNAs using 
dual luciferase assays. 
 Identify mRNAs targeted by OvHV-2 miRNAs in the cattle and sheep cells 
and validate those predicted targets by CLASH technique.  




Figure 1.5: Schematic diagram of OvHV-2 genome showing validated and 
predicted ovhv2-miRs.  
Sites of miRNAs are shown in red and black arrows. Red arrows indicated the 
miRNAs validated by northern blot analysis (Levy et al., 2012). Red circles around 
miRNAs are indicating three major cluster regions of ovhv2-miRs (cluster 1, 2 and 
3). OvHV-2 predicted ORFs are shown with closed boxes and arrows indicating the 
direction of transcription. 
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Table 1.2: Viral targets of herpesvirus encoded miRNAs  














ICP34.5 Establishment and maintainance 
of  latency 
 MDV-1/miR-M4 UL28, 
UL32 
Cleavage/packaging of viral DNA 
β- 
Herpesviridae 







RTA/ORF20 Viral transactivator 
 EBV/miR-BART2 BALF5 Viral DNA polymerase 
 EBV/miR-BART6-5p EBNA2 Viral transactivator 
 EBV/miR-miR-BART9, 
EBV/miR-BHRF1-1 















Chapter 1  Introduction 
69 
 
Table 1.3: Cellular targets of herpesvirus encoded miRNAs 
Sub-family Virus/miRNA Target Function 
α-
Herpesviridae 
MDV-1/miR-M3 SMAD2 Anti-apopototic 







HCMV/miR-UL112-1 MICB Role in immune evasion 
 HCMV/miR-UL-148D RANTES Chemokine 
 HCMV/miR-UL-112-1 BclAF1 transcriptional regulation 
 HCMV/miR-US25-1 Cyclin E2 Cell cycle inhibition 





MICB Role in immune evasion 
 EBV/miR-BHRF1-3 CXCL-11 Chemokine 
 KSHV/miR-K12-1, 
KSHV/miR-K12-9 
IRAK1 TLR signalling 
 KSHV/miR-K12-5, 
KSHV/miR-K12-11 
MYD88 TLR signalling 
 KSHV/miR-K12-1 p21 Cell cycle inhibotor 





THBS1 Tumor suppressor, anti agiogenic 





 Transcription regulation 
 KSHV/miR-K12-11 TWEAKR Role in immune evasion 
 EBV/miR-BART5 PUMA Pro-apoptotic factor 
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Table 1.4: Recent and previous nomenclature for OvHV-2 encoded miRNAs 
Recent nomenclature 
(Nightingale et al., 2014) 
Ovhv2-miR- 
Previous nomenclature 
(Levy et al., 2012; Riaz et al., 2014) 
Ovhv2- 
Ov2-2 miR-1  
Ov2-1  -miR-6 
17-30  -miR-34 
17-29  miR-2  
17-28  miR-36 
17-27  miR-37 
17-26  miR-38 
17-25  miR-39 
17-24  miR-40 
17-23  miR-41 
17-22  miR-42 
17-21  miR-43 
17-20  miR-3  
17-19  miR-45 
17-18  miR-46 
17-17  miR-4  
17-16  miR-48 
17-15  miR-49 
17-14  miR-50 
17-13  miR-51 
17-12  miR-53 
17-11  miR-54 
17-10  miR-5 
17-9  miR-57 
17-8  miR-58 
17-7  miR-60 
17-6  miR-6 
17-5  miR-62 







Foot notes: The eight OvHV-2 miRNAs validated by northern hybridization (Levy et al., 
2012) are indicated in blue.    
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 Molecular techniques 2.1
 Isolation of DNA 2.1.1
DNA was extracted from eukaryotic cells using the Qiagen DNeasy Kit according to 
the manufacturer’s protocol. Cells were pelleted at 300 x g for 5 min at room 
temperature and resuspended in sterile phosphate buffer solution (SPBS). The cells 
were lysed with sodium dodecyl sulphate (SDS) followed by treatment with 
proteinase K. RNA was degraded with RNase A. The lysate was combined with a 
chaotropic salt buffer to optimize DNA binding to the column membrane. Bound 
DNA was washed in two steps and eluted in the provided buffer. After purification 
all DNA samples were stored at either 4oC or at -20oC for long term storage. 
 Polymerase chain reaction  2.1.2
Pfu Turbo DNA polymerase (Stratagene) was used according to the manufacturer’s 
protocol. All samples were made up to a final volume of 50 µl in 0.2 ml thin walled 
PCR tubes. Each reaction mix contained 1× cloned Pfu DNA polymerase reaction 
buffer with MgSO4, 10-100ng of DNA template, 10-25mM each dNTP, 100-125 ng 
of both the forward and reverse primers (Eurofins MWG Operon) (Appendix-3), 1 
I.U. of Pfu DNA polymerase and nuclease free water. The reaction conditions 
consisted of one cycle of denaturation at 95oC for 5min, 35 cycles of 30sec 
denaturing at 95oC, 30 sec annealing at 55-60oC, and extension at the rate of 1 min 
per kb at 72oC, with a final extension cycle of 7 min at 72oC in a PCR Sprint 
Thermal Cycler, (Thermo Scientific). During the last cycle (extension) Taq DNA 
polymerase (Biolabs) (1µl) was added to each reaction mixture.  
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 PCR product purification 2.1.3
PCR products were purified using a QIAquick PCR Purification Kit (Qiagen) or 
MinElute PCR Purification Kit (Qiagen) according to the manufacturer’s protocol. 
5volumes of Buffer PB was added to 1 volume of the PCR product and applied to the 
supplied spin column. The columns were centrifuged at 12,000 x g for 30-60 sec, 
washed with Buffer PE (supplied with the kit) and the DNA eluted with 10-30 µl 
buffer EB (10mM Tris-Cl, pH 8.5) or water. 
 Agarose gel electrophoresis 2.1.4
PCR products or plasmid DNA were analysed by electrophoresis in 1-1.5% agarose 
(Invitrogen) or 3% intermediate melting temperature agarose (MetaPhor, Lonza) 
containing 0.05 mg ethidium bromide (Sigma) in 1x TAE (Tris-acetate-EDTA) 
buffer (Appendix-1). An appropriate volume of 6x loading dye was added to each 
sample and electrophoresis was carried out in horizontal gel tanks at 80V for 45 min 
to 1 hr. Samples were compared with 1 kb, 100bp, 25bp, and 10bp DNA ladders 
(New England Biolabs) for size estimation.  
 Restriction enzyme digestion of DNA 2.1.5
Restriction enzyme (New England Biolabs) digestion was carried according to the 
manufacturer’s instructions using the recommended buffer at 37oC for 1-2 hr. 
Digests were carried out in a total volume of 10-20 µl using 10U of each restriction 
enzyme with 1 µg of plasmid DNA. Digested DNA samples were analysed by 
agarose gel electrophoresis (Section 2.1.4).  
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 Extraction of DNA from agarose gels 2.1.6
DNA fragments were extracted from agarose gels using the QIAquick Gel Extraction 
Kit or MinElute Gel Extraction Kit (Qiagen) according to the manufacturer’s 
protocol. The gel slice with the DNA fragment of interest was excised from the gel, 
dissolved in the buffer QG at 55oC (for high melting temperature agarose) or 37oC 
(intermediate melting temperature agarose). Isopropanol was added to the dissolved 
gel and the mixture was applied to a QIAquick gel extraction column or a MinElute 
gel extraction column. Elution of DNA from column was as described in section 
2.1.3. 
  DNA ligation 2.1.7
For cloning PCR products the PCR 4-TOPO vector (Appendix-2 for vector map) 
(Invitrogen) was used according to the manufacturer’s protocol. 2 µl of the PCR 
product, 1 µl of salt solution (1.2M NaCl, 0.06M MgCl2) and 1 µl of the TOPO TA 
vector were mixed and incubated for 5 min at room temperature. 
Ligation of the restriction digested DNA insert with a digested and dephosphorylated 
vector was carried out at a molar ratio of 2 (insert):1 (vector). Each ligation mixture 
also contained 1 µl of T4 DNA ligase (New England Biolabs), 1 µl of 10x Ligase 
Buffer and water to a final volume of 10 µl. Ligation reactions were incubated 
overnight at 16oC. 
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 Quantification of nucleic acid by spectrophotometry 2.1.8
Nucleic acid concentration was determined using a NanoDrop ND1000 
Spectrophotometer (Thermo Fisher Scientific, UK) at an absorbance reading of 
OD260nm and OD280nm. A pure DNA or RNA had at a 260/280 ratio of ~1.8 or ~2.0 
respectively. Using the formula OD260of 1= 50 µgml
-1 DNA or 40 µg ml-1 RNA, 
absorbance of concentration of nucleic acid was calculated. 
  Sequencing of plasmid DNA 2.1.9
Plasmid DNA was sequenced using the Big Dye® Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems). Plasmid DNA (300-500 ng) was added to 
sequencing primers (3.2 pmol/μl) (for list of sequencing primers see Appendix-3), 
1.5 μl of 5 x Big Dye Buffer and 1 μl Terminator Ready Reaction Mix. The 
sequencing reaction was performed on a PCR Sprint Thermal Cycler, (Thermo 
Scientific) using the following reaction conditions for 30 cycles. 
96oC  10 sec  denaturation of plasmid DNA 
50oC  5 sec  annealing 
60oC  2 min  elongation  
4oC  hold 
Plasmids were sequenced by the Gene Pool, Ashworth Laboratory, Kings Building, 
University of Edinburgh or by the GATC Biotech, Germany. DNA sequences were 
analysed using NCBI nucleotide-nucleotide BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
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 Isolation of RNA 2.1.10
RNA was isolated from cultured cells using TRIzol® (Invitrogen) according to the 
manufacturer’s protocol. Briefly 0.75 ml of TRIzol® Reagent was added to 0.25 ml 
of cells in suspension (5–10 × 106 cells) or for adherent cells lines 1 ml TRIzol® 
Reagent was added directly to the cells in the culture dish per 10 cm2 area.  Cells 
were lysed by pipetting up and down several times. The sample was incubated for 5 
min at 23oC. 0.2 ml of chloroform was added to the reaction mixture and the tube 
was shaken vigorously for 15 seconds, incubated for 2–3 min at room temperature 
and centrifuged at 12,000 × g for 15 min at 4°C. The upper transparent aqueous 
phase of the sample was removed and 0.5 ml of 100% isopropanol was added to it. 
The sample was incubated at room temperature for 10 min and centrifuged at 12,000 
× g for 10 min at 4°C. The supernatant was removed and the pellet washed twice 
with 75% ethanol. After each wash the sample was vortexed briefly, and centrifuged 
at 7500 × g for 5 min at 4°C.  The RNA pellet was air dried for 5–10 min on ice, and 
re-suspended in 15-30 µl of nuclease free water. The RNA sample was then 
incubated in a water bath at 55–60°C for 10 min. The concentration of the RNA was 
determined as described in section 2.1.8 and stored at -80oC. 
 Reverse transcription of miRNAs 2.1.11
Reverse transcription of miRNAs for cDNA synthesis was performed using the 
miScript Reverse transcription Kit (Qiagen) according to the manufacturer’s 
protocol. Template RNA (section 2.1.9) (200 ng) was added to the reaction mix 
containing 4µl of the 5 x miScript RT buffer, 1 µl of the miScript Transcriptase mix, 
Chapter 2  Material & Methods 
77 
 
0.5 µl of RNaseOUT (Invitrogen) (40 U/µl) and nuclease free water to a final volume 
of 20 µl. The reaction was incubated for 60 min at 37oC and then for 5 min at 95oC.  
 Quantitative real time PCR  2.1.12
Real time quantitative PCR (RT-qPCR) for the detection of miRNAs was performed 
using the miScript SYBR Green PCR Kit. RT-qPCR was carried out in 0.2ml strip 
tubes in a Rotor-Gene Q (Qiagen). Template cDNA (0.1-10ng) was added to a 
reaction mix containing 10µl of 2x SYBR Green PCR master mix, 2µl of 10 x 
Universal Primer, 2µl of the miRNA specific forward primer (Invitrogen) 
(Appendix-3) and nuclease free water to a final volume of 20µl. RT-qPCR was 
performed using the following cycling conditions 
PCR initial activation step  15 min at 95oC 
3 step cycling for 40 cycles:  
Denaturation    15 sec at 94oC 
Annealing     30 sec at 55oC 
Extension    30 sec at 70oC 
 Bacterial techniques 2.2
 Bacterial culture 2.2.1
7.5 g Bacto agar (BD) was added to 500 ml Luria-Bertani (LB) broth (Merck) 
(Appendix-1) and autoclaved. The culture media was supplemented with ampicillin 
(100 µg/µl) (Sigma) at 45oC-50oC. The gel was gently swirled and then poured into 
petri dishes (Sterilin) aseptically and allowed to solidify. For liquid culture, agar was 
not added to LB broth. 
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 Transformation of chemical competent cells 2.2.2
One Shot® TOP10 Chemically Competent E. coli (Invitrogen) were transformed 
according to the manufacturer’s protocol. A vial of 50µl of the competent cells was 
thawed on ice. 1-5µl of the ligation reaction (section 2.1.7) or plasmid was added to 
the vial and incubated on ice for 30min. The cells were heat-shocked for 30sec at 
42oC without shaking and immediately placed on ice for 2 min. 250 µl of pre-
warmed SOC medium was added to the cells and cells were shaken in an orbital 
incubator at 225 rpm for 1 hr at 37oC. The transformation reaction was spread on to 
pre-warmed LB agar plate (supplemented with ampicillin) and incubated at 37oC 
overnight. 
 Small scale isolation of plasmid DNA from bacteria 2.2.3
Isolation of plasmid DNA from transformed bacteria was carried out using a 
QIAprep Spin Miniprep Kit (Qiagen) according to the manufacturer’s instruction. A 
single colony was picked from the freshly streaked LB agar plate, inoculated in 1-5 
ml of LB broth supplemented with 100 µg/µl of ampicillin and incubated at 37oC in 
an orbital shaker at 225 rpm for 24 hr. Bacterial cells were harvested by 
centrifugation at 3,000 x g in a bench top centrifuge for 5min at room temperature. 
The supernatant was removed and the bacterial pellet re-suspended in 250 µl of the 
buffer P1 containing RNase A, when there were no visible cell clumps, 250 µl of 
buffer P2 was added, followed by 350 µl of buffer N3. The lysate was centrifuged at 
18,000 x g for 10 min. The supernatant was carefully applied to the spin column and 
centrifuged at 18,000 x g for 30-60 sec. The flow through was discarded and the 
sample in the column was washed with 500 µl of buffer PB by centrifugation at 
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18,000 x g for 30-60 sec. The column was washed by adding 750 µl of ethanol 
containing buffer PE and centrifuged at 18,000 x g for 30-60 sec. To completely 
remove the residual ethanol the column was centrifuged at 18,000 x g for 1 min. The 
plasmid DNA was eluted into a 1.5 ml microcentrifuge tube by applying 50 µl of 
buffer EB (10mM Tris, PH8.5) and the column was then centrifuged for 1 min at 
18,000 x g. 
 Large scale isolation of plasmid DNA from bacteria 2.2.4
Isolation of plasmid DNA on large scale from transformed bacteria was carried out 
using a QIAGEN Plasmid Maxi Kit (Qiagen) according to the manufacturer’s 
instruction. A single colony was picked from a freshly streaked LB agar plate, 
inoculated into 1-5 ml of LB broth supplemented with 100 µg/µl of ampicillin and 
incubated at 37oC in an orbital shaker at 225 rpm for approximately 8 hr. 300-500 µl 
of this starter culture was inoculated into 200-500 ml of LB broth supplemented with 
100 µg/µl of ampicillin and incubated for 12-16 hr at 37oC in an orbital shaker at 225 
rpm. Bacterial cells were harvested by centrifugation at 6000 x g for 15 min at 4oC. 
The bacterial pellet was re-suspended in 10 ml of the supplied RNase containing 
buffer P1, 10 ml of buffer P2 was then added to the sample. The sample was 
incubated at room temperature for 5 min and 10 ml of buffer N3 was added. The 
sample was incubated on ice for 20 min and centrifuged at 20,000 x g for 30 min. 
The QIAGEN-tip 500 column was equilibrated with 10 ml of buffer QBT. The 
supernatant was carefully applied to the column and allowed to enter the resin by 
gravity flow. The column was washed with 30 ml of Buffer QC twice and plasmid 
DNA was eluted with 15 ml of Buffer QF and collected in a clean 30 ml glass Corex 
Chapter 2  Material & Methods 
80 
 
tube. 10.5ml of isopropanol was added and the sample centrifuged at 15,000 x g for 
30 min at 4oC. The DNA pellet was washed with 5ml of 70% ethanol and allowed to 
air dry it for 5-10 min. The pellet was re-dissolved in 300-500µl of buffer TE (10mM 
Tris-Cl, pH 8.5). 
 Preparation of bacterial stocks for long term storage 2.2.5
150 µl of sterile glycerol was added to 850 µl of the bacterial culture, The mixture 
was vortexed to ensure the proper mixing and stored at -80oC. 
 Protein techniques 2.3
 Isolation of protein from cultured cells 2.3.1
Cells were detached as described in section 2.5.1 and were pelleted by centrifugation 
at 1500 x g for 5 min at room temperature. Cells in suspension culture were pelleted 
by centrifugation at 1500 x g for 5 min at room temperature. Cell pellets were 
washed twice in phosphate buffer saline (PBS) (Appendix-1) and 5 x 104 cells were 
re-suspended in 250ul 1 x protein sample buffer (Appendix-1) The samples were 
denatured by heating at 95-100oC for 5 min.   
 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 2.3.2
10% acrylamide gels (Appendix-1) were used for SDS-PAGE. The resolving gel 
(Appendix-1) was poured between the plates. The resolving gel was allowed to 
polymerize for 20-30 min and stacking gel (Appendix-1) was poured over it and a 
comb was placed in it. The gel was allowed to polymerize for 30 min and placed in a 
Mini-Protean II apparatus (Bio-Rad) according to manufacturer’s instruction in 1 x 
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SDS running buffer (Appendix-1). After removing comb the wells were washed with 
1 x SDS running buffer to remove any un-polymerised acrylamide. Denatured 
protein samples were loaded onto the gel. One well was loaded with ColourPlus 
Prestained Protein marker (New England BioLabs) for protein size estimation. The 
gel was run at 150-200 Volts (V) for 1-1.5 hr or until the dye front reached the end of 
the gel.  
 Western blotting 2.3.3
Separated proteins in the gel were then transferred to polyvinylidene fluoride 
(PVDF) membrane (Millipore). The transfer was performed using a Semi Dry 
Electroblotter A (Acro). PVDF membrane and 6 pieces of 3MM Chr 
chromatography paper (Whatmann) were cut to the size of gel. The membrane and 
the blotting papers were soaked in methanol and the semidry transfer buffer 
(Appendix-1) respectively prior to use. Three sheets of blotting paper were placed in 
the centre of the anode of electroblotter. The membrane was placed on top of these 
followed by the gel. The remaining three sheets of blotting papers were placed on top 
of the gel and any trapped air bubbles were carefully squeezed out by gently rolling a 
pipette over the top blotting paper. The transfer was performed at 0.4mA/cm2 or 20-
25 V for 30 min.  
The membrane was carefully removed after transfer and rinsed in 1x Tris buffered 
saline (TBS) (Appendix-1). The membrane was transferred to blocking buffer 
(Appendix-1) at 4oC for 1-2 hr and then incubated overnight at 4oC in appropriate 
primary antibody diluted in blocking buffer. The membrane was washed four times 
in TBST for 20 min each.  Bound primary antibody conjugated with horseradish 
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peroxidase (HRP), was detected by incubating the membrane in equal amounts of 
ECL solutions A and B (ECL Plus Western Blotting Detection Kit, GE Healthcare). 
For bound primary antibodies which were not conjugated with HRP, the membrane 
was incubated with an appropriate secondary HRP conjugated antibody in blocking 
for 1 hr. The membrane was washed four times in TBST for 20 min each and bound 
antibody was detected as described above. 
  Tissue culture  2.4
 Culture of adherent cell lines and primary cell lines 2.4.1
Adherent cell lines baby hamster kidney cell (BHK-21), human embryonic kidney 
cells (HEK-293T), Madin-Darby bovine kidney cells (MDBK) and primary sheep 
embryo fibroblasts (SEF) were cultured in polystyrene cell culture flasks or dishes. 
BHK-21 were grown in Glasgow-modified Eagle’s medium (GMEM) (Gibco) 
supplemented with 10% new born calf serum (NBCS), 1% v/v 
penicillin/streptomycin, 1% (v/v) L-glutamine (Sigma) and 10% (v/v) tryptose 
phosphate broth. HEK-293T and SEF were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10-12% foetal calf serum (FCS) and 1% 
penicillin/streptomycin. Media for SEF was also supplemented with 1% (v/v) L-
glutamine.  MDBK were grown in Roswell Park Memorial Institute 1640 medium 
(RPMI-1640) supplemented with 5% FCS and 1% penicillin/streptomycin. Cells 
were cultured at 37oC with 5% CO2.  
Cells were passaged when they reached a cell density of approximately 90%.  
Confluent cells were washed first with phosphate buffered saline (PBS) and then 
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incubated with 0.05% (w/v) trypsin-EDTA (Gibco) for 2-5 min at room temperature 
or 37oC until the cells detached from the bottom of the flask. Cells were then re-
suspended in 5-10 ml of complete media containing FCS. The cells were pelleted by 
centrifugation at 1500 x g for 5 min at room temperature. The supernatant was 
removed and the cell pellet was re-suspended in fresh media. To count the viable 
cells, a sample of the cell suspension was diluted in Trypan Blue Solution (Sigma) 
and unstained live cells were counted in a haemocytometer. Cells were re-seeded at 
approximately 5 x 106 cells/ T175cm2 (Nunc). 
 Culture of suspension cell lines 2.4.2
BJ1035 cell were grown in suspension in Iscove’s Modified Dulbecco’s Medium 
(IMDM) (Invitrogen) (Hart et al; 2007) supplemented with 10% (v/v) FCS, 1% (v/v) 
penicillin/streptomycin and 350 U per ml Proleukin (IL-2) (Novartis 
Pharmaceutical). Cells were incubated at 37oC in 5% CO2. The growth of the cells 
was indicated by the formation of clumps in the suspension. When many large 
clumps were observed, the cells were passaged by pipetting up and down to break the 
clumps and 1/2 of that volume was transferred to a new flask with an equal volume 
of fresh complete medium. Viable cell counting was as described in the section 2.4.1. 
 Preparation of cell Lines for long term storage 2.4.3
For long term storage cells which were 70-80% were removed from the flask (section 
2.5.1) and re-suspended at a concentration of 5 x 106 cells per 1 ml of freezing 
medium containing 90% FCS and 10% v/v dimethylsulphoxide (DMSO). 1 ml of 
suspension was aliquoted in a cryovial, wrapped in cotton wool and slowly frozen 
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overnight at -80oC. The vials were then transferred to liquid nitrogen for long term 
storage.   
 Growing cell lines from frozen stock 2.4.4
Frozen cells were removed from liquid nitrogen and immediately thawed at 37oC. 
The thawed sample was transferred to 10 ml of pre-warmed complete medium. Cells 
were pelleted at 1500 x g for 5 min, re-suspended in 8-10 ml of the pre-warmed 
complete medium and added to a T25 cm2 flask. Cells were then placed in an 
incubator at 37oC with 5% CO2.  
 Transfection of cell lines with plasmid DNA using Lipofectamine 2000 2.4.5
BHK-21 cells and SEF were transfected using Lipofectamine 2000 (Invitrogen) with 
miRNA mimics (miScript miRNA Mimics, Qiagen) or plasmid DNA. The amounts 
and concentrations of Lipofectamine 2000, plasmid DNA/DNAs, miRNA mimics 
and Opti-MEM®  used with cells seeding densities are described as in Table 2.1. 
Cells were plated onto appropriate plates either on the day of transfection (BHK-21) 
or 24hr before transfection (SEF). The appropriate amounts of plasmid DNA with or 
without miRNA mimics and Lipofectamine 2000 were diluted in OptiMEM®  as 
described in Table 2.1. The Lipofectamine 2000 reaction mix was incubated at room 
temperature for 5min prior to addition of pre-mixed plasmid DNA or miRNA mimics 
in OptiMEM®. Samples were mixed and incubated for a further 20min at room 
temperature and added to cells in each well in a drop wise manner. The plates were 
gently swirled for proper mixing and the cells were incubated for 24 hr at 37oC with 
5% CO2.  
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Table 2.1: Detail of the quantities of ingredients used in the transfection of cell 
lines. 
Dish size 6 well plate  96 well plate  96 well plate  24 well plate 
Cell density/well 5 x 105 1 x 104  1 x 104  1 x 105 
Plasmid 1 amount (µg)  4  0.32  0.160  0.4-0.5 
Plasmid2 amount (µg)  ‐  ‐  0.160  ‐ 
Dilution volume for 
Plasmid DNA (µl) 
50  25  25  30 
Lipofectamine 2000 (µl)  10   0.5 0.5 3 
dilution volume for 
Lipofectamine 2000 (µl) 
50  25  25  30 
miRNA mimic 
concentration (nM) 
‐  50 /100   50 /100   25 / 50 
Transfection volume 
(µl) 
3000  150  150  560 
  
 Production of lentivirus particles  2.4.6
Lentivirus particles were generated by transient transfection of HEK293-T cells. 
150cm2 tissue culture dishes were seeded with 2 x 107 cells 24 hr before transfection. 
15µg of transfer vector [tagged AGO2 lentivector (AGO2-PTH) (a generous gift 
from Dr. Finn Grey) or pLenti CMV Blast lenti vector (AddGene) (Appendix-2) 
were used as transfer lentivectors in transfections along with 13.5µg of packaging 
plasmid psPAX2 and 2.5µg of envelop plasmid pMD2.G (generous gifts from Dr. 
Finn Grey). Plasmid DNA and 160µl FuGene® HD were diluted separately in 1650ul 
of OptiMEM® and incubated for 5 min at room temperature. Both mixtures were 
then mixed together and further incubated at room temperature for 15-20 min. The 
mixture was then added drop wise to the cells containing fresh medium with 
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supplements. The plate was rocked back and forth to mix and incbubated at 37oC 
with 5% CO2 for 24 hr. The supernatant containing lentivirus was collected after 24 
hr and then after 48hr. Both collections were pooled, filtered through 0.45µm filters 
(Sartorius) and stored at -80oC. 
 Determination of antibiotic resistance in lentivirus transduced cells (Kill 2.4.7
curve) 
To determine the minimum concentration of the antibiotic which causes complete 
cell death, cells were plated in 8 wells of three 24 well plates at a cell density of 1 
x104 per well. Puromycin (Sigma) and Blasticidin (Sigma) was used as a selection 
marker for the AGO2-PTH lentivirus and pLenti CMV Blast lentivirus respectively. 
Plates were seeded with cells on the same day and cells were added with dilutions of 
antibiotic ranging from 0µg/ml to 7µg/ml. The medium was replaced every 48 hr 
with complete medium containing appropriate antibiotic.  The viability of cells was 
examined for 10-14 days (every 24 hr). The minimum concentration of antibiotic that 
caused complete cell death within 4-6 days was used for subsequent selection of 
lentivirus transduced cells. 
 Transduction with lentivirus particles and selection of transduced cells  2.4.8
Cells were seeded in 24 well plates at a cell density of 1 x 104 per well, in 500µl of 
the medium with supplements, 24 hr before transduction at 37oC and 5% CO2. Cells 
were transduced with appropriate lentivirus (Section 2.5.6).  
Polybrene (Millipore) was used to enhance the efficiency of the lentivirus infection 
and 8µg per ml was diluted in 500µl of the medium with supplements. The original 
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medium was replaced with polybrene containing medium. For suspension cells old 
medium was removed by pelleting the cells by centrifugation at 1500 x g for 3-5 
min. The supernatant was removed and pellet was re-suspended in 500µl of 
polybrene containing media. The lentivirus stock (section 2.4.6) was thawed at 37oC. 
2 fold dilutions of lentiviruses were prepared and the cells were infected by adding 
each dilution in to a separate well. The plates were rocked back and forth to mix and 
incubated at 37oC with 5% CO2. After 24 hr virus containing medium was removed 
and fresh medium with supplements was added to cells. The cells were incubated for 
further 24 hr at 37oC with 5% CO2. The cells were split 48 hr post transduction in the 
medium containing the appropriate concentration of appropriate antibiotic, for 
selection of successfully transduced cells. The medium was replaced with fresh 
antibiotic containing media every 3-4 days until all the un-transduced and control 
cells (un-transduced cells) died. The dilution of virus at which most of the cells 
remained viable after 4-6 days of selection, was used to infect cells in future 
transductions. Antibiotic selection was stopped after 10-14 days and successfully 
transduced cells were transferred into T25 cm2 and then after a 1-2 passages into T75 
cm2 tissue culture flasks for generation of lentivirus expressing stable cell lines.  
 Site directed mutagenesis 2.5
For site directed mutagenesis the Quick Change Site-Directed Mutagenesis 
(Stratagene) protocol was followed.  
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 Mutagenic primers design 2.5.1
Primers for mutagenesis (HPLC purified) (Eurofins MWG Operon, Germany) were 
designed in such a way that each primer was 42-45 bases in length, with a melting 
temperature (Tm) of >78oC. To estimate the primer Tm following formula was used: 
Tm = 81.5 + 0.41(%GC) − 675/ primer length (nt) − % mismatch  
 The desired mutation sites included 6 bp sequences (See Appendix-3 for mutagenic 
primers and mutation sites) in the middle of the primer with ~10-15 bases of correct 
sequence on both sides and desired mutation sites were replaced by restriction 
enzyme site sequence in the primers. Both primers (reverse and forward) in each pair 
annealed to the same region on opposite strands of the plasmid during amplification.  
 Amplification of the mutated plasmid 2.5.2
To amplify the mutated plasmid 50µl reaction mixture was prepared as follows: 
Template DNA   = 20 ng 
10x Pfu DNA polymerase buffer = 5.0 µl 
Forward primer    = 125 ng  
Reverse primer   =125 ng 
dNTPs (10mM)   = 10mM 
ddH2O    = up to 50µl 
then add   
Pfu-Turbo (2.5 units)      = 1.0µl 
 
 




1st cycle = 95° for 30 seconds  
and then 18 cycles of: 
95°C for 30 sec  
55°C for 1 min 
68oC for 1 min per kb of template DNA 
After PCR amplification of the mutated DNA, the parental DNA (template DNA) in 
the reaction mixture was degraded by enzyme Dpn-I (New England BioLabs). 1-2 µl 
Dpn I was added to the PCR product and incubated at 37°C for 1 hr. The DpnI 
digested DNA was transformed into TOP10 chemically competent cells (section 
2.2.3). Plasmid DNA was purified as described in 2.2.4. Successful mutation was 
later confirmed by treating the sample with restriction enzymes (section 2.1.4) and 
by sequencing (section 2.1.8) (Appendix-3 for sequencing primers). Successfully 
mutated DNA templates were used for transfecting the BHK 21 cells (section 2.4.5) 
and for performing luciferase assays (section 2.6) 
 Dual luciferase assays  2.6
Luciferase reporter activity assays were performed using the Dual-Luciferase 
Reporter Assay System (Promega) according to manufacturer’s instruction.  
Transfections were performed in BHK21 cells in triplicate in 24 well plates and in 
six replicates in 96 well plates as described in section 2.4.5.   
The 3’UTRs/regions of genes of interest with predicted binding sites of OvHV-2 
miRNAs were cloned downstream of a renilla luciferase reporter gene (into the 
multiple cloning sites) in the psiCHECKTM-2 Vector (Promega) (Appendix-2 for 
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vector map). The psiCHECKTM-2 vector also possessed a secondary firefly luciferase 
reporter gene which acts as a normalization control for renilla luciferase. Cells were 
co-transfected with reporter vectors with or without the 3’UTR of interest and with 
mimic miRNAs in varying concentrations as described in section 2.4.5 and incubated 
for 24 hr at 37oC with 5% CO2. Medium from transfected cells was carefully 
removed and cells rinsed in PBS. The PBS was carefully removed, and 100µl of 1x 
Passive Lysis Buffer (PLB) was dispensed into each well. The plate was slowly 
shaken for 15 min at room temperature and 20µl of the lysate from each well of a 24 
well plate was transferred to a 1.5 ml tube. 100µl of the lyophilized Luciferase assay 
reagent II (LAR II) was added to the tube and mixed by pipetting. Firefly luciferase 
activity was recorded for 10 sec in DLR-0-INJ Promega GloMax 20/20 Luminometer 
(Promega). To the same tube 100µl of 1xStop & Glo reagent was added and Renilla 
luciferase activity was recorded as above. The procedure was repeated for all 
samples.  
For samples in 96 well plates cells were lysed in 20 µl of the PLB in each well by 
slow shaking for 15 min at room temperature and 10µl lysate from each well was 
transferred to flat bottom opaque 96 well plates. A GloMax® 96 Luminometer 
(Promega) with double injectors was used to measure the luminescence according to 
manufacturer’s instruction. Injector 1 of the luminometer was set to dispense 50µl 
LARII. For measurement, a 1-2sec delay and a 5-10sec read for firefly luciferase 
activity were selected. Injector 2 was then set to dispense 50µl Stop & Glo® 
Reagent, followed by a 1-2sec delay and 5-10sec read time for Renilla luciferase 
activity.  
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For dual luciferase assays for the validation of predicted OvHV-2 miRNA binding 
sites in the 5’UTRs of the genes of interest, 5’UTRs were cloned immediately 
upstream to firefly luciferase reporter gene into the multiple cloning sites in plasmid 
pGL4.10 (Promega). pGL4.10 was co-transfected into BHK-21 cells with mimic 
miRNAs in various concentrations as described in section 2.4.5 and another reporter 
vector PRL (Promega) encoding renilla luciferase gene to normalize the firefly 
luciferase expression. Dual luciferase assays were performed in 96 wells plates as 
described above. 
For luciferase assays to validate the predicted target genes obtained from CLASH 
analysis (Section 4.4.2 and 4.4.4) custom oligonucleotides were created. 
Oligonucleotides were designed in such a way that each primer was 85-90 bases in 
length with the miRNA target site in the middle of the primer. Both primers (reverse 
and forward) were complementary to each other. Restriction sites were put on 5’ and 
3’ ends of each primer. The primer pair was annealed using annealing buffer 
(Appendix-1). To anneal the primers pair 50 µl reaction mixture was prepared as 
follows: 
Primer 1(100 µM): 5 µl 
Primer 2(100 µM): 5 µl 
Annealing buffer: 5 µl 
ddH20:   up to 50 µl 
Chapter 2  Material & Methods 
92 
 
The above reaction mix was incubated to 95oC for 1-2 min and incubated room 
temperature for overnight. The annealed primers and psiCHECK vector were the 
digested with appropriate restriction enzymes, analysed by agarose gel 
electrophoresis, extracted from the gel, cloned and sequenced as described in section 
2.1.5-2.1.9. Successfully cloned vectors were used to carry out luciferase assays as 
described above in this section.  
 Crosslinking , Ligation And Sequnecing of Hybrids (CLASH) 2.7
CLASH (previously called as CRAC) was performed using protocols previously 
described (Granneman et al., 2009, Kudla et al., 2011, Helwak and Tollervey, 2014).  
 Crosslinking of RNA and lysate preparation 2.7.1
3 x 107 AGO2 expressing BJ1035 cells (BJ1035-AGO2) were suspended in 1 ml of 
PBS and spread evenly in a 10cm petri plate on ice (4 plates were used per sample). 
Crosslinking was performed in a Stratalinker® UV Crosslinker (Stratagene) at 
400mj/cm2. Cells were then transferred to 1.5 ml tube and centrifuged at 1500 x g for 
5 min at 4oC. To the cell pellet was added 2.5 ml of ice cold lysis buffer with 
protease inhibitor (appendix-1). Tubes were incubated on ice for 10 min and then 
centrifuged at 14,000 x g for 10 min at 4oC. Supernatant was then stored at -80oC in 
sterile vials. 
AGO2 expressing SEF (SEF-Cluster-3) with or without  OvHV-2 miRNAs 
expression were seeded in 15 cm cell culture dishes at a cell density of 1.2 x 107 per 
plate (10 plates were used per sample). Plates were incubated for 24 hr at 37oC with 
5% CO2. Media was then removed from each plate and cells were washed with cold 
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PBS. Plates were placed on ice and crosslinking carried out as above. After 
crosslinking 1ml of cold lysis buffer with protease inhibitor was added to the cells 
and the cells were removed with a sterile cell scrapper. The lysed cells were 
transferred to 15ml tubes and incubated on ice for 10 min.  The tubes were then 
centrifuged at 14,000 x g for 10 min at 4oC and supernatant was stored at -80oC in 
sterile vials. 
 Conjugation of Dynabeads with rabbit IgG 2.7.2
60mg of Dynabeads (Invitrogen) were re-suspended in 16ml of 0.1M sodium 
phosphate buffer pH7.4 (Appendix-1). Beads were washed with slow agitation on a 
rocking platform for 10min. The tube containing the bead suspension was then 
placed onto a magnetic holder (Dyna MPC-6 Magnetic Particle concentrator) and 
when all the beads were attached to the magnet, the buffer was aspirated. 20µg of 
Rabbit IgG (Sigma) in 0.1M sodium phosphate buffer pH7.4, 3M ammonium 
sulphate (Appendix-1)) was added per mg of washed Dynabeads, and incubated at 
30oC with slow tilt rotation for 16-24 hr. Dynabeads coated with IgG were washed 
on the magnetic  holder, once with 100mM glycine HCl pH2.5, once with 10mM 
Tris pH 8.8, once with 100mM triethylamine, 4 x with PBS and once with PBS 0.5% 
Triton X-100 (Appendix-1 for recipes). Finally the IgG coated Dynabeads were re-
suspended in PBS/0.02% sodium azide (Appendix-1) and stored at 4oC. 
 Small scale RISC immunoprecipitation on Dynabeads  2.7.3
The lysate (section 2.7.1) was added to the IgG coated Dynabeads (200g beads 
/100l sample) and incubated for 45min at 4oC with slow rotation to bind the cross-
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linked complex. The tube with beads was placed in the magnetic holder and when all 
the beads were attached to the magnet the flow through was aspirated and stored at -
20oC. The beads were washed with 5ml of low salt (LS-IgG-WB), 5ml of high salt 
(HS-IgG-WB) washing buffers and 1 x PNK5 (Tris HCl and 5mM 2-mercaptoethanol 
containing buffer) (Appendix-1 for buffers recipes) to remove non-specific 
interaction. All washings were performed on magnetic holder as described in section 
2.7.2. The Dynabeads were then re-suspended in 100l 1 x protein sample buffer 
(Appendix-1). 20-25l of the lysate (section 2.7.2) and the flow through (above) 
were also diluted in 3-5l of 10 x protein sample buffer. Western blot analysis was 
performed on the Dynabeads sample, the flow through sample and the lysate as 
described in section 2.3. 
 Large scale RISC immunoprecipitation on Dynabeads  2.7.4
The lysate (section 2.7.1) was added to the IgG coated Dynabeads (20mg beads /one 
sample) and incubated for 45min at 4oC with slow rotation to bind the RNA in the 
cross-linked complex. The beads were washed with 5ml of low salt (LS-IgG-WB), 
5ml of high salt (HS-IgG-WB) washing buffers and 1 x PNK5 (Tris HCl and 5mM 2-
mercaptoethanol containing buffer) (Appendix-1) to remove non-specific interaction. 
All the washings of Dynabeads were performed on magnetic holder as described in 
section 2.7.2. To reduce the size of cross-linked RNAs Dynabeads were re-
suspended in pre-warmed 500l PNK5 buffer, 0.5 unit RNAseA+T1 mix (1l of 1:20 
dilution in H2O of RNase-IT cocktail) (Agilent) and incubated it for 3min at 20
oC. 
The tube was snap cooled on ice for 1 min and then placed on to the magnetic holder. 
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When all the beads were attached to the magnet, the RNase mix was aspirated off 
and then discarded.  
Cross-linked complexes bound to Dyna-beads were then eluted by washing in a 3 x 
250l of 6M Guanidine-HCl containing buffer (Ni-WB-I) using the magnetic holder 
as described above. Before each elution beads were shaken for 10min at 20oC.  
 Affinity purification of RISC complex on nickel-charged resin 2.7.5
Nickel-charged resin (Ni-NTA superflow, Qiagen) was used for affinity purification 
of 6 x His-tagged protein in the cross-linked complexes in the eluate (section 2.7.4). 
50l of the resin were washed twice with Ni-WB-I buffer by centrifugation at 1000 x 
g for 20-30 sec. 750l of the eluate was then transferred to the resin and incubated at 
4oC for 2hr on a rotating platform. The resin was loaded onto a snap cap 
polyethylene spin column (Pierce) and washed, on the column, once with Ni-WB-I, 
once with buffer without Guanidine-HCl (Ni-WB-II) and once with 1 x PNK5 buffer 
(Appendix-1).  The cap from the bottom of the column was removed after each wash 
to remove the washing buffers by gravity flow and the cap replaced back on the 
column for the subsequent steps. 
 Phosphorylation, dephosphorylation and ligation of resin bound RNA in 2.7.6
cross-linked complexes 
To phosphorylate the RNAs in RISC complexes bound to resins in the column 
(section 2.7.5) the following reaction mix was made in a 1.5 ml tube. 







The above reaction mix was added to the resin in the column and incubated at 20oC 
for 2-3 hr on a thermo-shaker at 500 rpm. In the column a ligation reaction was then 
performed to ligate bound miRNAs to target mRNA in the cross-linked complexes. 
The following reaction mix was prepared in a separate 1.5 ml tube and added to the 





The column was then incubated at 16oC overnight on a thermoshaker at 500 rpm. 
The ligation reaction mix was discarded by gravity flow by removing the cap from 
the bottom of the column. The resin in the column was washed as described in 
section 2.7.4. RNAs in RISC complexes bound to resin in the column were 
dephosphorylated using Thermosensitive Alkaline Phosphatase (TSAP) (Promega). 
The following reaction mix was prepared in a 1.5 ml tube and then added to the 
column: 
ATP (stock 100mM, final 1mM(New England Biolabs) 0.8 µl 
RNAsin (20U/µl stock) (New England Biolabs) 2 µl 
T4 PNK (5µ/µl stock) (New England Biolabs) 4 µl 
5 x PNK10 buffer  (Appendix-2) 16 µl 
Nuclease free water 57.2 µl 
ATP (stock 100mM, final 1mM)  0.8 µl 
RNAsin (20U/µl stock )  2 µl 
T4 RNA ligase I  (New England Biolabs)  4 µl 
5 x PNK10 buffer  16 µl 
Nuclease free water  57.2 µl 
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The resin was then incubated at 20oC for 45min on a thermo-shaker at 500 rpm The 
dephosphorylation mix was discarded and the resin in the column were washed as 
described in section 2.7.4. After dephosphorylation RNA in the cross-linked 
complexes was ligated to 3´linkers (miRCat-33, Integrated DNA Technologies) (3´ 
linker sequence- Appendix-3) using truncated T4 RNA Ligase II (New England 







The above reaction mix was incubated at 16oC, overnight on a thermoshaker at 500 
rpm. The column was then washed as described in section 2.7.4. RNA in the cross-
linked complexes in the column was then radiolabeled with T4 polynucleotide kinase 
(New England Biolabs) and ATP [γ-32P] (6000Ci/mmol, 10mCi/ml EasyTide, 
TSAP  8 µl 
RNAsin (20U/µl  stock)  2 µl 
5 x PNK10 buffer  16 µl 
Nuclease free water   54 µl 
3’ linker (10µM) 8 µl 
T4 RNA Ligase II, truncated  4 µl 
RNAsin (20u/ul stock)  2 µl 
PEG 8000 (stock 25%, final 10%) (New England Biolabs) 32 µl 
5 x PNK10 buffer 16 µl 
Nuclease free water 18 µl 
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250µCi, Perkin Elmer) for visualization. The following reaction mix was prepared in 





Columns were incubated at 37oC, for 40min on a thermoshaker at 500 rpm and then 
washed as described in section 2.7.3. 
 Elution of RNA bound to cross-linked complexes from the nickel resin  2.7.7
Elution of the RNA bound to cross-linked complexes from the nickel resin (section 
2.7.6) was performed with 1ml of imidazole containing elution buffer (Ni-EB-200) 
(Appendix-1) at room temperature. The resin in the column was re-suspended in 200 
µl Ni-EB-200 and incubated in a thermoshaker at room temperature for 5 min. The 
elution was performed by removing the cap at the bottom of the column and eluate 
was collected in a 1.5 ml tube by gravity flow. The elution step was repeated twice 
with 200 µl and 600 µl of Ni-EB-200 respectively in the same 1.5 ml tube as 
described above.  
 
 
32P-γ-ATP 3 µl 
RNAsin (20U/µl stock) 2 µl 
T4 PNK (5U/µl stock) 4 µl 
5 x PNK10 buffer 16 µl 
Nuclease Free Water 55 µl 
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 Trichloroacetic acid (TCA) precipitation of RNA bound to cross-linked 2.7.8
complexes 
200µl of 100% TCA (Appendix-1) was mixed with 1ml of the eluate (section 2.7.7) 
and 2µg of bovine serum albumin (BSA) and the sample was centrifuged for 20min 
at 4oC at 14,000 x g. The pellet was washed twice by centrifugation at 14,000 x g for 
10min with 1 ml of ice cold acetone to remove any remaining TCA and vortexed 
before each centrifugation. The pellet was air dried and re-suspended in 10µl of 
nuclease free water and 10µl of 2 x Sample Buffer (NuPAGE). The sample was 
heated for 10min at 65oC and the RNA bound to cross-linked complexes was 
resolved on a 4–12% BisTris NuPAGE precast gel (Invitrogen) in NuPAGE 1 x 
MOPS SDS running buffer (Invitrogen) in Mini-PROTEAN electrophoresis system 
(BIO-RAD). ColourPlus Prestained Protein marker (BioLabs) was loaded into one 
well for protein size estimation. The gel was run at 150 V for 40min-1 hr or until the 
xylene cyanol reached the end of the gel. The separated proteins were then 
transferred to a Polyvinylidene fluoride (PVDF) membrane (Millipore). The transfer 
was performed using the wet transfer method using NuPAGE Transfer Buffer 
(Invitrogen) with methanol (20% v/v). PVDF, 6 pieces of 3MM Chr chromatography 
paper (Whatmann) and 2 sponges were cut to the size of gel. The membrane was 
soaked in methanol and the blotting papers and sponges were soaked in the transfer 
buffer prior to use. The membrane was then sandwiched between 3 sheets of soaked 
blotting papers and sponges. Trapped air bubbles were carefully squeezed out by 
gently rolling a pipette over the top of blotting papers. The transfer was performed at 
100V for 2hr on ice, in a vertical tank filled with transfer buffer. After transfer the 
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membrane was carefully removed, wrapped in a cling film and exposed to film 
(Kodak BioMax MS-1) for 24 hr at -80oC along with a fluorescent ruler. The film 
was put over the membrane and with a needle the film and the membrane was 
pierced in correspondence to an approximately 100Kd band. Using the holes as 
reference remove the membrane slice out with a sterile blade and transferred into a 
1.5 ml tube.  
 Extraction of the RNA bound to cross-linked complexes from the PVDF 2.7.9
Membrane 
100µg of proteinase K mixed with 400µl of proteinase K mix (Appendix-1) was 
added to the membrane slice (section 2.7.8)  to digest the proteins associated with the 
cross-linked complexes and  was incubated for 2hr at 55oC on thermoshaker at 500 
rpm. The membrane was then removed from the sample and proteinase K treated mix 
was used in the subsequent steps. 
  Phenol: Chloroform: Iso-amylalcohol (PCI) extraction and ethanol 2.7.10
precipitation 
RNA was subsequently extracted by adding 50µl 3M sodium acetate pH5.5 and 
500µl PCI to the proteinase K treated mix (section 2.7.9) and centrifuged at a 14,000 
x g at 4oC for 30 min. The upper phase of the sample was collected and 1ml 100% 
ethanol and 20 µg of glycoblue (Invitrogen) added. The reaction mix was then 
incubated at -80oC for 30min and centrifuged at a 14,000 x g at 4oC for 30min. The 
pellet was washed twice with 1 ml of 70% ethanol by centrifugation at 14,000 x g for 
5min,  air dried and re-suspended in 12.5 µl of nuclease free water. 
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 Phosphorylation and ligation 5´ linkers to the cross-linked RNA 2.7.11
12.5 µl recovered cross-linked RNA (section 2.7.10) was phosphorylated by adding 
1µl polynucleotide kinase, 1.5µl 10 x RNA ligase buffer I and 1mM ATP to make up 
total volume up to 15µl. The reaction mix was incubated for 30min at 37°C on a 
thermoshaker at 500 rpm. The RNA in the reaction mix was then ligated to 1µl 
barcoded 5′ linkers (Appendix-3) (a generous gift from Dr. Finn Grey) with 0.5µl T4 
RNA ligase I (New England Biolabs) and 2.5 µl of nuclease free water  at 16 °C 
overnight on a thermoshaker at 500 rpm. For each sample a different 5’ linker was 
used. After 5′ linker ligation another PCI extraction and ethanol precipitation was 
performed as described in section 2.7.10. The RNA pellet was re-suspended in 8µl of 
nuclease free water. 
 Reverse transcription (RT) and PCR amplification of cDNA 2.7.12
Cross-linked RNA (section 2.7.11) was used as a template for reverse transcription 
using the miRCat-33 primer (Integrated DNA Technologies IDT) for the production 
of cDNA. The following reaction mix was added to the 8µl of cross-linked RNA. 
dNTPs (2.5mM)     4 µl 
3’miRCat RT Primer (10µM)    1 µl 
The sample was incubated at 80oC for 3 min and on ice for 5 min. 6µl of the 
following reaction mix was then added to sample: 
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First Strand Buffer (Invitrogen)   4 µl 
0.1 M Dithiothreitol (DTT)    1 µl  
RNasin (20U/µl stock)    1 µl 
The sample was incubated at 50oC for 3min. 1µl of Superscript III (Invitrogen) was 
added to the sample and further incubated at 50oC for 1 hr. To inactivate the 
Superscript the sample was heated at 65oC for 15min and to degrade template RNA 
2µl RNase H (New England BioLabs) was added to the sample at 37oC for 30 min. 
The sample (cDNA) was used as a template for the PCR amplification. 
PCR was performed using TaKaRa Ex Taq Polymerase (Millipore) and was carried 
out in 0.2 ml thin walled tubes in a PCR Sprint Thermal Cycler, (Thermo Scientific). 
In each reaction 1x PCR buffer with 2mM MgCl2 was mixed with >500ng template 
DNA, 200 mM of both the forward (Invitrogen) and reverse (mirCat-33 IDT) 
primers, 2.5mM each dNTP, 5 I.U of  TaKaRa Ex Taq Polymerase and nuclease free 
water for a total of 50µl. The reaction conditions consisted of  
1 x cycle   initial denaturation at 95oC for 2 min  
21 x cycles of  denaturation at 98oC for 20 sec,  
annealing at 52oC for 20 sec, 
extension at 68oC for 20 seconds  
and a final extension cycle of 5 min at 72oC. 
The PCR product was purified using Qiaquick MINIELUTE Columns (Qiagen) as 
described in section 2.1.4. Purified PCR product was then resolved on 3% 
MethaPhor agarose gels (Lonza) as described in section 2.1.4. PCR fragments of 70-
120bp were excised from the gel. Gel purification of DNA was carried out as 
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described in section 2.1.6. The gel purified products were used as barcoded libraries 
for small scale and high throughput sequencing.   
 Small scale sequencing of gel purified PCR products 2.7.13
For small scale sequencing cloning of the purified cloned (section 2.1.4) into the 
PCR4-TOPO vector as described in section 2.1.8 and then transformed into TOP10 
chemically competent cells as described in section 2.2.3. At least 12 clones per 
sample were picked from the LB agar plate, supplemented with ampicillin and 
plasmid DNA was extracted as described in section 2.2.4. Sequencing of the clones 
was carried out using Big Dye Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems/Ambion) as described in section 2.1.9. The plasmids were sequenced by 
GATC Biotech, Germany. Sanger sequencing results were first analysed with Blast 
(http://blast.ncbi.nlm.nih.gov) to locate 3´ and 5´ linkers. Between pairs of linkers 
sequences of fragments (inserts) were also extracted and analysed with a second 
round of blast for homology with bovine or ovine RNA reference sequences 
(http://blast.ncbi.nlm.nih.gov).  
 High through put sequencing of gel purified PCR products and 2.7.14
bioinformatics analysis 
For high through put sequencing, the barcoded libraries (2.7.12) were pooled 
together and sent to ARK Genomics, The Roslin Institute, University of Edinburgh 
for sequencing by the Illumina Solexa (single-end sequencing, 100bp read length). 
Bioinformatics analysis were carried out in collaboration with Mr. Mick Watson 
(University of Edinburgh) and with the kind help of Dr. Finn Grey (University of 
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Edinburgh) (Section 4.3.1.4). Differentially enriched gene list was obtained using R 
(version 2.13.0) package EdgeR (Robinson, MD, and Smyth, GK., 2008) with p-
<0.05 and to control for false positive predictions a 5% false discovery rate (FDR) 
threshold was applied the datasets (Section 4.3.2.8). 
 Microarray study 2.8
 RNA processing and array hybridization 2.8.1
Total RNA was isolated as described in Section 2.1.10. A total 5 µg RNA per sample 
was sent to ARK Genomics, The Roslin Institute, University of Edinburgh. Samples 
were processed using Ambion GeneChip Whole Transcript Sense Target Labelling 
Assay and the microarray was run. Briefly total RNA of each sample was used as a 
template for synthesis of single stranded cDNA. Single stranded cDNA was then 
converted to double stranded cDNA which was then used as a template to generate 
antisense cRNA and amplified by in vitro transcription. cRNA was then purified and  
used for the synthesis of second cycle cDNA using random primers and the dUTP + 
dNTP.  cRNA was degraded using RNase H leaving intact single stranded cDNA.  
single stranded cDNA was purified to remove enzymes, salts and unincorporated 
dNTPs. 5.5 µg of cDNA was then fragmented, labelled, hybridized  to the 
Affymetrix GeneChip ovine 1.0 ST array and scanned by following the 
manufacturer’s protocol using The Affymetrix GeneChip® Whole Transcript 
Terminal Labelling kit and GeneChip® Hybridization, Wash, and Stain Kit.  
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 Microarray analysis 2.8.2
The analysis of the microarray data was performed with the help of Miss Alison 
Downing from ARK Genomics using Partek Genomic suite (Section 4.3.2.9). 
Differentially expressed genes with a statistical significance of p<0.05 were 
identified using ANOVA. A 5% false discovery rate was applied to avoid false 
positive predictions.  
 Software and programmes 2.9
 BLAST (Basic Local Alignment Search Tool) 2.9.1
http://blast.ncbi.nlm.nih.gov/Blast.cgi 
The nucleotide blast algorithms blastn was used to align a nucleotide query against 
nucleotide database available in GenBank (http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
 RNAhybrid 2.9.2
http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/welcome.html 
RNAhybrid was used for miRNA target prediction. It is a tool for finding minimum 
free energy (mfe) hybridization of a long and short RNA. 
 UNAfold 2.9.3
http://eu.idtdna.com/Unafold/ 
UNAfold is used for nucleic acid folding and hybridization prediction. It provides 
multiple folding of single-stranded RNA or DNA or hybridization between two 
single strands at different mfe (Markham and Zuker, 2008).  
 IBM SPSS statistics 22 2.9.4
http://www-01.ibm.com/software/uk/analytics/spss/ 
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SPSS statistics 22 was used to perform ANOVA and Post Hoc Tuckey’s HSD 
multiple comparison test to find the significance difference between the groups 
(Section 3.3.2). 
 Ingenuity Pathway analysis (IPA) 2.9.5
http://www.ingenuity.com/products/ipa 
IPA was used to interpret the data in the context of biological processes and 
canonical pathways and to analyse the involvement of different genes in different 
molecular and cellular functions (Section 4.3.2.12). 
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Note: This work has been published in (Riaz et al., 2014) (Appendix-4).  
  Aim 3.1
The aim of this study was to determine if OvHV-2 miRNAs target the predicted 
OvHV-2 ORFs.  
 Introduction 3.2
The identification and validation of predicted miRNAs targets is essential to allow an 
understanding of miRNA functions. The most common experimental approach for 
the analysis of the interaction of miRNAs with their predicted mRNAs targets is a 
reporter gene assay. After transient transfection into a cell, a miRNA binds to its 
specific mRNA target site and represses the reporter protein production, thereby 
reducing activity/expression of the reporter gene (Kuhn et al., 2008). In this study the 
validation of viral miRNAs (ovhv2-miRs) targets within the OvHV-2 genome was 
performed using dual luciferase assays. OvHV-2 encodes 46 predicted miRNAs; 
eight of which were validated by northern blot analysis (Levy et al., 2012). 
Bioinformatic analysis predicted several possible targets for these eight miRNAs 
within the OvHV-2 genome.  In this study six of the OvHV-2 ORFs which had 
predicted target sites for the ovhv2-miRs within their 5´UTR or 3´UTR, were 
selected for functional validation. The genes selected for the validation are predicted 
to be involved in virus replication/latency. These ORFs were Ov2, ORF20, ORF36, 
ORF49, ORF50 and ORF73. The functions of these ORFs in related 
gammaherpesviruses and the ovhv2-miRs which target them are described below: 
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 OvHV-2 Ov2 3.2.1
Ov2 is one of the unique ORFs of OvHV-2 and its transcript was also highly 
expressed in the BJ1035 cells (Levy PhD thesis, 2012). Ov2 is homologous to A2 in 
AlHV-1 and is predicted to encode a protein containing a basic leucine-zipper (bZIP) 
motif. It is also homologous to activating transcription factor (ATF), cAMP response 
element binding protein (CREB) and Jun dimerization proteins (Ensser et al., 1997, 
Hart et al., 2007). ATF is a member of the ATF/CREB family of transcription factors 
and can regulate gene expression by binding to the consensus ATF/CREB cis-
regulatory element via a bZIP domain (Wang et al., 2012). Martinez & Tang showed 
that the leucine zipper domain was required for the interaction of the KSHV bZIP 
protein with histone deacetylase and this interaction is important for KSHV 
replication (Martinez and Tang, 2012).  
ovhv2-miR-4 has a predicted target site in the 3´UTR of Ov2. 
 OvHV-2 ORF20 3.2.2
In related herpesviruses, homologues of ORF20 (UL24 in HSV-1, UL76 in HCMV 
and ORF20 in KSHV and MHV-68) are involved in controlling cell cycle. MHV-68 
ORF20 was characterized as being a nuclear protein which localized in the nucleus 
and caused cell cycle arrest at the G2/M phase of cell cycle, possibly leading to 
apoptosis. Its mechanism of action is to maintain Cdc2 in its phosphorylated inactive 
state, such that Cdc2–cyclin B complexes in cells expressing ORF20 exhibit little or 
no kinase activity (Nascimento et al., 2009, Nascimento and Parkhouse, 2007). In a 
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previous study in our laboratory it was shown that, like MHV-68 ORF20, OvHV-2 
ORF20 also localizes to the nucleus (Levy PhD thesis, 2012). 
ovhv2-miR-5, ovhv2-miR-6 and ovhv2-miR-7 have  predicted target sites in the 
3´UTR  and ovhv2-miR-2, ovhv2-miR-4 and ovhv2-miR-5 have predicted target 
sites in the 5´UTR of ORF20. 
 OvHV-2 ORF36 3.2.3
OvHV-2 ORF36 has homology to protein kinases which are conserved among the 
Herpesviridae family (ORF36 of KSHV, UL13 of HSV, ORF47 of VZV and BGLF4 
of EBV). These kinases share motifs with mammalian serine/threonine protein 
kinases (Kawaguchi et al., 2003). Herpesviruses utilise their protein kinases not only 
to regulate their own replicative processes but also to modify the host cellular 
machinery by phosphorylating target machinery (Kawaguchi and Kato, 2003). The 
importance of herpesvirus protein kinases for viral replication and disease has been 
investigated. Kinase-null mutants generated in alpha, beta, and gammaherpesviruses 
demonstrate decreased replication in tissue culture. Decreased virulence of HSV and 
VZV null mutants was also observed in a mouse model (Hamza et al., 2004).  
ovhv2-miR-8 has a predicted target site in the 3´UTR of ORF36. 
 OvHV-2 ORF50 3.2.4
OvHV-2 ORF50 is a homologue of ORF50 (KSHV, RRV, MHV68 and AlHV-1) 
and BRLF1 of EBV (Damania et al., 2004, Gonzalez et al., 2006, Hart et al., 2007). 
ORF50 encodes a viral immediate-early transactivator protein; Rta (Section 1.3.2). In 
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KSHV this protein is indispensable for reactivation from latency and introduction of 
ORF50 into the latently infected cells alone is sufficient to initiate the viral lytic 
cascade (Damania et al., 2004) which results in viral protein production, assembly 
and release of virus. Rta can also initiate transcriptional activation of viral promoters, 
by binding in a sequence specific manner to viral DNA via Rta responsive elements, 
which in turn can start a cascade of lytic lifecycle (Sun et al., 1998). Thonur et al 
showed expression of OvHV-2 ORF50 and some other productive genes in OvHV-2 
infected T cells after treating those with drug doxorubicin (Thonur et al., 2006). A 
transient peak in OvHV-2 DNA and OvHV-2 transcripts including ORF50 was also 
found in lungs of bison experimentally infected with OvHV-2, 9-12 days post 
infection, suggesting occurrence of viral replication (Cunha et al., 2012).   
ovhv2-miR-5 has one predicted target site in the 3’UTR, ovhv2-miR-3 and ovhv2-
miR-8 has one predicted target site each in the CDS and ovhv2-miR-6 has one 
predicted target site in the 5’UTR  of ORF50. 
 OvHV-2 ORF49 3.2.5
In both KSHV (Gonzalez et al., 2006) and MHV68 (Lee et al., 2007) ORF49 lies 
adjacent and in the opposite orientation to ORF50. The protein encoded by ORF49 is 
expressed during the KSHV lytic cycle and shows early transcription kinetics. 
ORF49 is able to cooperate with ORF50 to activate several KSHV lytic promoters 
and could induce phosphorylation and activation of the transcription factor c-Jun, the 
Jun N-terminal kinase (JNK), and p38. The work suggests that ORF49 protein 
functions to activate the JNK and p38 pathways during the KSHV lytic cycle 
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(Gonzalez et al., 2006). The EBV homologue of ORF49 (BRRF1) has been shown to 
act as a transcriptional transactivator that co-operates with the BRLF1 to induce lytic 
replication in certain cell types (Hong et al., 2004). Hart et al  predicted that OvHV-2 
encodes an ORF49 homologue while AlHV-1 does not (Hart et al., 2007).  
ovhv2-miR-6 has two predicted target sites in 3’UTR of ORF49 (Fig-6). 
 OvHV-2 ORF73 3.2.6
ORF73 is predicted to encode for the latency-associated nuclear antigen (LANA) in 
KSHV and functions to transactivate the viral latent origin of replication and tethers 
viral episomes to host chromosomes, thereby ensuring faithful segregation of the 
viral genome during cell mitosis (Grundhoff and Ganem, 2003). LANA and its 
functional homologue EBNA1 in EBV are consistently expressed in cells during 
latency and are crucial for the maintenance of viral episome in proliferating cells 
(Purushothaman et al., 2012, Sivachandran et al., 2012). 
ovhv2-miR-6 has one predicted target site each in the 3´UTR  and 5’UTR of ORF73 
whereas ovhv2-miR-8 has two predicted target sites in the 5´UTR of ORF73. 
There is no suitable cell culture system to propagate OvHV-2 therefore it is difficult 
to study the regulation of viral proteins under the influence of OvHV-2 encoded 
miRNAs. To confirm if the miRNAs are targeting the predicted targets in the 3´UTR 
or in the 5´UTR of the selected ORFs and for the functional validation of those 
targets sites, dual luciferase reporter assays were performed. The reduction of 
luciferase expression due to the targeting of miRNA target site/s upon treatment with 
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corresponding miRNA/s is easily measurable and expression of control luciferase 




















 Investigation of OvHV-2 miRNA regulation of OvHV-2 ORFs  3.3.1
To investigate the effect of Ovhv2-miRs on the expression of the OvHV-2 ORFs 
containing predicted target sites (Section 3.2), luciferase assays were performed. The 
3´UTRs of Ov2, ORF20, ORF36, ORF49, ORF50, ORF73 and the 5´UTR of ORF20 
and ORF73 were selected for OvHV-2 miRNA target validation. To determine the 
potential regulatory effect of these miRNAs, 3´UTRs and 5´UTRs of the selected 
ORFs were amplified by PCR. For 3´UTRs primers were designed for the regions 
from the stop codon to the predicted polyA site. For the 5´UTRs primers were 
designed for the region from the start codon to 1000 bp upstream to allow correct 
expression from the natural promoter. For each ORF a separate PCR was setup and 
carried out using template DNA isolated from BJ1035 cells (Section 2.1.1). 
Successfully amplified 3´UTRs were cloned into the psiCHECK plasmid 
downstream of the renilla luciferase reporter gene (Rluc) and 5´UTRs were cloned 
into the pGL4.10 plasmid upstream of the firefly luciferase reporter gene (Fluc). 
BHK21 cells were co-transfected with the 3´UTRs constructs (LUC/Ov2-3’, 
LUC/20-3’,LUC/36-3’,LUC/49-3’,LUC/50-3’and LUC/73-3’) or the 5´UTRs cloned 
plasmids (LUC/20-5’ and LUC/73-5’) with or without test or control miRNAs.  
Samples were harvested and luciferase levels were measured after 24 hrs (Section 
2.6). The predicted targets which showed a significant knockdown in luciferase gene 
expression compared to their controls were then tested again by knocking out the 
predicted target sites using site directed mutagenesis (Section 2.5).  
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For site directed mutagenesis the parental luciferase constructs were used as template 
and a mutation was introduced in the predicted target site. Successfully mutagenized 
plasmids and template plasmids were used to perform luciferase assays (Section 2.6) 
to determine if there was a significant difference in luciferase gene expression with 
and without miRNA target sites. 
 Validation of OvHV-2 miRNAs targets in the 5’UTR of the selected 3.3.2
OvHV-2 ORFs 
BHK21 cells were co transfected with the LUC/20-5’ or the LUC/73-5’ luciferase 
constructs along with the PRL-TK plasmid (PRL) (Appendix-2). PRL contains a 
gene encoding Rluc and was used as an internal control to allow normalization of the 
Fluc expression. Test or control miRNAs were also transfected in two different 
concentrations (50 nM and 100 nM). All the transfections were carried out in 96 well 
plates for 24 hours. The pEGFP-N3 (Clontech) plasmid was used as a transfection 
control. For each region of interest three independent experiments were performed 
with 6 replicates for each sample. The following combinations were tested for each 
target: 
1. No transfection (control) 
2. Mock transfection (control) 
3. pEGFP-N3 (transfection control) 
4. Empty vector (control) 
5. Empty vector + target miRNA mimics (control) 
6. Target in pGL4.10 (positive control) 
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7. Target in pGL4.10 + each of the test miRNA mimics (Test) 
8. Target in pGL4.10 + all of the test miRNAs mimics (Test) 
9. Target in pGL4.10 + scramble miRNA (negative control) 
10. Target in pGL4.10 + irrelevant miRNA mimic (mimics of Ovhv2-miRs that 
were not predicted to target the 5’UTR of the selected ORF and were used as 
additional negative control) 
After 24 hours samples were harvested and luciferase levels were measured. The 
non-transfected and mock transfected sample values were used to correct for 
background luciferase readings. Corrected Fluc to corrected Rluc luciferase ratio 
values (Fluc/Rluc) were calculated. To calculate luciferase activity, luciferase level 
of each sample was compared with the mean luciferase level of the negative control 
(scramble miRNA) value. To determine if there was a significant difference between 
groups, a Post Hoc Tukey’s HSD (honest significant difference) multiple comparison 
test was performed followed by a single factor analysis of variance (ANOVA). For 
all experiments an empty vector (lacking OvHV-2 ORF’s sequence) was used to 
investigate off-target effects however no significant reduction in luciferase 
expression was observed using any of the ovhv2-miRs (Supplemental data file-3.1). 
  Validation of ORF73 as a predicted target of ovhv2-miR-6 and ovhv2-3.3.2.1
miR-8  
No significant changes were observed in the expression of the luciferase gene tagged 
with the 5’UTR of ORF73 when test miRNA mimics (ovhv2-miR-6, 8 or 6+8) or 
irrelevant miRNA (ovhv2-miR-7) were used at 50 nM concentration [(LUC/73-
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5’+miR7) p=0.999, (LUC/73-5’+miR6) p=1, (LUC/73-5’+-miR8) p=0.945, 
(LUC/73-5’+miR6+8) p=0.997]. While in the absence of any miRNA (test or 
control), the 5’UTR ORF73 showed a significantly higher luciferase expression 
[(LUC/73-5’) p>0.001]. Following co-transfection with 100 nM of ovhv2-miR-8, 
ORF73 showed a significant ~50% reduction in luciferase expression in comparison 
to negative control [(LUC/73-5’+miR8) p=0.002]. At 100 nM ovhv2-miR-6, ovhv2-
miR-6+8 and ovhv2-miR-7 showed a non-significant difference [(LUC/73-5’+miR6) 
p=1, (LUC/73-5’+miR6+8) p=0.479, (LUC/73-5’+miR7) p=1]. Consistent with the 
observations made at 50 nM, a significant enhancement of luciferase expression, 
over the negative control at 100 nM concentration, was seen in the absence of 
miRNAs (test or control) [(LUC/73-5’) p>0.001] (Figure 3.1). Sequencing analysis 
later revealed a one bp difference in the predicted target region of ovhv2-miR-6 in 
the 5’UTR of ORF73 in the BJ1035 isolate used in this experiment compared to the 
published ORF73 sequence (Figure 3.3). 
 Site directed mutagenesis to remove ovhv2-miR-8 sites in the 5’UTR of 3.3.2.2
ORF73 
Luciferase assays showed a significant reduction in luciferase expression with the 
5’UTR of ORF73 in the presence of 100 nM of ovhv2-miR-8 (Section 3.3.2.1). To 
analyse if the knockdown was due to specific targeting of the 5’UTR of ORF73 at 
the predicted ovhv2-miR-8 target sites, the sites were deleted by site directed 
mutagenesis (Section 2.5). The 5’UTR ORF73 was predicted to contain two ovhv2-
miR-8 target sites and each site was replaced by an appropriate restriction site 
(Appendix-3).  BHK21 cells were transfected with either ovhv2-miR-8 target site 1 
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deleted luciferase construct (LUC/73-5’-M1) or ovhv2-miR-8 target site 2 deleted 
luciferase construct (LUC/73-5’-M2). Parental template plasmid (LUC/73-5’) was 
transfected separately as a positive control. For each luciferase assay the following 
combinations were tested;  
1. Mutagenized or parental template constructs + ovhv2-miR-8 (test miRNA; 100 
nM concentration) 
2. Mutagenized or parental template constructs  +  negative control (scramble 
miRNA; 100 nM concentration) 
3. Mutagenized or parental template constructs  + irrelevant mimic miRNA 
(ovhv2-miR-7 an additional negative control; 100 nM concentration) 
The Fluc and Rluc values were corrected and Fluc/Rluc ratios of each group were 
calculated with respect to the negative control of the same group (Section 3.3.2). The 
parental template construct showed a significant repression in the luciferase 
expression with ovhv2-miR-8 and a significantly higher expression with ovhv2-miR-
7 as compared to the negative control [(LUC/73-5’+miR8) p>0.001, (LUC/73-5’-
miR7) p>0.001]. Deletion of ovhv2-miR-8 sites from the 5’UTR of ORF73 restored 
the luciferase expression levels to that comparable to the negative control [(LUC/73-
5’-M1+miR-8) p=0.08, (LUC/73-5’-M2+miR-8) p=0.102] (Figure 3.2).  
These results showed that deleting either the ovhv2-miR-8 site1 or the ovhv2-miR-8 
site2 from the 5’UTR of ORF73 caused a more than 20% and 50% increase in 
luciferase expression respectively as compared to the parental construct in the 
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presence of ovhv2-miR-8. This data strongly suggests that ovhv2-miR-8 can interact 














Figure 3.1: Luciferase expression levels in BHK21 cells transfected with the 
5’UTR of ORF73 luciferase construct (in the pGL4.10 plasmid) in the 
presence/absence of target miRNA at 100 nM concentration. 
Data is represented as luciferase activity with the *=p<0.05 and ***=p<0.001 
relative to the respective scramble miRNA (negative control) (light grey) value at 
100 nM concentration.  
 




Figure 3.2: Luciferase expression levels in BHK21 cells transfected with the 
5’UTR of the ORF73 luciferase constructs (in pGL4.10 plasmid) with or without 
deletion in the test miRNA target sites in the presence or absence of test miRNA 
at 100 nM concentration. 
 Data is represented as luciferase activity with the *=p<0.05, **=p<0.01, 
***=p<0.001 relative to the respective scramble miRNA (negative controls) (light 
grey) value at 100 nM concentration. Mimic of Ovhv2-miR-8 was used as test 
miRNA and ovhv2-miR-7 was used as an additional negative control miRNA.  




Figure 3.3: The 5’UTR of the OvHV-2 ORF73. 
 The 5’UTR of the OvHV-2 ORF73 (in black) amplified by polymerase chain 
reaction (PCR) has a one nucleotide difference in the predicted target region of 
ovhv2-miR-6 (highlighted in orange) from the published OvHV-2 strain BJ1035 
(AY839756.1) ORF73 5’UTR sequence (in red). Black boxes show two predicted 
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 Validation of ORF20 as a predicted target of ovhv2-miR-2  3.3.2.3
Co-transfection of the luciferase construct containing the 5’UTR of ORF20 
(LUC/20-5’) with ovhv2-miR-2 at both 50 nM and 100 nM concentrations resulted 
in a significant reduction, approximately 40% and 50% in luciferase expression 
respectively in comparison to the negative control [(LUC/20-5’-miR2, 50 nM) 
p>0.001, (LUC/20-5’-miR2, 100 nM) p>0.001]. 50 nM of ovhv2-miR-5 showed a 
significant increase [(LUC/20-5’miR5, 50 nM) p=0.015] but this effect was lost at 
the higher concentration tested (100 nM) [(LUC/20-5’+ovhv2-miR-5, 100 nM) 
p=0.064]. The presence of ovhv2-miR-4 at 50 nM and 100 nM showed no significant 
effect [(LUC/20-5’+miR4, 50 nM) p=0.434, (LUC/20-5’+miR4, 100 nM) p=0.982]. 
All of the three test miRNAs were also used together at a final concentration of either 
50 or 100 nM. At 50 nM no significant effect on luciferase expression on ORF20 
was observed while at 100 nM a significant knockdown in luciferase activity was 
observed [(LUC/20-5’miR2-4-5, 50 nM) p=0.939, (LUC/20-5’+miR2-4-5, 100 nM) 
p=0.021]. The ovhv2-miR-7 at 50 nM and 100 nM showed no significant difference 
to negative control [(LUC/20-5’+miR7, 50 nM) p=0.663, (LUC/20-5’+miR7, 100 
nM) p=0.975]. The ORF20 construct without control or test miRNAs showed a 
significantly higher expression in luciferase expression when compared to the 
negative control [(LUC/20-5’, 50 nM) p>0.001, (LUC/20-5’, 100 nM) p>0.001]. 
Figure 3.4 shows the results with 100 nM mimic concentrations.  
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 Site directed mutagenesis to remove predicted ovhv2-miR-2 sites in the 3.3.2.4
5’UTR of ORF20 
In order to confirm observed reduction in luciferase expression of LUC/20-5’ 
(Section 3.3.2.1) with the ovhv2-miR-2 and not with the other miRNAs tested 
(ovhv2-miR-4 and ovhv2-miR-5), deletion of the ovhv2-miR-2 site was performed 
by site directed mutagenesis (Section 2.5). BHK21 cells were transfected with 
ovhv2-miR-2 target site deleted luciferase construct (LUC/20-5’-M). Parental 
template plasmid (LUC/20-5’) was transfected separately as a positive control. For 
each luciferase assay different combinations as described in Section 3.3.2.2 were 
tested. The Fluc and Rluc values were corrected and Fluc/Rluc of each group were 
calculated as described in Section 3.3.2.  
No abrogation of inhibition was observed in levels of luciferase expression when 
LUC/20-5’-M was co-transfected with ovhv2-miR-2 as compared to that of the 
parental template [(LUC/20-5’+miR2) p>0.001, (LUC/20-5’+miR7) p=0.032, 
(LUC/20-5’-M+miR2) p>0.001, (LUC/20-5’-M+miR7) p=0.002] (Figure 3.5). Both 
ORF20 constructs (parental and mutated) showed a 50 to 60% reduction in the 
luciferase activity as compared to that of the negative controls. These results suggest 
that the observed reduction of ORF20 (Figure 3.4) is not a direct result of miRNA 
binding to the predicted target site and may require the presence of other 
factors/target sites not yet identified.   
Subsequently bioinformatic analysis identified at least three more target sites with 
G:U pairing in the seed region in the 5’UTR of OvHV-2 ORF20. The presence of 
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these additional putative binding sites may explain the failure to recover the 











Figure 3.4: Luciferase expression levels in BHK21 cells transfected with the 
5’UTR of ORF20 luciferase construct (in the pGL4.10 plasmid) in the 
presence/absence of target miRNA at 100 nM concentration. 
Data is represented as luciferase activity with the *=p<0.05, **=p<0.01 and 
***=p<0.001 relative to the respective scramble miRNA (negative control) (light 
grey) value at 100 nM concentration.  
 




Figure 3.5: Luciferase expression levels in BHK21 cells transfected with the 
5’UTR of the ORF20 luciferase constructs (in pGL4.10 plasmid) with or without 
deletion in the test miRNA target sites in the presence or absence of test miRNA 
at 100 nM concentration. 
Data is represented as luciferase activity with the *=p<0.05, **=p<0.01, 
***=p<0.001 being relative to the respective scramble miRNA (negative controls) 
(light grey) value at 100 nM concentration. Mimic of Ovhv2-miR-2 was used as test 
miRNA and ovhv2-miR-7 was used as an additional negative control miRNA.  
 
 

























Figure 3.6: Interaction between the predicted target sites and the seed region of 
ovhv2-miR-2 in 5’UTR of ORF20 with secondary structures predictions (right 
panel) using RNA hybrid programme. 
A:  predicted target site with perfect base pairing in the seed region. 
B, C and D:   predicted target sites with G:U pairing (in yellow) the seed region. 
Red:  Target sequence, Black: miRNA sequence 
mfe: Minimum free energy  
target 5'  C    U       CCUCCUC       U 3'   
   ACUG     UGU       CCAAGAU 
   UGAC     ACG       GGUUCUA 
miRNA  3' GA    UGUCU   CA              5' 
target 5'     A  U               G 3' 
               GG CAGA    UCCAGGG     
               CU GUCU    AGGUUCU     
miRNA  3' GAUGA       ACGC       A 5'
 
target 5'     A      C  G CACA       C 3' 
               GACAGG UG G    UCCAGGG     
               CUGUCU AC C    AGGUUCU     
miRNA  3' GAUGA         G            A 5' 
 
target 5' C  C   GAC        UUCACGUAGCAACA       U3' 
           CU CUG   ACAG UGC              CUGAGAU     
           GA GAC   UGUC ACG              GGUUCUA     
miRNA  3'    U          U   CA                    5' 
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 Validation of ovhv2-miR predicted targets located in the 3’UTRs of 3.3.3
selected ORFs 
The 3’UTRs of selected ORFs were cloned into the psiCHECK plasmid downstream 
of the Rluc translation stop codon (Section 2.6, Section 3.3.1). This vector also 
contained firefly luciferase, a second reporter gene, which acted as an internal 
control and allowed the normalization of Renilla luciferase expression. A positive 
control, psi-M23-2 (psiCHECK vector with the complementary sequence to mcmv-
miR-M23-2, kindly donated by Dr. Amy Buck, University of Edinburgh) was used 
and transfected with or without mcmv-miR-M23-2 mimic in the same concentrations 
as used for the test miRNAs. The pEGFP-N3 plasmid was used as a transfection 
control. The following combinations were tested for each target: 
1. No transfection control 
2. Mock transfection control 
3. pEGFP-N3 control (transfection control) 
4. psi-M23-2 
5. psi-M23-2 + mcmv-miR-M23-2 mimic (positive control). 
6. psiCHECK (no 3’UTR control) 
7. psiCHECK + target miRNA mimic/s 
8. Target in psiCHECK without test or control miRNAs mimic (no miRNA 
control) 
9. Target in psiCHECK  with each of the test miRNA mimic (Test) 
10. Target in psiCHECK with all of the test miRNAs mimics (Test) 
11. Target in psiCHECK with scramble miRNA (negative control) 
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After 24 hours samples were harvested and luciferase levels were measured. The 
non-transfected and mock transfected samples were used to correct for background 
luciferase readings. Corrected Rluc/Fluc ratios were used to calculate fold difference 
by dividing each of the Rluc/Fluc value with the mean of the Rluc/Fluc of the 
negative control value. The remaining statistical analysis was performed as described 
in Section 3.3.2.  For positive controls a one tailed independent t-test was performed.  
 Validation of the ORF50 as an ovhv2-miR-5 predicted target  3.3.3.1
Introduction of ovhv2-miR-5 at both concentrations led to a significant reduction of 
approximately 40% at 50 nM and approximately 50% at 100 nM, in the luciferase 
expression relative to the negative controls, [(LUC/50-3’-miR5, 50 nM) p>0.001, 
(LUC/50-3’-miR5, 100 nM) p>0.001] (Figure 3.7). LUC/50-3’ in the absence of any 
miRNA showed a non-significant and a significant difference in luciferase 
expression from the scramble negative control at 50 nM and 100 nM concentration 
respectively [(LUC/50-3’) p=0.871, (LUC/50-3’, 100 nM) p=0.002].  
The positive control psi-M23-2 co-transfected with mcmv-miR-M23-2 mimic 
showed a significant 80% and 90% decrease in the luciferase expression at both 50 
nM and 100 nM [(psi-M23-2/miR-M23-2, 50 nM) p>0.001, (psi-M23-2/miR-M23-2, 
100 nM) p>0.001] respectively (Figure 3.8). In all the other experiments positive 
controls (psi-M23-2 and miR-M23-2) worked in the same manner, that is the 
addition of miR-m23-2 caused significant knockdowns in the luciferase levels at 
either concentration (Luciferase readings in the Supplemental data file 3.1) and for 
the subsequent experiments the data is not shown.  




Figure 3.7: Luciferase expression levels in BHK21 cells transfected with the 
3’UTR of ORF50 luciferase construct (in the psiCHECK-2 plasmid) in the 
presence/absence of target miRNA at 100 nM concentration. 
Data is represented as luciferase activity with the *=p<0.05 relative to the respective 
scramble miRNA (negative control) (light grey) value at 100 nM concentration.  
 




Figure 3.8: Positive control for dual luciferase assay. 
Untreated samples (psi-m23-2) are shown in light grey while experimentally treated 
samples (with miR-m23-2) are shown in dark grey. Data is represented as luciferase 







Chapter 3                                      Analysis of OvHV-2 ORFs as Ovhv2-miRs Targets 
133 
 
 Site directed mutagenesis to remove ovhv2-miR-5 sites in the 3’UTR of 3.3.3.2
ORF50 
To confirm if the reduction in the luciferase expression (Section 3.3.3.1) was due to 
the targeting by ovhv2-miR-5 at the predicted target site in the 3’UTR of ORF50, the 
site was deleted by site directed mutagenesis (Section 2.5). BHK21 cells were 
transfected with ovhv2-miR-5 target site deleted luciferase construct (LUC/50-3’-M) 
or template plasmid (LUC/50-3’). For each luciferase assay following combinations 
were tested: 
1. Mutagenised or template construct + test miRNA mimic (test) 
2. Mutagenised or template construct + scramble miRNA (negative control) 
3. psi-M23-2 (positive control without targeting miRNA) 
4. psi-M23-2 + mcmv-miR-M23-2 mimic (positive control with targeting 
miRNA). 
The Rluc and Fluc values were corrected and Rluc/Fluc ratios of each group were 
calculated as described in section 3.3.3.  
The parental template construct showed a significant repression in the luciferase 
expression with ovhv2-miR-5 as compared to the negative control [(LUC/50-3’-
miR5, 100 nM) p>0.001)]. Deletion of the ovhv2-miR-5 target site from the 3’UTR 
of ORF50 restored the luciferase expression levels to that comparable to the negative 
control [(LUC/50-3’-M-miR5, 100 nM) p=0.837] (Figure 3.9).  
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These results indicated that the decrease in transcriptional activity was caused by the 
ovhv2-miR-5 site and abrogation of luciferase inhibition achieved by knocking out 
the target site provides evidence that the ovhv2-miR-5 site in 3’UTR of ORF50 











Figure 3.9: Luciferase expression levels in BHK21 cells transfected with the 
3’UTR of the ORF50 luciferase constructs (in psiCHECK plasmid) with or 
without deletion in the test miRNA target sites in the presence or absence of test 
miRNA at 100 nM concentration. 
Data is represented as luciferase activity with the *=p<0.05 relative to the respective 
scramble miRNA (negative controls) (light grey) value at 100 nM concentration. 
Mimic of ovhv2-miR-5 was used as a test miRNA.  
 
 
Chapter 3                                      Analysis of OvHV-2 ORFs as Ovhv2-miRs Targets 
136 
 
 Validation of ORF20 as predicted target for ovhv2-miR-5, 6 and 7 3.3.3.3
According to the results all the samples including the controls and tests treated with 
50 nM targeting mimic showed a non-significant difference in luciferase expression 
from the negative control [(LUC/20-3’) p=1, (LUC/20-3’-miR5-6-7, 50 nM) p=1, 
(LUC/20-3’-miR5, 50 nM) p=0.898, (LUC/20-3’-miR6, 50 nM) p=0.999, (LUC/20-
3’-miR7, 50 nM) p=0.989]. In the absence of any miRNA, LUC/20-3’showed a 
significantly higher luciferase expression compared to negative control at 100 nM 
concentration [(LUC/20-3’) p=0.001]. In contrast, psi-ORF20 co-transfected with all 
or either of the targeting mimic showed a non-significant increase compared to the 
negative control [(LUC/20-3’-miR5-6-7, 100 nM) p=0.194, (LUC/20-3’-miR5, 100 
nM) p=0.625, (LUC/20-3’-miR6, 100 nM p=0.998, (LUC/20-3’-miR7, 100 nM) 
p=1] (Figure 3.10) 
 Validation of ORF36 as a predicted target of ovhv2-miR-8  3.3.3.4
LUC/36-3’in the presence or absence of the test miRNA (ovhv2-miR-8) showed no 
significant difference in the levels of luciferase  as compared to the negative control 
at 50 nM or 100 nM concentration  [(LUC/36-3’,50 nM) p=0.421, (LUC/36-3’,100 
nM) p=0.107, (LUC/36-3’-miR8,50 nM) p=0.991, (LUC/36-3’-miR8,100 nM) 
p=0.495] (Figure 3.11). 
 Validation of the ORF49 as as a predicted target of ovhv2-miR-6 3.3.3.5
LUC/49-3’ in the presence of test miRNA (ovhv2-miR-6) at 50 nM or 100 nM 
concentration showed no significant changes in luciferase activity from the negative 
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control miRNA when used at the similar concentrations [(LUC/49-3’-miR6, 50 nM) 
p=0.998, (LUC/49-3’-miR6, 100 nM) p=0.669)]. In the absence of any miRNA, 
LUC/49-3’ showed significantly higher luciferase expression only when compared to 
the negative control at 100 nM but not at 50 nM concentration [(LUC/49-3’, 50 nM) 
p=0.616, (LUC/49-3’, 100 nM) p>0.001]. (Figure 3.12) 
 Validation of the ORF73 as a predicted target of ovhv2-miR-6  3.3.3.6
All the LUC/73-3’constructs with or without the treatment of targeting mimic 
(ovhv2-miR-6) at 50 nM or 100 nM concentrations, showed no significant difference 
from the negative control at the similar concentrations [(LUC/73-3’,50 nM) p=0.124, 
(LUC/73-3’-miR6, 50 nM) p=0.552, (LUC/73-3’, 100 nM) p=0.053, (LUC/73-3’-
miR6, 100 nM) p= 0.105] (Figure 3.13).  
 Validation of Ov2 as as a predicted target of ovhv2-miR-4 3.3.3.7
Due to the unavailability of GloMax® 96 Luminometer, at the time the experiment 
was conducted, luciferase assays for LUC/Ov2-3’ were performed using a Glomax 
20/20 Luminometer (Promega) by manual mixing. Transfections were performed in 
24 well plates for 24 hours and each sample was transfected in 3 replicates (Section 
2.4.5). Two concentrations (25 nM and 50 nM) were used for mimic miRNA or 
scramble miRNA. Normalization of Rluc and Fluc readings and calculation of fold 
difference from negative control was done as described in Section 3.3.3.  
No significant difference was observed in the luciferase expressions between 
LUC/Ov2-3’ and negative control when transfected with or without 25 nm or 50 nM 
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of the targeting mimic; ovhv2-miR-4 [(LUC/Ov2-3’, 25 nM) p=0.228, (LUC/Ov2-3’, 
50 nM) p=0.948, (LUC/Ov2-3’-miR4, 25 nM) p=0.260, (LUC/Ov2-3’-miR4, 50 nM) 
p=0.785] (3.14). Subsequent analysis later identified a one bp difference in the 
predicted target region of ovhv2-miR-4 in the 3’UTR of Ov2 in the BJ1035 isolate 
used in this experiment compared to the published Ov2 sequence (Figure 3.15). Due 
to the difference in the target region further experiments using 100 nM concentration 











Figure 3.10: Luciferase expression levels in BHK21 cells transfected with the 
3’UTR of ORF20 luciferase construct (in the psiCHECK-2 plasmid) in the 
presence/absence of target miRNA at 100 nM concentration. 
Data is represented as luciferase activity with the ***=p<0.001 relative to the 








Figure 3.11: Luciferase expression levels in BHK21 cells transfected with the 
3’UTR of ORF36 luciferase construct (in the psiCHECK-2 plasmid) in the 
presence/absence of target miRNA at 100 nM concentration. 
Data is represented as luciferase activity relative to the respective scramble miRNA 
(negative control) (light grey) value at 100 nM concentration.  
 




Figure 3.12: Luciferase expression levels in BHK21 cells transfected with the 
3’UTR of ORF49 luciferase construct (in the psiCHECK-2 plasmid) in the 
presence/absence of target miRNA at 100 nM concentration. 
Data is represented as luciferase activity with the *=p<0.05 relative to the respective 
scramble miRNA (negative control) (light grey) value at 100 nM concentration.  
 
 




Figure 3.13: Luciferase expression levels in BHK21 cells transfected with the 
3’UTR of ORF73 luciferase construct (in the psiCHECK-2 plasmid) in the 
presence/absence of target miRNA at 100 nM concentration. 
Data is represented as luciferase activity relative to the respective scramble miRNA 
(negative control) (light grey) value at 100 nM concentration.  
 
 




Figure 3.14: Luciferase expression levels in BHK21 cells transfected with the 
3’UTR of Ov2 luciferase construct (in the psiCHECK-2 plasmid) in the 
presence/absence of target miRNA at 50 nM concentration. 
Data is represented as luciferase activity relative to the respective scramble miRNA 
(negative control) (light grey) value at 100 nM concentration.  
 




Figure 3.15: OvHV-2 Ov2-3’UTR sequence 
The OvHV-2 Ov2-3’UTR sequence from BJ1035 cell line (444bp) (in black) isolated 
by PCR has one nucleotide difference at the predicted target site of ovhv2-miR-4 
(highlighted in orange) as compared to the published OvHV-2 ORFOV2 3’UTR 
sequence (in red).  
 




All herpesviruses so far studied have been shown to encode miRNAs with the 
exception of VZV, however the role of those miRNAs in virus biology and 
pathogenesis is partly understood for only a very small number of herpesvirus 
miRNAs (Boss et al., 2009, Zhu et al., 2013). It has been shown that OvHV-2 
encodes at least 35 miRNAs (Levy et al., 2012, Nightingale et al., 2014). The aim of 
this study was to experimentally validate the OvHV-2 ORFs that were predicted to 
be targeted by eight of the ovhv2-miRs originally validated (Levy et al., 2012). 
These ovhv2-miRs have predicted targets within cellular and viral transcripts (Levy 
PhD thesis, 2012). Due to the lack of a productive culture system for OvHV-2 there 
was no experimental means to study the virus life cycle (Reid et al., 1983) and hence 
the regulation of viral or cellular proteins under the influence of ovhv2-miRs in cell 
culture systems. To study the role of those miRNAs on the regulation of viral ORFs 
it was necessary to use a system which could determine the effects of miRNA-
mRNA interactions. Dual luciferase reporter assays have been widely used to 
evaluate direct binding of a miRNA to its target mRNA and to validate the 
functionality of that interaction. Luciferase assays allow quantification of the 
magnitude of target silencing by miRNAs (Hansen et al., 2010).  In this experimental 
model the UTR of interest is cloned downstream or upstream of a luciferase gene in a 
reporter plasmid. An interaction of a miRNA with the mRNA of the cloned UTR 
containing predicted miRNA target site, will block or inhibit the translation of the 
luciferase mRNA which results in a decrease in the luciferase proteins levels. The 
effect on the luciferase levels is easily measurable. Dual luciferase assays have the 
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additional benefit of co-expression of a control luciferase gene which is used as an 
internal control to control for discrepancies in expression readings.  
In this study, luciferase assays were used to experimentally investigate six of the 
OvHV-2 ORFs that were predicted to contain target sites for ovhv2-miRs in their 
3’UTR and/or 5’UTR. These ORFs (Ov2, ORF20, ORF36, ORF49, ORF50 and 
ORF73) have homologues in related herpesviruses which have functions related to 
virus latency, replication, cell cycle regulation or reactivation from latency (Section 
3.2).  
ORF73 is predicted to encode for LANA and is involved in viral episomal 
maintenance (Grundhoff and Ganem, 2003).  An important role for KSHV miRNAs 
in targeting ORF73/LANA has also been reported in various studies. KSHV-miR-K-
12-10a-3p and -10b-3p each can directly target two target sites in the 3’UTR of 
ORF73 transcripts in reporter constructs. Transfection of these miRNAs into KSHV 
infected cells, repressed the LANA protein levels significantly (Bai et al., 2014). 
OvHV-2 ORF73 was predicted to contain two target sites for ovhv2-miR-8 and one 
target site for ovhv2-miR-6 in the 5’UTR. ORF73 also has a predicted target site for 
ovhv2-miR-6 in the 3’UTR. The data from the luciferase assays showed that only 
ovhv2-miR-8 targeted the predicted target site in the ORF73 5’UTR and caused a 
significant reduction in the luciferase expression levels (Figure 3.1). This indicates 
that ovhv2-miR-6 may not interact with the target site within the mRNA and may not 
cause any cleavage or subsequent degradation of it. When ovhv2-miR-6 and ovhv2-
miR-8 were used in combination at a 50 nM concentration of each, a <20% decrease 
in luciferase levels was observed and possibly that was due to only the activity of 
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ovhv2-miR-8. It is also worth noting that decrease in the luciferase activity at 50 nM 
concentration of the ovhv2-miR-8 was nearly half of the decrease when it was used 
at 100 nM concentration. Sequencing analysis later revealed a one bp difference in 
the predicted target region of ovhv2-miR-6 in the 5’UTR of ORF73 in the BJ1035 
isolate used in this experiment compared to the published ORF73 sequence 
(accession no: AY839756.1) (Figure 3.3). It is possible that ovhv2-miR-6 might not 
be able to recognize the target site due to one bp change, and that there might not any 
contribution of ovhv2-miR-6 in this result. This sequence difference was confirmed 
in three separate PCR/cloning reactions. 
To determine if the translational repression and decreased expression of luciferase 
gene was due to ovhv2-miR-8, the ovhv2-miR-8 target sites were deleted from the 
5’UTR of ORF73. Results showed that disrupting each site restored the luciferase 
activity to a level comparable to negative control (Figure 3.2). The ovhv2-miR-8 
sites in the 5’UTR overlapped each other. The seed region of the Ovhv2-mir8-site2 
was located 9 nucleotides from that of the ovhv2-mir8-site1 (Figure 3.3). Further 
analysis of the binding of the region with in the 5’UTR of ORF73 with both target 
sites, using RNAhybrid programme (Kruger and Rehmsmeier, 2006) showed that 
site-1 can bind to the ovhv2-miR-8 with high efficiency. Site-2 lies in the region that 
interacts with the 3’ end of the miRNA. It is therefore possible that only site-1 is 
functional and abrogation in the inhibition observed after the mutation in site-2 was 
due to the loss in non-seed sequence interactions. It is also possible that both of these 
sites work in a synergistically manner with each other and disruption in one affects 
the activity of the other. Closely spaced miRNA target sites often act synergistically 
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and two proximal target sites for same miRNA, individually mediate only subtle 
reduction, whereas both sites together can mediate more robust reduction, which was 
significantly cooperative (Grimson et al., 2007). In addition, a propensity for 
synergistic effect was also found for moderate distances greater than about 13 nt 
between seed starts and an optimal reduction was obtained when two seed sites were 
separated by between 13 and 35 nt (Saetrom et al., 2007).  
ORF50 is a homologue of RTA of EBV and KSHV (Section 1.3.2; Section 3.2.4).  
The 3’UTR of ORF50 was predicted to be targeted by ovhv2-miR-5. Luciferase 
assays confirmed the interaction between predicted target site and ovhv2-miR-5. A 
~50% significant reduction in the luciferase expression was observed (Figure 3.7). 
Deletion of the predicted target site resulted in a recovery of the luciferase levels to 
that seen in the intact construct (Figure 3.9). Further experiments in the lab carried 
out by Dr. Inga Dry have shown that the ORF50 mRNA levels can be inhibited in 
BJ1035 cells transfected with ovhv2-miR-5 (Riaz et al., 2014). The luciferase assay 
and inhibition assay results demonstrate that expression of ORF50 can be inhibited 
by a viral encoded miRNA. In other gamma herpesviruses, the expression of Rta in 
latently infected cells is sufficient to initiate the entire viral lytic cascade (Damania et 
al., 2004). After experimental infections of OvHV-2, ORF50 transcripts were 
detected in experimental animals indicating that it was related to viral transcription 
(Cunha et al., 2012).  miRNAs encoded by other related  gammaherpesviruses have 
been shown to target RTA. Bellare & Ganem showed that KSHV miR-K9 targets a 
region in the 3’UTR of RTA and ectopic expression of miR-K9 stabilizes the latency 
by attenuating the RTA accumulation (Bellare and Ganem, 2009). miR-K9 targeting 
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of a gene involved in triggering of lytic reactivation can be  a safety mechanism for 
the virus to  prevent RTA transcription from triggering inappropriate entry into the 
lytic cycle (Bellare and Ganem, 2009).    
Based on the data and proposed function of ORF73 it can be speculated that a 
reduction in the protein levels due to ovhv2-miR-8 binding to the 5’UTR of ORF73 
might suppress the expression of the latency associated antigen and thereby support 
the switch to lytic gene expression. In contrast specific miRNAs targeting of the 
3’UTR of ORF50 shows that ovhv2-miR-5 might support the maintenance of viral 
episomes and stop the virus initiating the lytic lifecycle. The presence of miRNAs 
that cause reduction of expression of genes related to opposite functions suggests that 
the cultured T cells from infected cattle (BJ1035) may contain a mixture of the latent 
and lytically infected cells. Thonur et al found that cultured T cells from diseased 
cattle and rabbits contained both circular and linear genome conformations indicating 
a mixture of latent and productive cycle virus and that there was a mixture of 
latently- and productively-infected cells in both lines (Thonur et al., 2006). They also 
found that most of the OvHV-2 unique genes (Ov2-Ov10) were transcribed in these 
cells but the productive cycle genes ORF50 and ORF9 were only expressed after 
doxorubicin treatment (Thonur et al., 2006). However, sequencing analysis of 
OvHV-2 transcriptome in BJ1035 (Levy PhD thesis, 2012) described a different 
transcript profile. In the transcriptome data all the genes focused on by Thonur et al 
were expressed in BJ1035 cells, but to differing degrees and ORF50 was detectable 
without treatment with doxorubicin. There are a number of possible explanations 
regarding this difference in gene expression; First a different experiment 
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methodology was used in that study, Secondly, with the passage of time the cell line 
may develop a different ratio of latent:reactivated virus leading to an increase in 
reactivated virus.  
Another selected target for validation was ORF20. In related viruses ORF20 is 
involved in controlling the cell cycle. In MHV68 ORF 20 was characterized as a 
nuclear protein and caused cell cycle arrest at G2/M phase of cell cycle by keeping 
Cdc2-cyclin B complex in an inactive form, leading to apoptosis (Nascimento et al., 
2009).  ORF20 of OvHV-2 was observed to localize in the nucleus like other related 
herpesviruses (Levy PhD thesis, 2012). OvHV-2 ORF 20 has predicted target sites 
for ovhv2-miR-5, ovhv2-miR-6 and ovhv2-miR-7 in the 3’UTR and ovhv2-miR-2, 
ovhv2-miR-4 and ovhv2-miR-5 in the 5’UTR. Within the 3’UTR no target site was 
found to be functional. No significant reduction in transcriptional activity and no 
synergistic effects of the three Ovhv2-miRs when transfected together, were 
observed (Figure 3.10). In the 5’UTR only one target site proved that it might be 
functional. A significant reduction in the ORF20 construct with a decrease in 
luciferase levels expression of 30-40% at 50 nM and 50-60% at 100 nM 
concentration of ovhv2-miR-2 was observed (Figures 3.4). When three ovhv2-miRs 
were transfected together at a final concentration of 100 nM, a significant <20% 
reduction was observed which might be due to the presence of ovhv2-miR-2 at 
33.3nM concentration.  Deletion of the ovhv2-miR-2 target site from the 5’UTR of 
ORF20 could not abolish the inhibition in luciferase expression (Figure 3.5) 
suggesting that either the target site is not a real functional site and the observed 
reduction was due to some other factors or that the target site is real but additional 
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target sites are present that are sufficient to cause a decrease in gene expression in the 
absence of the target site.  
The interaction between ovhv2-miR-2 seed region and predicted target site, had a 
perfect complementarity, and no G:U pairing was allowed. If G:U base pairing was 
considered between the seed region and target site, three more possible target sites 
were found with two G:U base pairs in each interaction (Figure 3.6). More than one 
G:U base-pair can reduce the activity of all the target sites (Brennecke et al., 2005). 
Didiano and Hobert reported that the perfect base pairing is not generally a reliable 
predictor of miRNA-target interaction. They found an efficient reduction even after 
the introduction of several G:U wobbles at various positions of miRNA or two G:U 
wobbles in the seed region of a functional let-7-binding site in the lyn-41 3’UTR 
(Didiano and Hobert, 2006). The minimum free energy for the canonical base pairing 
in the seed region of ovhv2-miR-2 and target site in ORF20 was -16.9 kcal/mol while 
for the other target sites with G:U base pairing it was -18.2 kcal/mol, -23.2 kcal/mol 
and -15.4 kcal/mol. The lower the free energy of two paired RNA strands is, the 
more energy is needed to disrupt this duplex formation. An RNA duplex is more 
stable thermodynamically, which means the binding of miRNA to the mRNA is 
stronger, when free energy is low (Lewis et al., 2003, Huang et al., 2010). Thus one 
possible explanation for observing no abrogation in luciferase inhibition even after 
the predicted target site in the 5’UTR of ORF20 was disrupted by mutagenesis is that 
ovhv2-miR-2 interacted with one or more target site with G:U wobbles which have 
an almost as equal or as low free energy as the original interaction within 5’UTR of 
ORF20. 
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During further experiments done by Dr Inga Dry, in the lab, the existence of ORF20, 
ORF50 and ORF73 as transcripts including the miRNA target sites was confirmed, 
using an RT-qPCR strategy. The inhibition of ORF20, ORF50 and ORF73 transcripts 
by targeted miRNA mimics was also investigated by RT-qPCR analysis and results 
showed a successful reduction in the levels of ORF50 transcripts. Although, there 
was an apparent reduction in the levels of ORF20 transcripts it was not significant. 
Furthermore no reduction was observed in ORF73 transcript levels (Riaz et al., 
2014). 
Ov2 (Section 3.2.1) was also tested for the validation of predicted targets located in 
the 3’UTR (Figure 3.14). Ov2 is one of the unique OvHV-2 ORFs and encodes a 
DNA binding protein homologous to cellular transcription factors CREB and Jun 
(Hart et al., 2007). In the OvHV-2 transcriptome analysis Ov2 had a very high 
transcript level suggesting its importance in the pathogenesis of MCF (Levy PhD 
thesis, 2012). Luciferase assays showed no significant changes in expression levels 
when Ov2 was transfected with test miRNA ovhv2-miR-4. Further analysis 
identified a point mutation in the target region in the BJ1035 isolate which was used 
in this study (Figure 3.15), which might be the reason why ovhv2-miR-4 could not 
target Ov2.  
ORF36, and ORF49 (Section 3.2.3 and 3.2.5) were also tested for the validation of 
predicted targets located in their 3’UTRs but neither of those showed any significant 
changes in the luciferase expression levels (Figure 3.11 ORF36 Figure 3.12 for 
ORF49). ORF36 is predicted to encode for a protein kinase and is conserved among 
the Herpesviridae family (Section 3.2.3). In most herpesviruses ORF49 is expressed 
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during the lytic cycle and shows early transcription kinetics. ORF49 protein is able to 
cooperate with RTA to activate several lytic promoters in the lytic life cycle (Section 
3.2.5). These targets were predicted by bioinformatic analysis so it is possible that 
these are not real functional targets. However, it remains a possibility that within the 
3’UTRs of ORF36 and ORF49 are real target sites and that the ovhv2-miRs do bind 
to the target transcript but due to other contributing factors or requirement of specific 
cellular factors translational repression cannot be detected in this model. Further 
investigation is required to exclude this possibility. 
In this study eight UTRs from six OvHV-2 ORFs were functionally investigated as 
ovhv2-miRs targets. The selected ORFs had predicted targets located in 3’UTRs 
and/or 5’UTRs. miRNA mediated silencing of mRNA transcripts is regulated 
predominantly through binding to sequences within 3′UTRs (Farh et al., 2005, Gu et 
al., 2009). My results also prove that ORF50 can be regulated by ovhv2-miR-5 by 
targeting the complementary sequence within the 3’UTR. The other target sites 
located in the 3’UTRs of ORF73, ORF20, ORF36 and ORF49 were not found as 
miRNAs functional target sites. As these targets were identified by bioinformatics 
analysis it is a real possibility that these are false targets. I also tested predicted 
ovhv2-miRs targets located in 5’UTRs of OvHV-2 ORFs and found functional 
targets in the 5’UTR of ORF73 and ORF20. miRNA could associate to any position 
of the target mRNA and binding sites located in 5’UTRs could efficiently be 
repressed by miRNAs (Lytle et al., 2007). In another study, Grey et al reported the 
first example of a highly expressed viral (HCMV) miRNA mir-US25-1 mediated 
inhibition of gene expression through the novel mechanism of targeting 5’UTR 
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sequences. In that study the targeting of cellular transcript by miR-US25-1 has been 
shown using luciferase reporter assay and a recently developed biochemical 
approach called RISC immunoprecipitation and deletion of the identified seed sites 
from the 5’UTRs resulted in a loss of enrichment in the luciferase transcript 
measured using RT-qPCR (Grey et al., 2010). My results show that ovhv2-miR-8 
can efficiently down-regulate ORF73 by binding its target sequence located within 
the 5’UTR and deletion of the target site can abrogate that reduction. Whereas 
ovhv2-miR-2 also can inhibit ORF20 expression by targeting complementary 
sequence in the 5’UTR, knocking out of that target site could not abrogate inhibition. 
As shown above it might be due to the presence of other target sites with G:U base 
pairing.  
Due to technical complexity and time constraint it is beyond the scope of this project 
to functionally validate each of those target sites. To find out the regulation by 
ovhv2-miRs, identification of real targets is required and that work is in progress in 
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To identify the cellular targets of OvHV-2 encoded miRNAs. 
 Introduction 4.2
OvHV-2 causes a severe lymphoproliferative disease in cattle but not in sheep 
(described in detail in Section 1.4). The basis of the difference in disease outcomes in 
two phylogenetically closely related species is unknown. We hypothesized that virus 
encoded miRNAs may play a role in these different disease outcomes. To test this 
hypothesis experiments were performed to identify the targets of OvHV-2 encoded 
miRNAs (ovhv2-miRs) in sheep and cattle mRNAs.  
Identification of potential miRNAs targets has been one of the greatest challenges 
since the discovery of miRNAs. Several experimental and computational approaches 
(Section 1.5.5) have been used to predict targets and their interactions with their 
respective miRNAs. More recent approaches involve UV cross-linking and 
immunoprecipitation (CLIP) of the miRNA targeted mRNA within the RISC, using 
antibodies specific for the proteins present in the RISC, and then mapping protein-
mRNA interactions using high throughput sequencing (Hafner et al., 2010, Skalsky 
et al., 2012). The development of CLIP has allowed the mapping of RNA interacting 
with a variety of proteins and can also provide useful information about protein-
mRNA interacting with corresponding miRNAs. Recent CLIP related studies 
identified many putative miRNA binding sites, using transcriptome wide analysis of 
argonaute and mRNA interactions (Chi et al., 2009, Leung et al., 2011). However 
using these approaches it is not possible to get evidence for direct and physical 
mRNA-miRNA interactions. A newly developed technique, Crosslinking, Ligation 
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And Sequencing of Hybrids (CLASH) (previously known as crosslinking and 
analysis of cDNA (CRAC) allows the study of transcriptome-wide analysis of RNA-
RNA interactions (Kudla et al., 2011).  CLASH allows direct observation of nucleic 
acid interctomes (e.g miRNA-mRNA) as chimeras or hybrids in deep sequencing 
data (Kudla et al., 2011). CLASH has many experimental steps in common with the 
CLIP method, but was optimized for the recovery of RNA-RNA duplexes (Travis et 
al., 2014) and has been successfully used to find RISC-miRNA-mRNA interactions 
and/or miRNA-mRNA interactions in cells (Granneman et al., 2009, Helwak et al., 
2013, Kudla et al., 2011, Helwak and Tollervey, 2014). CLASH is a highly sensitive 
technique which allows the identification of miRNA’s targets or binding sites in 
mRNAs and also helps to understand the functions of ovhv2-miRs. The objective of 
the study was to use CLASH technique to identify the cellular targets of ovhv2-
miRs.  
 Crosslinking, ligation and sequencing of the hybrids (CLASH) 4.2.1
In these studies CLASH was used to attempt to find targets in cattle transcripts for 
the 46 ovhv2-miRs. In addition, CLASH was also used to identify targets of three of 
the ovhv2-miRs (ovhv2-miR-17-1 (ovhv2-miR-8), ovhv2-miR-17-2 (ovhv2-miR-
67), and ovhv2-miR-17-3 (ovhv2-miR-7) in the sheep cells. The protocol for CLASH 
is described in detail in Section 2.7 and an overview of the CLASH procedure is 
illustrated in Figure 4.1. Briefly CLASH involves using UV light (Step1; Figure 4.1) 
in vivo to crosslink the Ago2 protein (tagged with HTP (His6-TEV-ProteinA) to the 
miRNA-mRNA complexes within the RISC. The cross-linked proteins and miRNA-
mRNA complexes were purified, under stringent condition, in two stages. The first 
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of these two stages involved; the binding of Protein A tag of Ago2 present in the cell 
lysate to IgG antibody coated magnetic beads and then isolating the bound 
complexes (Step2; Figure 4.1).  Isolated complexes were subjected to limited RNase 
A and T1 digestion to remove overhanging transcripts leaving the RISC incorporated 
mRNA corresponding to the miRNA targets (Step3; Figure 4.1). miRNA-mRNA-
RISC complexes were then eluted from the beads and loaded on Ni-NTA agarose (Ni 
beads). An intra-molecular ligation reaction was performed using T4 RNA ligase 1 
resulting in the formation of hybrids between the miRNA and the target mRNA. 3’ 
linker ligation using T4 RNA Ligase and radiolabelling using γ -32P ATP of 5’ends 
of the RNAs was performed while the complexes were still immobilized on Ni beads 
(Step4; Figure 4.1). The radiolabelled complexes were separated and eluted from the 
Ni beads (Step5; Figure 4.1). The second purification step was carried out by 
separating the complexes by SDS polyacrylamide gel electrophoresis, and 
transferring to a nitrocellulose membrane. The regions containing the radiolabelled 
protein-RNA complexes were excised from the membrane and subjected to 
proteinase K treatment to digest proteins associated with the RISC complex. The 
released miRNA-mRNA hybrids (chimeras) were extracted with phenol-chloroform 
and ethanol precipitation and a 5’ linker ligation was performed on each sample 
(Step6; Figure4.1). Addition of a 5’ linker containing a known variable sequence 
(barcode) allowed identification of each sample through the downstream processing. 
Reverse transcription of RNA and PCR amplification of the cDNA libraries was 
carried out. PCR products were separated on a gel and then extracted from the gel 
(Step7; Figure4.1). Purified cDNA libraries were either cloned and Sanger sequenced 
or submitted to ARK Genomics for Solexa sequencing (Step8; Figure 4.1). 





Figure 4.1: The CLASH technique 
(A) Schematic diagram showing HTP tag fused to Argonaut 2 (Ago2) protein. (B) 
















The CLASH approach was used to identify host cellular targets of ovhv2-miRs. The 
OvHV-2 infected bovine LGL cell line BJ1035 expresses all identified ovhv2-miRs 
and was used to identify bovine targets. Due to the unavailability of appropriate 
control bovine cells, only BJ1035 cells were used in this experiment and the targets 
for ovhv2-miRs were determined primarily by analysing CLASH hybrid data 
(Section 4.3.3).  
To identify ovine targets for ovhv2-miRs, it was not possible to transduce and 
develop sheep lymphocytes expressing tagged Ago2 and ovhv2-miRs therefore sheep 
embryo fibroblasts (SEF) were used. For this purpose stable sheep fibroblast cell 
lines expressing the ovhv2-miRs and control cells were generated (Section 4.3.2).  
BJ1035 and SEF expressing tagged Ago2 were generated, to allow purification of 
miRNA-mRNA complexes associated with the RISC.   
 CLASH for the LGL cell line BJ1035 4.3.1
 Expression of tagged Ago2 Protein in the LGL cell line BJ1035 4.3.1.1
The pLVX-tight-puro lenti vector (pLVX-puro) (Appendix-2) into which was cloned 
HTP tagged human Ago2 (gift from Dr. Grey) was used to produce a tagged Ago2 
expressing lentivirus in HEK293 cells.  Those lentivirus particles were used for the 
stable transduction (section 2.4.8) and expression of tagged Ago2 in the BJ1035 
cells. The amino acid sequence of bovine Ago2 is almost identical to that of the 
human Ago2 sequence with only two amino acids found to be different (Figure 4.2). 
Western blot analysis (Section 2.3.3) using anti-human Ago2 antibodies showed 
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successful expression of tagged Ago2 in BJ1035 cells (Figure 4.3A). Successfully 
transduced cells (BJ1035-AGO2) selected by Puromycin resistance (Section 2.4.7) 
were used to perform CLASH. 
 Analysis of tagged Ago2 protein Immunopreciptiation in BJ1035-AGO2 4.3.1.2
at small scale 
Before carrying out CLASH experiments the efficiency of the magnetic dynabeads 
conjugated with purified IgG antibody (dynabeads-IgG) was tested by protein A-tag 
mediated immunoprecipitation (IP), to test the quality of lysate. Cell lysates were 
obtained by lysis of UV irradiated BJ1035-AGO2 as described in Sections 2.7.1-
2.7.3. Dynabeads-IgG were used to pull down the tagged Ago-2 in the RISC. During 
the first washing step of IP, the flow through (FT) was also carefully collected. 
Enrichment of the proteins during purification was monitored by western blotting 
using equal quantities of cell lysates, IP samples, and the FT samples.  The western 
blot results showed that the expression of tagged Ago2 in the cell lysate and IP 
samples were comparable, indicating an efficient IP. The FT sample contained very 
little tagged Ago2, indicating minimum loss of proteins during the washing steps 
(Figure 4.3B). 
 CLASH experiments for BJ1035-AGO2  4.3.1.3
CLASH experiments (Section 2.7.4) were performed for one sample of BJ1035 cells 
(BJ1035 sample for the rest of the chapter).  
miRNA-mRNA complexes can be visualized at two stages during the CLASH 
experiment. The radio-labelled tagged Ago2 miRNA-mRNA complexes were 
visualized by autoradiography, after the Ni affinity purification and enzymatic 
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modification steps (Sections 2.7.4-2.7.8, Figure 4.1). Ago2 has a molecular weight of 
approximately 100 KDa and a band of this size was visible on the blot (Figure 4.3 
C1). A contaminant of approximately 50 to 60 kDa was also detected (Figure 4.3 C1 
asterisk*). The region associated with 100 kDa was excised from the membrane 
(indicated by red box in Figure 4.5A) (section 2.7.8). The RNA recovered after 
proteinase K treatment and 5’ linker ligation was reverse transcribed and cDNA 
libraries were prepared (section 2.7.9 to 2.7.12). The second visualization stage of 
the CLASH experimental product was performed using a small quantity of the cDNA 
library which was amplified by PCR. A PCR product of ~150bp was detected by gel 
electrophoresis and excised from the gel (red squares in Figure 4.3 C2) for DNA 
extraction. To assess the quality of the cDNA and to confirm the successful ligation 
of the linkers, the sample was cloned and sequenced (section 2.7.13). An example of 
a typical cDNA fragment generated from CLASH experiment is illustrated in Figure 
4.4. Sequencing results confirmed the presence of the 5’linker, barcodes, insert and 
3’linker sequences. The size of the inserts ranged from 0-39nt in lengths. For further 
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Bos             MYSGAGPALAPPAPPPPPIQGYAFKPPPRPDFGTSGRTIKLQANFFEMDIPKIDIYHYEL 
Homo            MYSGAGPALAPPAPPPP-IQGYAFKPPPRPDFGTSGRTIKLQANFFEMDIPKIDIYHYEL 
                ***************** ****************************************** 
 
Bos             DIKPEKCPRRVNREIVEHMVQHFKTQIFGDRKPVFDGRKNLYTAMPLPIGRDKVELEVTL 
Homo            DIKPEKCPRRVNREIVEHMVQHFKTQIFGDRKPVFDGRKNLYTAMPLPIGRDKVELEVTL 
                ************************************************************ 
 
Bos             PGEGKDRIFKVSIKWVSCVSLQALHDALSGRLPSVPFETIQALDVVMRHLPSMRYTPVGR 
Homo            PGEGKDRIFKVSIKWVSCVSLQALHDALSGRLPSVPFETIQALDVVMRHLPSMRYTPVGR 
                ************************************************************ 
 
Bos             SFFTASEGCSNPLGGGREVWFGFHQSVRPSLWKMMLNIDVSATAFYKAQPVIEFVCEVLD 
Homo            SFFTASEGCSNPLGGGREVWFGFHQSVRPSLWKMMLNIDVSATAFYKAQPVIEFVCEVLD 
                ************************************************************ 
 
Bos             FKSIEEQQKPLTDSQRVKFTKEIKGLKVEITHCGQMKRKYRVCNVTRRPASHQTFPLQQE 
Homo            FKSIEEQQKPLTDSQRVKFTKEIKGLKVEITHCGQMKRKYRVCNVTRRPASHQTFPLQQE 
                ************************************************************ 
 
Bos             SGQTVECTVAQYFKDRHKLVLRYPHLPCLQVGQEQKHTYLPLEVCNIVAGQRCIKKLTDN 
Homo            SGQTVECTVAQYFKDRHKLVLRYPHLPCLQVGQEQKHTYLPLEVCNIVAGQRCIKKLTDN 
                ************************************************************ 
 
Bos             QTSTMIRATARSAPDRQEEISKLMRSASFNTDPYVREFGIMVKDEMTDVTGRVLQPPSIL 
Homo            QTSTMIRATARSAPDRQEEISKLMRSASFNTDPYVREFGIMVKDEMTDVTGRVLQPPSIL 
                ************************************************************ 
 
Bos             YGGRNKAIATPVQGVWDMRNKQFHTGIEIKVWAIACFAPQRQCTEVHLKSFTEQLRKISR 
Homo            YGGRNKAIATPVQGVWDMRNKQFHTGIEIKVWAIACFAPQRQCTEVHLKSFTEQLRKISR 
                ************************************************************ 
 
Bos             DAGMPIQGQPCFCKYAQGADSVEPMFRHLKNTYAGLQLVVVILPGKTPVYAEVKRVGDTV 
Homo            DAGMPIQGQPCFCKYAQGADSVEPMFRHLKNTYAGLQLVVVILPGKTPVYAEVKRVGDTV 
                ************************************************************ 
 
Bos             LGMATQCVQMKNVQRTTPQTLSNLWLKINVKLGGVNNILLPQGRPPVFQQPVIFLGADVT 
Homo            LGMATQCVQMKNVQRTTPQTLSNLCLKINVKLGGVNNILLPQGRPPVFQQPVIFLGADVT 
                ************************ *********************************** 
 
Bos             HPPAGDGKKPSIAAVVGSMDAHPNRYCATVRVQQHRQEIIQDLAAMVRELLIQFYKSTRF 
Homo            HPPAGDGKKPSIAAVVGSMDAHPNRYCATVRVQQHRQEIIQDLAAMVRELLIQFYKSTRF 
                ************************************************************ 
 
Bos             KPTRIIFYRDGVSEGQFQQVLHHELLAIREACIKLEKDYQPGITFIVVQKRHHTRLFCTD 
Homo            KPTRIIFYRDGVSEGQFQQVLHHELLAIREACIKLEKDYQPGITFIVVQKRHHTRLFCTD 
                ************************************************************ 
 
Bos             KNERVGKSGNIPAGTTVDTKITHPTEFDFYLCSHAGIQGTSRPSHYHVLWDDNRFSSDEL 
Homo            KNERVGKSGNIPAGTTVDTKITHPTEFDFYLCSHAGIQGTSRPSHYHVLWDDNRFSSDEL 
                ************************************************************ 
 
Bos             QILTYQLCHTYVRCTRSVSIPAPAYYAHLVAFRARYHLVDKEHDSAEGSHTSGQSNGRDH 
Homo            QILTYQLCHTYVRCTRSVSIPAPAYYAHLVAFRARYHLVDKEHDSAEGSHTSGQSNGRDH 
                ************************************************************ 
 
Figure 4.2: Sequence of Bos taurus Argonaute 2 protein 
Sequence of Bos taurus Argonaute 2 protein showed two amino acids difference from Homo 
sapiens Argonaute 2 protein (highlighted in yellow).  
Bos= Bos taurus Homo= Homo sapiens.  
*= Identical amino acids in Bos taurus Argonaute2 and Homo sapiens Argonaute2 protein. 
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Figure 4.3: Different stages of CLASH for the visualization of CLASH 
experimental products.  
A: Western Blot analysis with antibody against human Ago2 or GAPDH showing expression 
of Ago2 or GAPDH in BJ1035 cells. 
Lane 1: BJ1035 transduced with HTP tagged human Ago2 
Lane 2: Un-transduced BJ1035. 
 
B: Western blot analysis to monitor the enrichment of HTP tagged Ago2 using protein A-tag 
mediated immuno-precipitation (IP) in the BJ1035 transduced with tagged Ago2. Cell lysate, 
FT and IP samples were probed with antibodies against human Ago-2 using magnetic Dyna-
beads. FT: Flow through obtained during washing steps of IP.  
 
C: Visualization of CLASH experimental product; C1: Autoradiograph of radiolabelled HTP 
tagged Ago2 with miRNA-mRNA complex after Ni-affinity purification and 3’linker 
ligation. Red box indicates region on the membrane that was excised and further used for 
miRNA-mRNA complexes and cDNA synthesis. Asterisk indicates a common contaminant 
of 50-60KDa. Protein size marker is indicated on the left. C2: MetaPhor gel electrophoresis 
of cDNAs library amplified by PCR. The region which was excised from the gel for DNA 
extraction is indicated in red box. A 100bp DNA size marker is indicated on the left. 
BA 
C1 C2





Figure 4.4 Sequencing result of a TOPO cloned cDNA sample generated from 
CLASH experiment from BJ1035-AGO2. 
The 5’ linker, barcode and 3’ linker is highlighted in cyan, grey and yellow 
respectively. RNA insert is shown in bold. Adapter sequences from PCR primers are 
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 High throughput sequencing of cDNA library obtained from BJ1035 4.3.1.4
sample 
Bioinformatic analysis was carried out in collaboration with Mr. Mick Watson 
(University of Edinburgh) and with the kind help of Dr. Finn Grey (University of 
Edinburgh). In brief, Solexa sequencing reads of 100 bp length were selected and 
were separated according to the barcode associated with the BJ1035 sample. Barcode 
was matched with all the reads, allowing a 1bp mismatch and zero insertions or 
deletions.  If a read matched the barcode, it was assigned to the BJ1035 sample. 
Approximately 21 million reads were assigned to the barcode associated with the 
BJ1035 sample. However a small number of reads (70,000) were found with a 
barcode which was not used in this study. The possible reason for this was the 
contamination of barcodes during synthesis and it was assumed that the dataset had 
some contamination of barcodes used during sequencing. The sequencing adapter 
was then removed from reads using Cutadapt (Martin, 2011) and the resulting reads 
were mapped by BLAST (NCBI), against all of the 46 ovhv2-miRs (Levy PhD 
thesis, 2012) and against the entire database of miRBase V19. The results were used 
to count the occurrence of miRNAs within each dataset. Each read in the dataset was 
assumed to contain 0, 1 or more miRNAs at the 5’ end.  Using the BLAST results, if 
an miRNA was found at the 5’ end, it was trimmed along with the barcode; if no 
microRNA was found, just the barcode was trimmed. To examine the expression of 
targeted genes/mRNAs, the remaining parts of the reads were mapped to the 
predicted cattle transcripts (UMD 3.1) and the ORFs extracted from the Ovhv-2, 
complete genome sequence (accession AY839756.1). After applying these filters, a 
total of approximately 700,000 reads were obtained, for the BJ1035 sample. An 
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overview of this data set is described in Figure 4.5A. Finally, if a read hit both an 
miRNA and a mRNA, it was recorded as a chimera and the occurrence of all 
chimeras were counted. 
 CLASH data analysis for the presence of ovhv2-miRs 4.3.1.5
For the BJ1035 sample, Solexa sequencing reads were obtained as described in 
4.3.1.4 and were mapped against ovhv2-miRs and cellular-miRs present in the 
miRBase database. A total of 468881 miRNA reads were obtained and of these 
142367 (31.2%) and 313036 (68.7%) reads were matched with ovhv2-miRs and 
cellular miRNAs respectively (Figure 4.5B). 
 Ovhv2-miR-217M was the most abundant ovhv2-miRs with more than 28000 hits 
contributing 19.8% of all ovhv2-miRs and 6.2% of all miRNA. Ovhv2-mir-217M 
has seed (nucleotide 1-7 at 5’end of miRNA) sequence homology with cellular miR-
216a (Figure 4.5C). However when the reads were mapped against cellular-miRs in 
the BJ1035 sample, no miR-216a was found. All the sequence reads recovered with 
ovhv2-miR-217M had full length mature ovhv2-miR-217M sequence. ovhv2-miR-57 
and ovhv2-miR-53 were the next most abundant miRNAs accounting for 9.2%  each, 
of the total ovhv2-miRs and 3% of all miRNAs abundance with more than 14000 hits 
each (Table 4.1). Thirty five of the previously reported 46 ovhv2-miRs (Levy PhD 
Thesis) were also expressed in this data in varying proportions. The number of reads 
for each ovhv2-miRs and their percentages as compared to total miRNA counts are 
shown in Table 4.1. Among those forty six ovhv2-miRs, eight were pre-validated by 
northern hybridization (Levy et al., 2012). Those eight ovhv2-miRs also showed a 
high abundance in this data set and collectively made 22% of the total ovhv2-miRs 
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read counts with 31924 hits (shown in red bars in Figure 4.6). A comparison of the 
reads of ovhv2-miRs obtained from the RNA seq data (Levy et al., 2012) and from 
the CLASH data set is shown in Table 4.2. 
The most abundant cellular-miRs expressed in the BJ1035 sample were miR-21, 
miR-142-3p and miR-155 which made up 30% of the cellular-miRs identified and 
19% of the total miRNA count (Table 4.3). Additionally, miR-15b-5p, miR29a, 
miR29b, miR-146a and miR-29a-3p were also found to be significantly (~17% of 
cellular-miRs) enriched in the BJ1035 sample. All the cellular-miRs with read counts 
of greater than 1000 in the BJ1035 sample are presented in table 4.3 and figure 4.7. 
A complete list of miRNAs with read counts and percentage expression is provided 

















     C 
Figure 4.5: An overview of CLASH data 
A: Data obtained from the high throughput sequencing of the cDNA library 
generated from LGL cell line BJ1035 expressing HTP tagged Ago2 using CLASH. 
B: Proportional distribution of total of miRNA reads in CLASH data.  
Pie charts indicate the proportion of mapped reads that correspond to the ovhv2-
miRs (Levy PhD Thesis), cellular-miRs, OvHV-2 mRNAs, (accession AY839756.1) 
present in miRbase and cellular mRNA (cattle transcripts from UMD 3.1). Others 
indicate presence of ribosomal RNAs, pseudogenes, snRNA and snoRNA in this data 
set.  




                                                              A         GGC   ACUGUG 
miR‐216a                    5’ UAAUCUC    GCU          A                 A  3’ 
ovhv2‐mir‐217M       5’ UAAUCUC    GCU          A                 A  3’ 
                                                              U        CCA    UUGUAA




Figure 4.6: The distribution of reads that mapped to ovhv2-miRs in the CLASH 
dataset for BJ1035 sample. 
Red bars show the ovhv2-miRs which were validated by northern hybridization 














Figure 4.7: The distribution of reads that mapped to cellular-miRs present in 
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Table 4.1: Proportion of the ovhv2-miRs in the CLASH dataset. 
ovhv2-miRs Reads counts 
% (as compared to the 
total ovhv2-miRs) 
% (as compared to the  total 
miRNAs count) 
ovhv2-miR-217M 28300 19.9 6.2 
ovhv2- miR-57 14386 10.1 3.2 
ovhv2- miR-53 14345 10.1 3.1 
ovhv2- miR-61 10737 7.5 2.3 
ovhv2- miR-8 9044 6.4 2.0 
ovhv2- miR-35 6210 4.4 1.4 
ovhv2- miR-46 5714 4.0 1.3 
ovhv2- miR-36 5296 3.7 1.2 
ovhv2- miR-37 5199 3.7 1.1 
ovhv2- miR-60 4542 3.2 1.0 
ovhv2- miR-43 4305 3.0 0.9 
ovhv2- miR-45 4071 2.9 0.9 
ovhv2- miR-67 3602 2.5 0.8 
ovhv2- miR-50 2837 2.0 0.6 
ovhv2- miR-56 2711 2.0 0.6 
ovhv2- miR-49 2298 1.6 0.5 
ovhv2- miR-54 2103 1.5 0.5 
ovhv2- miR-48 2029 1.4 0.4 
ovhv2- miR-39 2017 1.4 0.4 
ovhv2- miR-44 2005 1.4 0.4 
ovhv2- miR-40 1869 1.3 0.4 
ovhv2- miR-34 1686 1.2 0.4 
ovhv2- miR-62 1536 1.1 0.3 
ovhv2- miR-51 1350 0.9 0.3 
ovhv2- miR-58 1215 0.9 0.3 
ovhv2- miR-41 866 0.6 0.2 
ovhv2- miR-42 703 0.5 0.2 
ovhv2- miR-66 654 0.5 0.1 
ovhv2- miR-5 306 0.2 0.07 
ovhv2- miR-47 257 0.2 0.06 
ovhv2- miR-63 116 0.1 0.03 
ovhv2- miR-6 33 0.02 0.007 
ovhv2- miR-3 19 0.01 0.004 
ovhv2- miR-38 4 0.003 0.0009 
ovhv2- miR-3P 1 0.0007 0.0002 
ovhv2- miR-83 1 0.0007 0.0002 
Foot notes: Percent values were calculated using read counts of each ovhv2-miR to the total 
read counts of ovhv2-miRs (142367) or the total read counts of ovhv2-miRs+cellular-miRs 
(468881). 
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Table 4.2: Comparative analysis of read counts of forty six ovhv2-miRs 
obtained from from RNA-seq study (Levy PhD thesis) and CLASH dataset. 
Ovhv2-miRs 
 Read counts 
(RNA-seq) 







ovhv2- miR-3p 25 1 ovhv2- miR-48 8095 2029 
ovhv2- miR-64p 2 0 ovhv2- miR-49 2967 2298 
ovhv2- miR-96p 1 0 ovhv2- miR-50 3794 2837 
ovhv2- miR-1 21 0 ovhv2- miR-51 24497 1350 
ovhv2- miR-3 196 19 ovhv2- miR-53 14966 14345 
ovhv2- miR-4 1 0 ovhv2- miR-54 1357 2103 
ovhv2- miR-1 10588 306 ovhv2- miR-5 11187 2711 
ovhv2- miR-6 253 33 ovhv2- miR-57 5457 14386 
ovhv2- miR-13 1 0 ovhv2- miR-58 942 1215 
ovhv2- miR-34 434 1686 ovhv2- miR-60 351 4542 
ovhv2- miR-2 39169 6210 ovhv2- miR-6 10378 10737 
ovhv2- miR-36 6200 5296 ovhv2- miR-62 1535 1536 
ovhv2- miR-37 6015 5199 ovhv2- miR-63 517 116 
ovhv2- miR-38 322 4 ovhv2- miR-7 16574 654 
ovhv2- miR-39 4717 2017 ovhv2- miR-67 7834 3602 
ovhv2- miR-40 1014 1869 ovhv2- miR-8 46048 9044 
ovhv2- miR-41 21686 866 ovhv2- miR-83 1 1 
ovhv2- miR-42 740 703 ovhv2- miR-95 1 0 
ovhv2- miR-43 31227 4305 ovhv2- miR-128 1 0 
ovhv2- miR-3 14694 2005 ovhv2- miR-163 1 0 
ovhv2- miR-45 6487 4071 ovhv2- miR-181 1 0 
ovhv2- miR-46 9219 5714 ovhv2- miR-182 1 0 
ovhv2- miR-4 17508 257 ovhv2-miR-217M6064 28300 
Foot notes: The eight of the ovhv2-miRs validated by northern hybridization (Levy et al., 
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Table 4.3: Proportion of the cellular-miRs in the CLASH dataset. 
cellular-miRs Reads counts 
% (as compared to the 
total cellular-miRs) 
% (as compared to the  total 
miRNAs count) 
miR-21 32163 10.3 6.9 
miR-142-3p 30272 9.7 6.5 
miR-155 29902 9.6 6.4 
miR-15b-5p 19426 6.2 4.1 
miR-29a 18763 6.0 4.0 
miR-29b 18405 5.9 3.9 
miR-146a 12873 4.1 2.7 
miR-29a-3p 9931 3.2 2.1 
miR-16-5p 8261 2.6 1.8 
miR-181a 7947 2.5 1.7 
let-7a 6444 2.1 1.4 
miR-26a 6112 2.0 1.3 
let-7f 5900 1.9 1.3 
miR-1224 5463 1.7 1.2 
miR-222-3p 4933 1.6 1.1 
miR-92a 4548 1.5 1.0 
miR-24 4349 1.4 0.9 
miR-30e 3670 1.2 0.8 
miR5662 3529 1.1 0.8 
miR-27a 3267 1.0 0.7 
miR-23a 3247 1.0 0.7 
miR-181a-5p 3194 1.0 0.7 
miR-15a-5p 3176 1.0 0.7 
miR-16b 2947 0.9 0.6 
miR-16a 2890 0.9 0.6 
miR-142-5p 2624 0.8 0.6 
miR-27b 2514 0.8 0.5 
let-7i-5p 2091 0.7 0.4 
miR-10a-5p 1997 0.6 0.4 
miR-26b-5p 1845 0.6 0.4 
miR-23b 1627 0.5 0.3 
miR-30b 1275 0.4 0.3 
miR-423-5p 1268 0.4 0.3 
miR-30d-5p 1152 0.4 0.2 
miR-181b-5p 1095 0.3 0.2 
miR-106b-5p 1041 0.3 0.2 
miR-30c 1003 0.3 0.2 
Foot notes: Percent values were calculated using read counts of each cellular-miR to the total 
read counts of cellular-miRs (313036) or the total read counts of ovhv2-miRs+cellular-miRs 
(468881). 
Chapter 4           Identification and characterization of cellular targets of Ovhv2-miRs 
175 
 
 CLASH data analysis for the presence of cellular and viral mRNAs 4.3.1.6
For the BJ1035 sample a total of 206709 sequence reads from 5366 genes were 
obtained. A large proportion of the reads mapped to 5S ribosomal RNAs (rRNA). 
Due to its high abundance (168903 out of 206709), rRNA can be co-purified 
frequently during CLASH experiments, and in other CRAC and CLASH related 
studies rRNAs were also identified as common contaminants (Granneman et al., 
2009, Hahn et al., 2012).  
 The remaining reads (34226) were associated with mRNAs (cellular and viral) and 
other known target classes including pseudogenes, and non-coding RNAs (Figure 
4.9, Table 4.4). A total of 31269 sequence reads out of 34226 were mapped to 
mRNAs derived from the cattle genome and constituted nearly 15% of the total RNA 
reads. The three most highly targeted genes were: ankyrin repeat domain containing 
protein26 (Ankrd26) with 1580 reads; zinc finger MYM type-protein 3 (ZMYM3) 
with 1038 reads and par-3 partitioning defective 3 homolog B (PARD3B) 1004 
reads. Other highly targeted genes were leucine-rich repeat-containing protein 30 
(LRRC30) (537 reads), olfactory receptor family 10 subfamily K member 1 
(OR10K1) (486 reads), serine racemase (SRR) (433 reads), vacuolar protein sorting-
associated protein 33B (VPS33B) (368 reads), F-box/LRR-repeat protein 21 
(FBXL21) (350 reads), zinc finger protein3 (ZNF3) (284 reads) and U11/U12 small 
nuclear ribonucleoprotein 25KDa (SNRNP25) (283 reads). mRNAs which had read 
counts greater than 100 in the BJ1035 sample are presented in Figure 4.9. A 
complete list of mRNAs with the raw read data and their percentages as a total of 
mRNAs, is provided in the supplemental data file 4.1.  
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Other classes of stable RNAs e.g small nuclear ribonucleic acid (snRNA), small 
nucleolar RNA (snoRNA) and tRNA were also recovered in small proportions in this 
dataset (Figure 4.8) 1.5% of the total reads were spliceosomal RNAs (snRNAs). 
Among the different classes of snRNAs (U1, U2, U4, U5, U6, U7, U12), U2 snRNA 
was the most enriched snRNA constituting ~68% of the total snRNA read counts. 
One of the OvHV-2 miR (ovhv2-miR-36) was found to form a chimera with U2 
spliceosomal RNA. Details of the U2 spliceosomal RNA and ovhv2-miR-36 
chimeric read are discussed in section 4.3.3. Nearly 0.7% of the total reads were 
mapped to the regions which were annotated as pseudogenes (Figure 4.8, Table 4.4).  
A very small proportion (~0.05%) of reads mapped to the OvHV-2 predicted ORFs. 
ORF64 (large tegument protein), Ov8 (putative glycoprotein), ORF7 (subunit of 
terminase) and ORF61 (ribonucleotide reductase) were the top targeted ORFs with 
read counts of 16, 8, 7 and 7 respectively.  (Supplemental data file 4.1 for full list of 








Figure 4.8: Summary of mRNAs and other RNA classes present in the CLASH 
dataset of BJ1035 sample. 
Pie chart indicates the proportion of mapped reads that corresponds to the OvHV-2 
mRNAs, cellular mRNAs, SnRNA (spliceosomal RNAs), pseudogenes, tRNAs, 
snoRNA (small nucleolar RNAs) and 5s_rRNA (ribosomal RNAs).  
Table 4.4: Targeted classes identified in the CLASH data of BJ1035 sample.  
Targeted classes in CLASH Read counts Percentage (%) 
Cellular mRNA 31339 15.3 
OvHV-2 mRNA 95 0.05 
SnRNA 3083 1.5 
Pseudogenes 1487 0.7 
tRNA + SnoRNA 502 0.2 
5S_rRNA 168903 82 
Foot note: Percent values were calculated using read counts of each targeted class to the 
total mapped read counts (206709). 
SnRNA: spliceosomal RNAs, snoRNA: small nucleolar RNAs, rRNA: ribosomal 
RNAs  
 





Figure 4.9: Distribution of reads that mapped to cellular mRNAs present in 
cattle transcripts.  
Data obtained from high throughput sequencing of cDNA library generated from 
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 CLASH for sheep embryo fibroblasts expressing ovhv2-miRs 4.3.2
 Transient transfections of ovhv2-miRs in sheep embryo fibroblasts 4.3.2.1
Unlike BJ1035 cells sheep embryo fibroblasts (SEF) do not express ovhv2-miRs. 
Two regions of the OvHV-2 genome predicted to express, two clusters of ovhv2-
miRs were cloned into a lentivirus vector (Section 2.1.7). Cluster-2 was 4.4kb long 
(coordinates: 27698-32075) and Cluster-3 was 260bp long (coordinates: 36313-
36575) (Figure 1.5). Cluster-2 and Cluster-3 are predicted to encode for twenty seven 
and three ovhv2-miRs respectively (Levy PhD thesis, 2012). Successful 
amplification (Section 2.1.2) and cloning of each of the cluster region was confirmed 
by agarose gel electrophoresis (Section 2.1.4) and sequencing (Section 2.1.9). 
Transient transfections were performed and total RNA was extracted (Section 2.1.10) 
from the cells transfected with either pLenti-blast cloned with Cluster-2 (pLenti-
Cluster-2), Cluster-3 (pLenti-Cluster-3) or empty vector (pLenti-empty). cDNA 
synthesis of miRNAs and RT-qPCR for cloned ovhv2-miRs expression were 
performed as described in section 2.1.11 and 2.1.12 respectively (Appendix-3 for 
RT-qPCR forward primers).  
RT-qPCR analysis was used to show that SEF transduced with pLenti-Cluster-3 
showed the expression of three ovhv2-miRs (ovhv2-miR-7 , ovhv2-miR-67 and 
ovhv2-mR-8) at levels comparable to the positive control (miR-16), a highly 
expressed stable cellular miRNA (Kroh et al., 2010). pLenti-Cluster-2 is predicted to 
encode for 27 ovhv2-miRs and  RT-qPCRs were carried out for ovhv2-mir-43, 
ovhv2-mir-41, ovhv2-mir-2, ovhv2-mir-3, ovhv2-mir-62 and ovhv2-mir-63. None of 
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the miRNAs showed expression (data not shown). Based on these results pLenti-
Cluster-3 was selected only for stable transfections of SEF for further investigations.  
 Transduction of SEF with lentiviruses expressing ovhv2-miRs and 4.3.2.2
tagged Ago2 protein  
After initial screening based on the RT-qPCR (Section 4.3.2.1), only pLenti-Cluster-
3 was selected to produce lentivirus expressing ovhv2-miR-7, ovhv2-miR-67, ovhv2-
miR-8 in SEF (Section 2.4.6 and 2.4.8). After transduction with lentiviruses 
expressing pLenti-Cluster-3 or pLenti-empty, blasticidin selection of the cells was 
performed (Section 2.4.7). RT-qPCRs were carried out to detect the expression of 
ovhv2-miRs as described in section 4.3.2.1. Results showed that each of the three 
miRNAs expression was comparable to the positive control (miR-16).   
SEF stably expressing Cluster-3 and SEF transduced with pLenti-empty were again 
transduced with tagged Ago2 expressing lentivirus (section 2.4.8). Doubly 
transduced cells were selected by puromycin and later used to perform CLASH. 
Western blot analysis also indicated a successful expression of tagged Ago2 in 
cluster-3 expressing SEF (SEF-Cluster-3) and SEF transduced with pLenti-empty 
(SEF-Empty) (Figure 4.10A). 
 Small scale immunoprecipitation of analysis of tagged Ago2 in SEF-4.3.2.3
Cluster-3 and SEF-Empty  
Before proceeding to CLASH experiments a protein A-tag mediated 
immunoprecipitation (IP) was performed with SEF-Cluster-3 and SEF-Empty as 
described in section 4.3.1.2. The western blot results showed that, the cell lysate and 
IP samples of SEF-Cluster-3 and SEF-Empty contained tagged Ago2, whereas the 
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FT sample contained very little tagged Ago2, indicating an efficient IP and no 
significant loss of proteins during the washing steps (Figure 4.10B and C 
respectively). 
 CLASH experiments for SEF-Cluster-3and SEF-Empty samples 4.3.2.4
CLASH experiments (section 2.8.4) were performed with three replicates each of 
SEF-Cluster-3 and SEF-Empty as tests (T1, T2 and T3) and negative controls (C1, 
C2, and C3) respectively as described in section 4.3.1.3. Bands representing the 100 
KDa tagged Ago2 were identified in all the samples (Figure 4.11A). The T1 sample 
of SEF-Cluster-3 showed a low level of labelled radioactivity signal as compared to 
the other two test samples which might be due to the loss of some of the cross-linked 
sample during the washing steps following radiolabelling. The C3 sample of SEF-
Empty showed smears above the band of desired size which might be due to 
presence of other RNAs. A more stringent washing during the IP and Ni affinity 
purification step could reduce smearing, but relevant interactions may also be lost. 
Common contaminants of approximately 50 to 80 Kda were detected in all samples 
(Figure 4.11A asterisk*). The regions associated with 100 Kda were excised from the 
membranes (indicated in red boxes in Figure 4.11A) as outlined in section 2.8.8. The 
RNA recovered after proteinase K treatment and 5’ linker ligation was reverse 
transcribed and cDNA libraries were prepared (section 2.8.9 to 2.8.12). A small 
quantity of the cDNA libraries of each of the sample was amplified by PCR (PCR 
primers Appendix-3) and the products were visualized on the agarose gel (Figure 
4.11B). In all of the samples, a PCR product of ~150bp was excised from the gel (red 
squares in Figure 4.11B). Sequencing results provided sufficient evidence that all the 
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samples have miRNAs and/or mRNA, 5’linker, barcodes and 3’linker sequences. 
Insert lengths observed were in the range between 0-59nt. Ovhv2-mir-67 was one of 
the ovhv2-miRs that were stably expressed by the transduced SEF (Section 4.3.3). 
Sequencing of the T2 sample identified the complete sequence of ovhv2-mir-67. This 
initial sequencing therefore confirmed that the viral miRNAs were being correctly 
processed and incorporated into the RISC complex (Figure 4.12). For further analysis 




















              
Figure 4.10: Western blot analysis to monitor tagged Ago-2 in sheep embryo 
fibroblasts (SEF). 
A: Western blot with antibody against human Ago2 or GAPDH showing expression of 
tagged Ago2 in SEF. 
Lane 1: SEF transduced with three ovhv2-miRs and HTP tagged Ago2 
Lane 2: SEF transduced with tagged Ago2  
Lane 3: Un-transduced SEF 
 
B and C: Western blot analysis to monitor the enrichment of HTP tagged Ago2 using 
protein A-tag mediated immuno-precipitation (IP) in the SEF transduced with tagged Ago2 
and/or three ovhv2-miRs. Cell lysate, FT and IP samples were probed with antibodies 
against human Ago-2 using magnetic Dyna-beads. FT: Flow through obtained during 
washing steps of IP.  
B: SEF-Cluster-3: SEF transduced with three ovhv2-miRs and tagged Ago2 
C: SEF-Empty: SEF transduced with tagged Ago2  










Figure 4.11: Visualization of CLASH experimental products. 
(A) Autoradiograph of radiolabelled tagged Ago2 with miRNA-mRNA complex 
after Ni-affinity purification and 3’linker ligation. Red boxes indicate regions on the 
membrane that were excised and used for downstream analysis. Asterisk sign shows 
a common contaminant of 50-60KDa. The protein size marker is indicated on the 
left.  
(B) MetaPhor agarose gel electrophoresis with 3% agarose and 1xTBE, of cDNAs 
libraries amplified by PCR. The regions which were excised from the gel for DNA 
extraction are indicated in red boxes. A 100bp DNA size marker (NEB) is indicated 
on the left. 
T1, T2, T3:  Three replicates of SEF-Cluster-3  









Figure 4.12: Sequencing of a cloned cDNA sample generated from the T2 
sample of SEF-Cluster-3.  
5’ linker, barcode and 3’ linker is highlighted in cyan, grey and yellow respectively. 
RNA insert is shown in bold. ovhv2-miR-67 sequence was also observed as a part of 
the insert and is shown in green. Adapter sequences from PCR primers are shown as 
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 High Throughput sequencing of cDNA libraries obtained from SEF-4.3.2.5
Cluster-3and SEF-Empty 
Bioinformatic analysis of the test and control samples were carried out as described 
in section 4.3.1.4. The total number of reads which could be matched with the 
barcodes associated with the T1, T2, T3, C1, C2 and C3 samples were 15,939,277, 
14,483,617, 7,188,832, 19,151,198, 18,673,973 and 43,709,491 respectively. The 
resulting reads were mapped against ovhv2-miR-7, ovhv2-miR-67 and ovhv2-miR-8 
and the entire database of miRBase V19 using Blast, after removing the sequencing 
adapter. To look for the expression of targeted genes, the reads were also mapped to 
the sheep genome OAR v3.1. A total of 565,833, 1,149,259 and 443,918 reads were 
obtained for the T1, T2 and T3 samples of SEF-Cluster-3, whereas 964,658, 237,685 
and 712,257 reads were obtained from the C1, C2 and C3 samples of SEF-Empty 
(Table 4.5). The number of reads mapping to sheep genes and the occurrence of all 
chimeras were recorded. 
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Foot notes: T1, T2 and T3 are test samples expressing ovhv2-miR-7, 67 and 8.  
C1, C2, C3 are control samples. 
































T1 15939277  565833  14635, (3%)  470518, (83%)  80398, (14%)  107, (0.02%)  95, (0.02%)  80, (0.01%) 
T2 14483617  1149259  96387, (8%)  1036058, (90%)  16619, (1%)  23, (0.00%)  115, (0.01%)  57, (0.00%) 
T3 7188832  443918  155673, (35%)  275409, (62%)  11856, (3%)  21, (0.00%)  917 (0.21%)  42, (0.01%) 
C1 19151198  964658  5606, (1%)  941923, (98%)  17000 (2%)  12, (0.00%)  0, (0.00%)  117, (0.01%) 
C2 18673973  237685  4027, (2%)  208573, (88%)  24997 (11%)  35, (0.01%)  4, (0.00%)  49, (0.02%) 
C3 43709491  712257  17242, (2%)  643365, (90%)  51509, (7%)  52, (0.01%)  28, (0.00%)  61, (0.01%) 
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 Analysis of ovhv2-miRs in the CLASH data from SEF-Cluster-3 and 4.3.2.6
SEF-Empty  
The number of reads obtained for ovhv2-miRs (ovhv2-miR-7, 67 and 8) in the test 
samples T1, T2 and T3 are shown in Figure 4.13. The percentages of those counts as 
compared to the total number of reads of their respective samples were ~3%, 8% and 
35%. The presence of other ovhv2-miRs (ovhv2-miRs which were not used in this 
part of the study) in tests and controls was detected in a very low numbers is most 
likely due to the contamination of barcodes as described in the section 4.3.1.4 (Table 
4.5). Sequencing results showed that ovhv2-mir-67 was the most abundant of the 
three ovhv2-miRs and constituted 75%, 89% and 89% of total ovhv2-miRs reads in 
T1, T2 and T3 samples, respectively. The abundance of ovhv2-miR-8 was 2734 
(19%), 6386 (7%) and 12039 (8%) in T1, T2 and T3 samples, respectively. ovhv2-
miR-7 was the least abundant of the three ovhv2-miRs with 824 (6%), 2039 (2%) 
and 5342 (3.4%) reads in T1, T2 and T3 respectively (Figure 4.14).  
In the tests and control samples a large number of cellular-miRs was also found. The 
percentages of read counts for cellular-miRs as compared to the total reads counts in 
T1, T2 and T3 samples were 83%, 90% and 62% whereas for  C1, C2 and C3  the 
percentages were ~98%, 87% and 90% of their total reads counts respectively (Table 
4.5). It is worth noting that in test samples due to the abundance of ovhv2-miR-7, 
ovhv2-miR-67 and ovhv2-miR-8 the percentage of cellular-miRs is less than that of 
control samples. 
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Figure 4.13: Read counts of the three ovhv2-miRs obtained from the three 
samples of SEF-Cluster-3. 
The distribution of the ovhv2-miRs (ovhv2-miR-7, -67 and -8) in the Test samples 
(T1, T2, and T3) is shown. 
 
Figure 4.14: The proportion of ovhv2-miR-7, ovhv2-miR-67 and ovhv2-miR-8 in 
test samples (T1, T2 and T3) of SEF-Cluster-3. 
Percentages of the three ovhv2-miRs as compared to the total read counts of the 
ovhv2-miRs, in each sample, are shown. 
7 
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 Analysis of sheep mRNAs in SEF-Cluster-3 and SEF-Empty  4.3.2.7
For the SEF-Cluster-3 and SEF-Empty samples Solexa sequencing reads were 
obtained as described in 4.3.2.5 and were mapped to predicted genes from the sheep 
genome. Read counts for mRNAs of tests and control samples and percentages 
relative to the respective samples are shown in column 5 of Table 4.5.  The T1 
sample showed the highest abundance of sheep mRNA reads among the three 
datasets of the test groups. Less than 0.02% of the total sequence reads could be 
matched to other RNA classes such as rRNA, tRNA, snRNA, snoRNA and 
transposons in each of the test and control groups (Table 4.5).  
To identify the sheep genes which were differentially enriched in the test and control 
samples a differential gene enrichment analysis was performed. 
 Identification of differentially enriched sheep genes obtained in CLASH  4.3.2.8
To determine which genes showed differential enrichment in SEF-Cluster-3 samples 
as compared to SEF-Empty samples, the test and control sample datasets were 
analysed with the help of using the R (version 2.13.0) package EdgeR (Robinson et 
al., 2010). Genes with less than 100 mapped reads in the test or control groups were 
excluded from the analysis. P-values were obtained for all comparisons of interest. 
Twenty nine differentially enriched genes (DEnGs) with a p-value<0.05, between the 
test and control groups were identified.  To control for false positive predictions a 
5% false discovery rate (FDR) threshold was applied the datasets. A 5% FDR 
adjusted p-value (q-value<0.05) means that 5% of significant tests will result in false 
positives.  
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At a FDR threshold for 5%, only five DEnGs out of 29 were still significant. Those 
genes included delta-like protein 1(DLL1) (also known LOC101117853) (q=0.03), 
zinc finger protein GLI2 (GLI2) (q=0.03), sec1 family domain containing 1 (SCFD1) 
also known as SLY1 (q=0.03), active BCR related gene (ABR) (q=0.035) and an 
uncharacterized protein (q=0.03) (Table 4.6). Using EdgeR positive and negative 
log2 fold change (logFc) values in the DEnGs was calculated. The positive logFc 
indicated that the number of read counts was higher in the test samples as compared 
to the control samples and vice versa for the negative fold change values. The five 
top DEnGs (shown above) were found to have positive logFc values; 6.1 (DLL1), 8.7 
(GLI2), 12.7 (SCFD1), 10.4 (ABR) and 10 (uncharacterized).  
The remaining 24 DEnGs with p-value<0.05 were also analysed to identify genes 
which could be biologically important. Eighteen of those showed a positive log fold 
change ranging from 3.7 to 10.6 and a q-value from 0.07 to 0.29.  The remaining six 
genes showed a negative log fold change ranging between -9.5 to -6.  These genes 
include translationally-controlled tumor protein TCTP also known as TPT1 (q=0.16), 
cold shock domain-containing protein E1 (CSDE1) (q=0.14), TBC1 domain family 
member 9 (TBC1D9) (q=0.082), ubinuclein-1 (UBN1) (0.13), putative RNA-binding 
protein Luc7-like 2 (LUC7L2) (q=0.072) and lysosomal-associated transmembrane 
protein 4B (LAPTM4B) (q=0.13).  A complete list of the DEnGs with log fold 
change, p-values and q-values is shown in Table 4.6. 
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 Identification of differentially expressed sheep genes obtained by 4.3.2.9
microarray data analysis 
To validate CLASH data and to identify genes whose expression changed in the 
presence of ovhv2-miR-7, ovhv2-miR-67 and ovhv2-miR-8, a microarray study was 
carried out using SEF-Cluster-3 and SEF-Empty. Total RNA from three replicates 
each of test and control groups were analysed using the Affymetrix ovine gene 1.0 
ST array, for whole-transcript analysis using sheep genome OAR v2.0 as described 
in section 2.8. The analysis of the microarray data was performed with the help of 
Miss Alison Downing from ARK Genomics using Partek Genomic suite.  
The microarray data analysis of test vs control samples showed a total of 1900 
statistical significant DEG with a p<0.05. Out of those 1900 genes, 977 showed a 
negative fold change which was an indication of down regulation in the expression of 
those genes. The remaining 904 showed a higher expression of genes in the control 
as compared to the test samples (Supplemental data file 4.3). When a 5% FDR was 
applied to avoid false positive predictions, no DEG with p<0.05 could pass through 
the filter. Therefore another less stringent filter (fold change >1.5 or <-1.5 and 
p<0.01) was applied to get highly up regulated and down regulated genes. A total of 
32 genes were obtained. The hierarchical clustering in the heat map showed that 
there was excellent intra-group agreement between test and control samples. Figure 
4.16 shows the heat map for the 32 DEG identified by microarray analysis of the 
transduced-SEF. Twenty five of those genes are highly down-regulated and seven are 
highly up-regulated in the SEF-Cluster-3 as compared to SEF-Empty.   
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The top down-regulated genes were ferritin heavy chain (FTH1) and Ectonucleotide 
pyrophosphatase/phosphodiesterase family member 2 (ENPP2) also referred to 
Autotaxin, which showed a fold change of -2.2 and -2.03 respectively. The two top 
up-regulated genes were Solute carrier family 3 (neutral and basic amino acid 
transporter) member 1 (SLC3A1) and Desmin (DES), which showed a fold change of 
2.15 and 2.25 respectively (Table 4.7).  
 Comparison of the DEnGs identified from CLASH and DEG from 4.3.2.10
microarray data analysis 
DEnGs obtained from the CLASH (Section 4.3.2.8) and DEG from microarray 
datasets (Section 4.3.2.9) were also compared for common sets of genes but at the 
defined significance levels no genes were found in common between the two data 
sets. There may be a number of reasons. Firstly CLASH is involved in the physical 
binding of the transcript to the miRs and their immuno-precipitation along with the 
RISC complex. In contrast microarray global analysis involves changes in the 
expression of genes possibly due to the downstream effects of targeting by ovhv2-
miRs. Secondly miRNA induced translational repression of targeted transcripts often 
produces changes at a smaller level in gene expression, which may be missed by the 
stringent condition of CLASH and microarray data analysis. For example Endothelial 
PAS domain-containing protein 1 (EPAS1) was present in both data sets. In the 
CLASH data EPAS1 was one of the DEnGs but it could not pass the filter for 
differential gene expression measurement in microarray data with a p=0.038 
(supplemental data file 4.2).  
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 Identification of Ovhv2-miRs target sites within DEnGs and DEGs 4.3.2.11
In the previous sections (4.3.2.8 and 4.3.2.9) CLASH and microarray data analysis 
was used to identify genes which might be regulated by ovhv2-miR-7, ovhv2-miR-
67 and/or ovhv2-miR-8. To proceed further it was necessary to also identify if target 
sequences for those ovhv2-miRs were present within the 5’UTR, CDS or 3’UTR of 
the DEG.  
To confirm the presence of miRNA targets sites, a target prediction analysis was 
performed using the miRNA target prediction programe; RNAhybrid. Only those 
DEnGs which showed a positive fold change in CLASH data and DEG which 
showed a negative fold change in the microarray data were analysed using 
RNAhybrid. Parameters for the prediction of the miRNA target were set to identify a 
miRNA seed region similarity from position 1-7 or 2-8 nucleotides from the 5’end. 
G:U pairing was also allowed. The information on the location of the 5’UTR or 
3’UTR of some of the genes was not available. In those cases the CDS was used for 
miRNA target site identification. Uncharacterized and non-annotated genes were also 
excluded from the analysis. The number of predicted target sites for ovhv2-miRs in 
DEnGs and DEG is shown in Table 4.8 and 4.9 respectively.  
All of the DEnGs and DEG showed predicted target site/s for one or more of the 
three ovhv2-miRs and it is possible that the differential expression of those genes in 
both datasets was due to targeting of these genes by ovhv2-miRs.  
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Table 4.6: Differentially enriched genes (DEnGs) identified by the CLASH data 
analysis. 
CLASH Differentially expressed genes 
logF
C 
p-value *q value 
DLL1: Delta-like protein 1 (ligand for Notch receptors) 6.1 0.0004 0.030 
Uncharacterized 10.4 0.0005 0.030 
GLI2:  zinc finger protein 8.7 0.0006 0.030 
SCFD1; Sec1 family domain-containing protein 1 12.7 0.0007 0.030 
ABR;Active breakpoint cluster region-related protein 10.0 0.001 0.035 
DHX57; Putative ATP-dependent RNA helicase 8.7 0.003 0.072 
POLN; DNA polymerase theta subunit 9.4 0.004 0.072 
FOXRED2;FAD-dependent oxidoreductase domain-containing 
protein 2 
7.5 0.004 0.072 
LUC7L2; Putative RNA-binding protein Luc7-like 2 -6.1 0.004 0.072 
C10ORF71; Uncharacterized protein 7.8 0.005 0.074 
AGTPBP1; Cytosolic carboxypeptidase 1 4.4 0.007 0.102 
TBC1D9; TBC1 domain family member 9 -7.0 0.007 0.082 
LAPTM4B; Lysosomal-associated transmembrane protein 4B -6.1 0.010 0.13 
SLC9A5; solute carrier family 9, member 3 : SL9A5_HUMAN 
Sodium/hydrogen exchanger 5 
10.1 0.012 0.13 
UBN1; Ubinuclein-1 -6.4 0.012 0.13 
CCDC88B; Coiled-coil domain-containing protein 88B 10.6 0.012 0.13 
CYP4F22; Cytochrome P450 4F22 10.1 0.015 0.14 
CSDE1; Cold shock domain-containing protein E1 -8.5 0.016 0.14 
HIC1; Hypermethylated in cancer 1 protein 9.8 0.016 0.14 
ALMS1; Alstrom syndrome protein 1 8.0 0.017 0.14 
TCTP; Translationally-controlled tumor protein (TPT1) -9.5 0.02 0.16 
ADAMTSL4;ADAMTS-like protein 4 5.8 0.031 0.24 
ZBTB7C; Zinc finger and BTB domain-containing protein 7C 9.5 0.032 0.24 
EPAS1; Endothelial PAS domain-containing protein 1 3.7 0.034 0.24 
Uncharacterized 9.4 0.039 0.26 
ADAT3; tRNA-specific adenosine deaminase-like protein 3 9.4 0.041 0.27 
CD177; CD177 antigen 5.3 0.044 0.27 
USP19; Ubiquitin carboxyl-terminal hydrolase 19 7.1 0.046 0.29 
RXFP3; Relaxin-3 receptor 1 5.6 0.047 0.29 
Foot notes: p<0.05 for the statistical significance. 
LogFC: Log2 fold change.  
*: DEnGs are ranked by q-values 
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Figure 4.15: Differentially enriched genes (DEnGs) identified by the CLASH 
data analysis with statistical significance (adjusted p<0.05). 
Blue bars show  the positive fold change indicating the higher enrichment of DEnGs 
in test samples as compared to control samples, whereas negative fold (red bars) 
indicates the lower enrichment of DEnGs in test samples as compared to control 
samples.  
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Figure 4.16: Heat map comparing differentially expressed genes obtained from 
microarray analysis of tests and control samples. 
Shown are the genes which had p-value <0.05. The samples are represented in rows and the 
genes in the columns. Blue blocks indicate down regulation and red blocks indicate up-
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Figure 4.17: Differentially expressed genes (DEG) identified by the microarray 
analysis (fold change >1.5 or <-1.5 and p<0.01). 
Blue bars show  the negative fold change indicating the down regulation of DEG  in 
test samples as compared to control samples, whereas negative fold (red bars) 
indicates the up-regulation of DEG in test samples as compared to control samples.  
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Table 4.7: Differentially expressed genes (DEG) identified by microarray data 
analysis. 
Microarray differentially expressed genes  *Log FC p-value  
FTH1; Ferritin heavy chain -2.18 0.0057 
ENPP2; Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 -2.03 0.0013 
Not annotated -1.86 4.42E-07 
PRSS35; Inactive serine protease 35 -1.86 0.0057 
Not annotated -1.82 0.0089 
GUCY1A1; guanylate cyclase soluble subunit alpha -1.78 0.0016 
PDE1A; Calcium/calmodulin-dependent 3'; 5'-cyclic nucleotide 
phosphodiesterase 1A 
-1.74 0.0075 
VLDLR; Very low-density lipoprotein receptor -1.71 0.0006 
ITGA8; Integrin alpha-8 -1.69 0.0020 
C3ORF49; uncharacterized protein -1.61 0.0098 
ZNF608; Zinc finger protein 608 -1.61 0.0007 
APBB1IP; Amyloid beta A4 precursor protein-binding family B member 1-
interacting protein 
-1.60 0.0039 
RGS17; Regulator of G-protein signaling 17 -1.59 0.0002 
KHDRBS3; KH domain-containing; RNA-binding; signal transduction-
associated protein 3 
-1.56 0.0031 
SEMA3A; Semaphorin-3A -1.56 0.0019 
ARHGAP20; Rho GTPase-activating protein 20 -1.54 0.0029 
NRXN1; Neurexin-1-alpha -1.54 0.0006 
GATM; Glycine amidinotransferase; mitochondrial -1.53 0.0015 
NRXN1; Neurexin-1-alpha -1.53 0.0053 
UPK1B; Uroplakin-1b -1.53 0.0013 
NIPAL2; NIPA-like protein 2 -1.53 0.0058 
SEMA3D; Semaphorin-3D -1.52 0.0018 
ISLR2; mmunoglobulin superfamily containing leucine-rich repeat protein 2 -1.51 0.0021 
NAV2; Neuron navigator 2 -1.51 0.0017 
SLC25A16; solute carrier family 25 -1.51 0.0004 
FAM71F1; Protein FAM71F1 1.51 0.002 
PFKFB3; 6-phosphofructo-2-kinase/fructose-2; 6-biphosphatase 3 1.56 0.0045 
ADAMTS1; ADAM metallopeptidase with thrombospondin type 1 motif 1.7 0.0013 
LPHN3; Latrophilin-3 1.71 0.0048 
ANKRD1; ankyrin repeat domain 1 1.74 0.0018 
SLC3A1; solute carrier family 3 (neutral and basic amino acid transporter) 
member 1 
2.15 0.0017 
DES; Desmin 2.25 0.0014 
Foot notes: Statistical significance of differential expression was determined at fold 
change >1.5 or <-1.5 and p<0.01.  
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7  67  8  7  67  8  7  67  8  7  67  8  7  67  8  7  67  8 
SCFD1  ‐  ‐  ‐  ‐  1  ‐  ‐  ‐  ‐  2  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 
GLI2  NI  NI  NI  NI  NI  NI  ‐  3  4  4  2  8  ‐  ‐  ‐  2  ‐  ‐ 
DLL1  NI  NI  NI  NI  NI  NI  ‐  1  ‐  3  2  3  ‐  2  ‐  ‐  ‐  1 
ABR  ‐  ‐  ‐  ‐  ‐  ‐  1  ‐  ‐  2  2  3  ‐  ‐  ‐  ‐  ‐  ‐ 
POLN:  NI  NI  NI  NI  NI  NI  ‐  2  ‐  2  5  5  NI  NI  NI  NI  NI  NI 
DHX57  NI  NI  NI  NI  NI  NI  ‐  ‐  1  2  2  3  ‐  ‐  ‐  2  1  ‐ 
FORED2  NI  NI  NI  NI  NI  NI  ‐  1  1  1  1  5  ‐  ‐  ‐  ‐  ‐  ‐ 
CJ071  NI  NI  NI  NI  NI  NI  ‐  2  3  5  ‐  4  NI  NI  NI  NI  NI  NI 
AGTPBP1  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  1  ‐  2  ‐  ‐  ‐  ‐  ‐  1 
CCDC88B  NI  NI  NI  NI  NI  NI  ‐  ‐  2  ‐  7  7  NI  NI  NI  NI  NI  NI 
SLC9A5  NI  NI  NI  NI  NI  NI  1  1  2  3  1  5  ‐  ‐  ‐  2  7  5 
CYP4F22  NI  NI  NI  NI  NI  NI  ‐  ‐  ‐  2  2  2  ‐  1  ‐  ‐  ‐  ‐ 
HIC1  NI  NI  NI  NI  NI  NI  ‐  ‐  ‐  1  1  1  ‐  ‐  1  ‐  1  1 
ALMS1  NI  NI  NI  NI  NI  NI  ‐  ‐  ‐  9  6  8  ‐  ‐  1  ‐  ‐  ‐ 
ZBTB7C  NI  NI  NI  NI  NI  NI  ‐  2  1  1  2  2  ‐  ‐  ‐  ‐  ‐  ‐ 
ADAMTSL
4 
‐  ‐  ‐  ‐  ‐  3  ‐  1  2  3  9  9  ‐  ‐  ‐  1  ‐  1 
EPAS1  NI  NI  NI  NI  NI  NI  2  1  1  ‐  2  4  ‐  ‐  1  ‐  ‐  ‐ 
ADAT  ‐  ‐  ‐  2  ‐  2  ‐  ‐  ‐  1  2  1  NI  NI  NI  NI  NI  NI 
CD177  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  1  1  2  4  NI  NI  NI  NI  NI  NI 
USP19  ‐  ‐  ‐  ‐  ‐  ‐  1  ‐  2  5  3  5  NI  NI  NI  NI  NI  NI 
RXFP3  NI  NI  NI  NI  NI  NI  1  1  1  4  1  4  ‐  ‐  ‐  ‐  ‐  ‐ 
Foot notes: DEnGs were subjected to target prediction program RNAhybrid, for the 
prediction of targets of ovhv2-miR-7, ovhv2-miR-67 and ovhv2-miR-8.  
- : No target 
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7  67  8  7  67 8 7 67 8 7 67 8  7  67  8 7 67 8
FTH1  ‐  ‐  ‐  ‐  ‐ ‐ ‐ ‐ ‐ ‐ ‐ 1  ‐  ‐  ‐ ‐ ‐ 1
ENPP2  ‐  ‐  ‐  ‐  ‐ ‐ 1 1 ‐ 4 ‐ 4  ‐  ‐  ‐ 1 ‐ ‐
PRSS35  ‐  ‐  ‐  1  ‐ ‐ ‐ 1 1 1 2 1  ‐  ‐  ‐ 3 1 4
GUCY1A1  ‐  ‐  ‐  1  1 ‐ 1 1 3 1 1 4  ‐  ‐  ‐ ‐ 1 ‐
PDE1A  ‐  ‐  ‐  2  1 1 ‐ ‐ ‐ 1 ‐ ‐  ‐  ‐  1 6 2 1
VLDLR  NI  NI  NI  NI  NI  NI  ‐ ‐ ‐ ‐ 1 5  ‐  ‐  ‐ ‐ ‐ ‐
ITGA8  ‐  1  ‐  ‐  ‐ ‐ ‐ ‐ ‐ 3 1 9  ‐  ‐  ‐ 2 ‐ 3
C3ORF49  NI  NI  NI  NI  NI  NI  ‐ ‐ ‐ 1 1 1  NI  NI  NI  NI  NI  NI 
ZNF608  ‐  ‐  ‐  ‐  1 ‐ ‐ ‐ ‐ 2 3 5  NI  NI  NI  NI  NI  NI 
APBB1IP  ‐  ‐  ‐  ‐  ‐ ‐ 1 1 ‐ 2 ‐ 2  ‐  ‐  ‐ 1 ‐ ‐
RGS17  ‐  ‐  ‐  ‐  ‐ ‐ ‐ ‐ ‐ 1 ‐ 1  ‐  ‐  ‐ ‐ ‐ ‐
KHDRBS3  NI  NI  NI  NI  NI  NI  ‐ ‐ ‐ 1 ‐ 1  ‐  ‐  ‐ ‐ ‐ ‐
SEMA3A  ‐  ‐  1  ‐  ‐ ‐ ‐ ‐ ‐ 2 2 2  ‐  ‐  ‐ ‐ ‐ 2
ARHGAP2  NI  NI  NI  NI  NI  NI  ‐ ‐ 1 2 1 7  ‐  ‐  ‐ 1 1 3
NRXN1  ‐  1  ‐  1  ‐ 2 ‐ ‐ 1 2 2 5  ‐  ‐  ‐ 7 1 ‐
GATM  ‐  ‐  ‐  ‐  ‐ ‐ ‐ ‐ 1 1 ‐ 2  ‐  ‐  ‐ 1 1 1
UPK1B  ‐  ‐  ‐  ‐  ‐ ‐ ‐ ‐ ‐ 2 1 2  ‐  ‐  ‐ 1 1 1
NIPAL2  NI  NI  NI  NI  NI  NI  ‐ ‐ ‐ 4 2 ‐  ‐  ‐  ‐ 2 ‐ ‐
SEMA3D  ‐  ‐  ‐  1  ‐ ‐ ‐ ‐ ‐ 1 ‐ 3  ‐  ‐  1 2 1 5
ISLR2 2  ‐  ‐  ‐  ‐  ‐ ‐ 1 3 2 2 2 2  NI  NI  NI  NI  NI  NI 
NAV2  ‐  ‐  ‐  ‐  ‐ ‐ ‐ 1 2 2 3 8  ‐  ‐  1 1 ‐ ‐
SLC25A16  NI  NI  NI  NI  NI  NI  ‐ ‐ ‐ 1 ‐ 1  ‐  ‐  ‐ 1 1 ‐
Foot notes: DEG were subjected to target prediction program RNAhybrid, for the 
prediction of targets of ovhv2-miR-7, ovhv2-miR-67 and ovhv2-miR-8.  
-  No target 
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 Biological processes and pathway analysis of the DEnGs identified from 4.3.2.12
CLASH and DEG identified from microarray data 
CLASH and microarray analysis enabled the identification of highly enriched and 
strongly down-regulated and up-regulated genes. To determine the relationship 
among the differential genes in the datasets (4.3.2.8 and 4.3.2.9) and their 
involvement in different pathways, Ingenuity Pathway Analysis (IPA) was applied. 
IPA can help to determine the biological relevance of the collective effects on gene 
expression induced by ovhv2-miRs. DEnGs and DEG and their fold change values 
were submitted to IPA to interpret the data in the context of biological processes and 
canonical pathways. Significance of the biological processes and the pathways were 
tested by the Fisher Exact test p-value and relationships between genes and their 
associated biological processes were considered statistically significant (p-value ≤ 
0.05). 
IPA analysis identified the involvement of CLASH identified DEnGs in different 
molecular and cellular functions, based on their roles. The top cellular processes 
include cell morphology, cellular development, cell to cell signaling and interaction, 
cellular assembly and organization, and cellular growth and proliferation (Figure 
4.18). DEnGs with their associated biological processes and p-values are shown in 
table 4.11. GLI2, DLL1, EPAS1, HIC1, ZBTB7C and TPT1 were found to be 
involved in most of the IPA identified processes. 
DLL1 and GLI2 were identified as the top two highly expressed DEnGs (Table 4.7). 
DLL1 is a part of the Notch signaling pathway. The CLASH data analysis showed 
that ovhv2-miR-67 formed a chimera with DLL1 (Section 4.3). GLI2 is a part of the 
Chapter 4           Identification and characterization of cellular targets of Ovhv2-miRs 
   203 
 
sonic hedgehog (SHH) signaling pathway. EPAS1 which is one of the highly 
expressed DEnGs in CLASH, involved in angiopoitin-Tie2 (endothelial tyrosine 
kinase gene) signalling pathway.  
DEG identified from microarray data analysis were also analysed in IPA to identify 
significant biological processes involved. The top cellular processes identified were 
similar to those identified in the CLASH (Figure 4.18, Table 4.10).  The DEG 
involved in most of these processes include; SEMA3A, SEMA3D, ENPP2, VLDLR, 
DES, NRXN1 and ITGA8.  
SEMA3A and SEMA3D belong to class-3 semaphorins which are involved in 
semaphorin signalling pathway to regulate immune cell responses. ENPP2 is 
involved in the NAD (nicotinamide adenine dinucleotide) metabolism pathway. 
ITGA8 (integrin alpha 8) and DES (desmin) were found to be a part of the Rho 
pathway and Rho family GTPases pathways respectively. IPA analysis also 
identified the integrin pathway for ITGA8.  One of the down-regulated DEG, 
PDE1A (Table 4.7) is a cyclic nucleotide phosphodiesterase (PDE) and is involved in 
G-protein coupled receptor signalling, cAMP mediated signalling and Protein kinase 
A signalling pathways. The most down-regulated DEG, FTH1 (Ferritin heavy chain) 
was also found to be the part of the NRF2 (Nuclear factor like 2)-mediated oxidative 
stress response pathway.   
In the analysis of both data sets (CLASH and Microarray), whilst no common 
pathways could be found, two of the pathways (SHH and cAMP dependant PKA) are 
found to be related. These results indicated that many of the differential genes 
obtained from both data sets are involved in biological processes related to 
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transcription, cell growth/ proliferation, differentiation, angiogenesis and tumour 
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Figure 4.18: Biological processes affected by ovhv2-miRs expression in sheep 
embryo fibroblasts.  
The pie charts represent the number of DEnGs (A) and (DEG) changing expression 
with known roles in biological processes, affected by three of the transduced ovhv2-
miRs in sheep embryo fibroblasts. The biological processes determined by Ingenuity 
Pathways Analysis (IPA) of CLASH (A) and microarray (B) data sets. Correlation 
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Table 4.10: Biological processes identified by Ingenuity Pathway Analysis (IPA) 
Biological processes identified by Ingenuity Pathway Analysis (IPA) for the 
differentially expressed genes DEnGs identified in CLASH (A) and DEG identified 







CLASH identified DEnGs involved in the 
processes 
p-values 







GLI2, EPAS1,AGTPBP1,  











GLI2, DLL1, EPAS1, ALMS1, UBN1, 

























Cellular Movement 6 




Cell Morphology 10 
ENPP2, SEMA3A, SEMA3D, , NRXN1, 







ENPP2, NRXN1, SEMA3A, SEMA3D, 












ARHGAP20, ISLR2, SEMA3A, SEMA3D, 





Foot notes: Significance of the biological processes were tested by the Fisher Exact 
test p-value and relationships between genes and their associated biological 
processes were statistically significant with a p-value ≤ 0.05 
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 CLASH analysis of OvHV-2 miRNAs hybrids with bovine or ovine 4.3.3
transcripts  
CLASH is a method for transcriptome-wide analysis of RNA-RNA interaction 
duplexes bound to a protein (tagged Ago2 in this study), ligation between the two 
strands of RNA duplexes to form chimeric RNAs (chimeras), high throughput 
sequencing of resulting cDNAs and bioinformatics analysis of the resulting 
sequencing data to annotate chimeric reads (Travis et al., 2014). The chimeric reads 
contain, part of the 5’ linker, cDNA insert (miRNA ligated to targeted 
mRNA/miRNA or only miRNA or only mRNA) and part or all of the 3’ linker 
(Figure 4.1).  
As described in the previous section (4.3.1 and 4.3.2) the CLASH was used to 
identify targets of ovhv2-miRs within bovine and ovine cells. For the identification 
of targets for ovhv2-miRs analysis of chimeric read data was performed. 
Identification of chimeric reads containing ovhv2-miRs and host mRNA/miRNA 
sequence would provide direct evidence of an interaction.  
 miRNA-mRNA Chimeras identified in BJ1035 sample 4.3.3.1
The initial bioinformatic analysis was performed as described in the section 4.3.1.4. 
Sequencing reads derived from CLASH experiments using BJ1035 cells (section 
4.3.1.5) were analysed using stringent quality filters to identify those reads which 
contained two distinct fragments and could be mapped separately. Fragments from 
49 genes were found to form a chimera with ovhv2-miRs. Other types of RNAs were 
also identified, including one spliceosomal RNA (U2) and one long non-coding RNA 
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(MATR3). It is worth noting that among the targeted single reads obtained from 
BJ1035 data set (section 4.3.1.6), U2 spliceosomal RNA was also one of the highly 
targeted class in CLASH results (section 4.3.1.6). In the BJ1035 dataset 0.04% of all 
reads were identified as chimeric reads with ovhv2-miR (Table 4.11). This is 
consistent with the data from related studies, which showed chimeric reads to 
constitute less than 1% total (Kudla et al., 2011).  
Table 4.11: Chimeric sequencing reads associated with BJ1035 sample. 
 Total reads 
chimeric reads  
with ovhv2-miRs 
chimeric reads  
with cellular-miRs 
Number  676003 285 91 
Percentage 100% 0.04% 0.01% 
 
The predicted ovhv2-miR and mRNA interactions were analyzed using RNAhybrid; 
and UNAfold programes. Before analysing the chimeric reads using the programs, 
the lengths of mRNA fragments were adjusted by adding 25 nucleotides downstream 
and by extending the miRNA fragment to the full length mature miRNA (Kudla et 
al., 2011) (Supplemental data file 4.4). RNAhybrid identified miRNA-mRNA 
interactions within the 5’UTRs, CDS and 3’UTRs of the genes. Approximately 59% 
of the target sites were located in the CDS whereas 27.4% and 13.7% interactions 
were located in the 3’UTR and the 5’UTR respectively.  
Ten percent of the miRNA-mRNA interactions were found to have perfect 
complementarity between the seed region of the miRNA and the target site in the 
mRNA. Additionally 27.5% of interactions were also found in the same region but 
with the presence of G:U base pairing. The remaining 63% of interactions were non-
canonical and were found in the regions other than the 5’end of the miRNAs. The 
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binding energies for the miRNA-mRNA interactions ranged from -32 to -12.3 
kcal/mol, indicating that the recovered chimeras formed stable base-paired 
interactions.  
The top three mRNAs forming chimeras with ovhv2-miR-57, ovhv2-miR-34 and 
ovhv2-miR-54 were C17ORF85 (30.5%), ribosomal protein S6 kinase-like 1 
(RPS6KL1) (12.3%) and WD repeat domain 60 (WDR60) (6%) respectively (Table 
4.15). ovhv2-miR-53, 43, 53, 50 and 43 formed chimeras with other transcripts 
including active BCR-related gene (ABR) (4.2%), integrin alpha-10 precursor 
(ITGA10) (2.8%), melanoma antigen family A, 10-like (LOC100298021) (2.8%), 
MYHC-Embryonic (myosin-3) (2.6%) and PRP39 pre-mRNA processing factor 39 
homolog (S. cerevisiae) (PRPF39) (2.1%), respectively (complete list in 
supplemental data file 4.4). ovhv2-miR-217M formed chimeras with six different 
transcripts including LIX1-like protein (LIX1L), polycomb protein SCMH1 
(SCMH1),  catsper channel auxiliary subunit beta (CATSPERB), cleavage 
stimulation factor subunit 3 (CSTF3), ATPase, H+ transporting, lysosomal 
56/58kDa, V1 subunit B1 (ATP6V1B1) and U11/U12 small nuclear 
ribonucleoprotein 25 kDa protein (SNRNP25). Ovhv2-miR-53 and ovhv2-miR-5 
each formed chimera/s with the fragments of five different mRNAs fragments. 
Ovhv2-miR-53 formed chimeras with ABR, LOC100298021, tudor domain 
containing 12 (TDRD12), mitogen-activated protein kinase kinase kinase 2 
(MAP3K2) and myeloid/lymphoid or mixed-lineage leukemia 5 (MLL5) whereas 
ovhv2-miR-5 with fragments of A disintegrin and metalloproteinase with 
thrombospondin motifs 1 (ADAMTS1), MCF.2 cell line derived transforming 
sequence-like (MCF2L), sine oculis-binding protein homolog (SOBP), centrosomal 
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protein 152kDa (CEP152) and SEC13 homolog (SEC13). A total of 19 ovhv2-miRs 
out of forty six ovhv2-miRs formed chimeras with bovine transcripts (Table 4.12). 
The length of transcript fragments in the chimeras ranged from 12-39 nucleotides. 
Two of the transcripts; U2 spliceosomal RNA (U2) (20bp long fragment) and 
transmembrane 6 superfamily member 1 (TM6SF1) (39bp long fragment), were 
found to have the target sites for respective miRNA within the chimeric fragment 
without the addition of 25 nucleotides. Ovhv2-miR-36 and ovhv2-miR-8 formed 
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57 C17orf85 87 30.53 61 MCOLN3 2 0.70 
34 RPS6KL1 35 12.28 7 TUBA1A 2 0.70 
54 WDR60 17 5.96 8 TBR1 2 0.70 
56 LOC101906939 15 5.26 217M SCMH1 2 0.70 
43 ITGA10 12 4.21 217M CATSPERB 2 0.70 
53 LOC100298021 8 2.81 217M CSTF3 2 0.70 
50 myosin-3 8 2.81 217M ATP6V1B1 2 0.70 
53 ABR 7 2.46 217M SNRNP25 2 0.70 
43 PRPF39 7 2.46 36 U2 1 0.35 
39 FHOD1 6 2.11 8 TM6SF1 1 0.35 
39 PNPLA6 5 1.75 34 SPNS1 1 0.35 
40 C9H6orf211 4 1.40 35 ATRN 1 0.35 
43 TDRD7 4 1.40 35 ZFX 1 0.35 
53 MLL5 3 1.05 39 SERINC1 1 0.35 
58 CACNG4 3 1.05 39 ZC3H4 1 0.35 
61 BAZ1A 3 1.05 53 TDRD12 1 0.35 
7 CPNE9 3 1.05 53 MAP3K2 1 0.35 
217M LIX1L 3 1.05 56 CEP152 1 0.35 
35 FREM3 3 1.05 56 SEC13 1 0.35 
39 CA12 2 0.70 57 PDCL3 1 0.35 
51 CRB2 2 0.70 58 FLVCR2 1 0.35 
54 THSD1 2 0.70 61 ZNF550 1 0.35 
56 ADAMTS1 2 0.70 63 MAGI3 1 0.35 
56 MCF2L 2 0.70 67 LSMEM2 1 0.35 
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Figure 4.19: ovhv2-miRs formed chimeras with BJ1035 transcripts. 
ovhv2-miR-36 and ovhv2-miR-8 formed chimeras with U2 spliceosomal RNA (U2) 
and transmembrane 6 superfamily member 1 (TM6SF1) respectively.  
Sequence of U2 (A) and TM6SF1 (D) chimeric reads with their respective miRNAs. 
Barcode, mRNA fragment, miRNA and 3’ linker are shown in blue, black, green and 
red respectively. miRNA target regions are shown in bold.  
Figure B (U2) and E (TM6SF1) showed the results obtained from RNAhybrid 
software for the ovhv2-miRs target predication in the mRNA fragment of the 
chimeric reads. 
Figure C (U2) and F (TM6SF1) showed results obtained from UNAfold software to 







GTGAGCATATACTTGTCTTCCTGTCTGGGCTGGTTTCAGAATCTTGGCTCAGCGTGACTGCTCTTTGGAAT         
 1437                   1474 
 
E
target 5'               U     CU       C      U                   G 3' 
                              GU      UC   UG   CUGGGCU     
                              CG      AG   GC   GACUCGG     
miRNA  3' UUCU       UC      U                             U 5’ 
mfe: -18.3 kcal/mol 










target      5'                     U                               U 3'          
                        AC  GCA           CGACCUGG     
                        UG  CGU           GUUGGAUC     
miRNA  3' GA    U        UUUAC                    U 5‘ 
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 Validation of ovhv2-miRs targets in BJ1035 samples identified by 4.3.3.2
CLASH 
Some of the bovine transcripts which were identified to form chimeras with ovhv2-
miRs using the CLASH approach might be the potential targets of ovhv2-miRs and 
involved in MCF related pathology. To further investigate those targets a reporter 
gene assay (dual luciferase assay) was used to validate the predicted targets. A total 
of 9 transcripts were found which showed to have interactions with ovhv2-miRs in 
the seed regions (section 4.3.3.1). Due to time constraint it was not possible to 
validate all the identified targets.  
Two of the targets; U2 spliceosomal RNA (U2) and transmembrane 6 superfamily 
member 1 (TM6SF1) were selected for validation. TM6SF1 formed a chimera with 
ovhv2-miR-8. TM6SF1 was chosen for further study as it was known to be a target 
of both the KSHV encoded miRNA miR-K-12-11 and the human oncogenic miRNA 
hsa-miR-155 (Skalsky et al., 2007). The RNAhybrid analysis also predicted an 
interaction between miRNAs; ovhv2-miR-36 and ovhv2-miR-8 seed regions with the 
target sites in U2 and TM6SF1 (Figure 4.19).  
Luciferase assays were performed using constructs containing target sites from U2 or 
TM6SF1 cloned downstream of the renilla luciferase reporter gene of the 
psiCHECK2 plasmid. Luciferase constructs were created using custom 
oligonucleotides (section 2.6) corresponding to the regions of U2 and TM6SF1 
transcripts from nucleotides 109-191 (Transcript ID: ENSBTAG00000028094) and 
1455-1461 (accession number: XM_005221887.1) respectively.  The target sites for 
ovhv2-miRs were located from nucleotide 152-158 (U2) and 1455-1461 (TM6SF1).  
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Luciferase constructs (LUC/U2 for U2 and LUC/TM6SF1 for TM6SF1 construct) 
were co-transfected with test mimic miRNAs or negative control scramble miRNA in 
100 nM or 200 nM concentration, into BHK21 cells. For each region of interest each 
experiment was performed three times as described in the Sections 2.6 and 3.3.3, 
with 6 replicates in 96 well plates. For all experiments an empty vector was used to 
investigate off-target effects however no significant reduction in luciferase 
expression was observed using any of the ovhv2-miRs (Supplemental data file 4.6). 
In all the other experiments positive controls (psi-M23-2 and miR-M23-2) worked in 
the same manner as described in Section 3.3.3.1, that is the addition of miR-m23-2 
caused significant reduction in the luciferase levels at either concentration 
(Luciferase readings in the Supplemental data file 4.6 ).  
4.3.3.2.1 Validation of U2 as a predicted target of ovhv2-miR-36  
The LUC/U2 was co-transfected with a scrambled miRNA mimic (negative control) 
to compare to the luciferase levels of the same plasmid co-transfected with targeting 
mimics. Transfection of the ovhv2-miR-36 mimic at a concentrations of 200 nM led 
to significant down regulation (approximately 20%) in luciferase expression relative 
to the negative control (LUC/U2+ovhv2-miR-36, 200 nM) p=0.004 (Figure 4.20). 
Introduction of the ovhv2-miR-36 mimic at a concentration of 100 nM showed a 
non-significant difference (LUC/U2+ovhv2-miR-36, 100 nM) p=0.6) in the 
luciferase expression, compared to the negative control. The LUC/U2 in the absence 
of any miRNA (no miRNA control), showed significant higher expression of 
luciferase gene as compared to negative control at both concentrations (LUC/U2, 100 
nM) p<0.001 and LUC/U2, 200 nM) p<0.001 (Figure 4.20 for 200 nM).  
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4.3.3.2.2 Validation of TM6SF1 as a predicted target of ovhv2-miR-8  
A significant increase in the luciferase expression was observed when LUC/TM6 
was transfected with the ovhv2-miR-8 mimic at both concentrations (100 nM or 200 
nM) as compared to the negative control (LUC/TM6+ovhv2-miR-8, 100 nM) 
p<0.001 and (LUC/TM6+ovhv2-miR-8, 200 nM) p<0.001. An approximately 60% 
and 80% increase in luciferase expression was observed at 100 and 200 nM 
concentrations respectively. According to the luciferase assay results, the samples 
transfected with LUC/TM6 also showed higher significant luciferase expression 
compared to the negative control at both concentrations (LUC/TM6, 100 nM) 
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Figure 4.20: Luciferase expression levels in BHK21 cells transfected with U2 
(LUC/U2) in the psiCHECK-2 plasmid in the presence/absence of target miRNA 
(Ovhv2-miR-36) at 200 nM concentration. 
Data are represented as luciferase activity with the **=p<0.01 and ***=p<0.001 
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Figure 4.21: Luciferase expression levels in BHK21 cells transfected with 
TM6SF1 (LUC/TM6) in the psiCHECK-2 plasmid in the presence/absence of 
target miRNA (Ovhv2-miR-8) at 200 nM concentration.  
Data are represented as luciferase activity with the ***=p<0.001 relative to negative 
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 miRNA-mRNA chimeras identified in sheep embryo fibroblasts 4.3.3.3
expressing ovhv2-miRs 
To identify chimeric reads and to determine the potential targets of ovhv2-miRs 
bioinformatics analysis was carried out on the data obtained from three replicates 
each of SEF-Cluster-3 (T1, T2 and T3) and SEF-Empty (C1, C2 and C3) as 
described in section 4.3.2.5. The total number of chimeras obtained from the T1, T2 
and T3 samples were 85 (0.02%), 113 (0.01%) and 914 (0.21%) respectively. 
Percentages were calculated from the total mapped reads of each sample (Table 4.5). 
In two of the control samples; C2 and C3, 4 and 24 chimeras between ovhv2-miRs 
and sheep transcripts, were found respectively. The percentages of those chimeric 
reads were 0.002% (C2) and 0.003% (C3) as compared to the total mapped reads 
(Table 4.5). Two of the chimeras in the C2 sample had the sequence of ovhv2-
miR217M which was not used in this experiment (Table 4.14). As no ovhv2-miR 
was transduced into the control samples (SEF-Empty) (4.3.2.2) and possible reason 
for the presence of chimeras with ovhv2-miRs may be the contamination of barcodes 
used during sequencing (section 4.3.1.4). In all the samples (Tests and controls) 
cellular miRs were also found to form chimeras with sheep mRNAs (Table 4.5).  
Fragments of a total of 17, 8 and 28 mRNAs formed chimeras in the T1, T2 and T3 
samples respectively (Table 4.13). ovhv2-miR-67 was the most abundant ovhv2-miR 
in the chimeric reads in the three test samples. In the T1 sample ovhv2-miR-67 
formed chimeras with fragments of 14 different sheep mRNAs, whereas ovhv2-miR-
7 and -8 formed chimeras with only 1 and 2 mRNAs, respectively. In the T2 sample 
ovhv2-miR-7, 67 and -8, formed chimeras with 1, 6 and 1 mRNA respectively. In the 
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T3 sample, ovhv2-miR-67 formed chimeras with 25 different mRNAs whereas 
ovhv2-miR-7 and -8 formed chimeras with only 1 and 2 mRNAs, respectively (Table 
4.13).  
The interactions between ovhv2-miRs and mRNAs were analysed using RNAhybrid; 
and UNAfold programs. RNAhybrid analysis showed most of the miRNA-mRNA 
interactions were in the coding regions of the transcripts (88% for T1, 75% for T2 
and 82% for T3 samples). Whereas 6%, 0% and 4% interactions were found in the 
5’UTR and 6%, 25% and 14% were found in the 3’UTRs of the mRNAs, in the T1, 
T2 and T3 samples respectively. 
RNAhybrid analysis also identified approximately 18%, 38% and 29% of the 
miRNA-mRNA canonical interactions had perfect complementarity between the seed 
regions and the target site in the mRNA in the T1, T2 and T3 samples respectively, 
whereas 29%, 25% and 21% interactions were found in the seed regions but with the 
presence of G:U pairing. The remaining 53% (T1), 38% (T2) and 50% (T3) 
interactions were non canonical. Binding energies for the miRNA-mRNA 
interactions ranged from -44.4 to -17.6 kcal/mol, indicating that these chimeras 
formed stable base-paired interactions.  
The mRNA which formed the highest number of chimeras in all the test groups was 
an uncharacterized protein with sequence similarity to delta-like protein 1 (DLL1). 
DLL1 was also found as one of the top DEnGs identified in the CLASH single reads 
dataset (Section 4.3.2.7 and 4.3.2.9, Table 4.7).  DLL1 formed chimeras with ovhv2-
miR-67 and constituted 42.4%, 80% and 84% of total chimeras in the T1, T2 and T3 
samples respectively. The chimeric fragments of DLL1 mapped to two regions of the 
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coding sequence in the DLL1 mRNA. UNAfold and RNAhybrid analysis also 
identified that both of the chimeric fragments had target sites for ovhv2-miR-67 and 
formed canonical interactions. One target site showed perfect base pairing between 
the seed region (position 2 to 8) of the miRNA whereas other target site showed an 
interaction with position 1 to 7 of the miRNA seed region, with one G:U base pairing 
(Figure 4.25).  
Another mRNA which was found to form chimeras with ovhv2-miR-7, in all test 
samples was kelch-like 2, Mayven (Drosophila) (KLHL2). KLHL2 constituted 
approximately 1.2%, 15% and 0.4% of the total chimeras in the T1, T2 and T3 
samples respectively. The fragment of the KLHL2 in the chimeric read mapped to 
the 3’UTR of KLHL2 mRNA.  RNAhybrid analysis identified that the KLHL2 
chimeric fragment had a target site for ovhv2-miR-7 interacting with the miRNA 
seed region (1-7 nucleotide) with two G:U base pairings.  
Multiple epidermal growth factor-like domains protein 8 (MEGF8) and Doublesex- 
and mab-3-related transcription factor C2 (DMRTC2) formed chimeric reads with 
ovhv2-miR-67 in two of the test samples; T1 and T3. MEGF8 constituted 2.4% of 
the total chimeric reads in T1 and 0.1% in T2. DMRTC2 constituted up 2.4% of the 
total chimeric reads in T1 and 3.8% in T2. The chimeric fragment of MEGF8 
showed perfect base pairing between the target site present in the fragment and the 
seed region of ovhv2-miR-67 (nucleotides 2-8). In contrast non-canonical 
interactions were also found between DMRTC2 and ovhv2-miR-67 (from miRNA 
position 4-11). Some of the other mRNAs which formed chimeras with ovhv2-miRs 
include fibroblast growth factor 19 (FGF19) (1.2%) and semaphorin-5B (SEMA5B) 
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(1.2%) in the T1 sample, probable helicase with zinc finger domain (HELZ) (0.9%) 
in the T2 sample and v-crk sarcoma virus CT10 oncogene homolog (avian) (CRK) 
(0.8%), serine/threonine-protein kinase PAK 7 (PAK7) (0.1%) and von Willebrand 
factor A domain-containing protein 5B2 (VWA5B2) (0.1%) in the T3 sample. The 
other mRNAs forming chimeras with ovhv2-miR-7, -67 and -8 in the test samples 
are shown in Table 4.14. The number and overlap of the chimeric mRNAs in the test 
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Ovhv2-miR-7  1 1 
Ovhv2-miR-67 14 81 
Ovhv2-miR-8 2 3 
T2 
Ovhv2-miR-7  1 17 
Ovhv2-miR-67 6 95 
Ovhv2-miR-8 1 1 
T3 
Ovhv2-miR-7  1 4 
Ovhv2-miR-67 25 905 
Ovhv2-miR-8 2 5 
C1 
Ovhv2-miR-7  0 0 
Ovhv2-miR-67 0 0 
Ovhv2-miR-8 0 0 
C2 
Ovhv2-miR-7  0 0 
Ovhv2-miR-67 2 2 
Ovhv2-miR-8 0 0 
 ovhv2-mir-217M 1 2 
C3 
Ovhv2-miR-7  1 3 
Ovhv2-miR-67 4 19 
Ovhv2-miR-8 2 2 
Foot notes: T1, T2 and T3: Test samples stably expressing ovhv2-miR-7, -67 and -8. 
C1, C2 and C3: Control samples. In control samples no ovhv2-miR was used in the 
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T1  67 MARK4 9  0.98
67  DLL1 36  42.35 67 CRK 7  0.77
67  ABCA3  14  16.47 67 PRRX2 5  0.55
67  FAM208B  9  10.59 67 GLTSCR1  5  0.55
67  STAB1 6  7.06 7 KLHL2 4  0.44
67  SLC3A2  3  3.53 8 BABAM1  4  0.44
67  MEGF8  3  3.53 67 FAM86A  3  0.33
67  DMRTC2  2  2.35 67 UPK3BL 2  0.22
67  TRANK1  2  2.35 67 B3GNTL1  1  0.11
8  TRIM27  2  2.35 67 TLX3 1  0.11
67  FGF19 1  1.18 67 WDFY4 1  0.11
67  TIM  1  1.18 67 MVP 1  0.11
8  SGPP2  1  1.18 67 SDK2 1  0.11
67  SEMA5B  1  1.18 67 VWA5B2  1  0.11
67  IGSF3 1  1.18 67 ATG2B 1  0.11
67  LOC101109723  1  1.18 67 NPHS1 1  0.11
67  PHF17  1  1.18 67 MEGF8 1  0.11
7  KLHL2 1  1.18 8 PITRM1 1  0.11
T2  67 PAK7 1  0.11
67  DLL1 90  79.65 67 SLC38A4  1  0.11
7  KLHL2 17  15.04 67 UBE2Q2  1  0.11
8  HELZ 1  0.88 C1
67  COPZ2  1  0.88 ‐ ‐ 0  0
67  BAHCC1  1  0.88 C2
67  KIAA0913  1  0.88 217M SCMH1 2  50
67  RP9  1  0.88 67 ABCA3 1  25
67  HMX2 1  0.88 67 DLL1 1  25
T3  C3
67  DLL1 768 84.03 67 DLL1 16  66.67
67  DMRTC2  35  3.83 7 KLHL2 3  12.50
67  TMEM222  13  1.42 8 GPR137B  1  4.17
67  DMRT2  13  1.42 8 CRCP 1  4.17
67  SMN1 12  1.31 67 MOXD2 1  4.17
67  USP24  12  1.31 67 UBE2Q2  1  4.17
67  MOGS  9  0.98 67 HMGXB3  1  4.17
Foot notes: T1, T2 and T3: Test samples. C1, C2 and C3: Control samples. 
Sheep mRNAs which formed chimeras in more than one samples are highlighted; 
DLL1: pink, KLHL2: green, DMRTC2: purple, MEGF8: orange, ABCA3: dark grey 
and UBE2Q2: light grey.  
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Figure 4.22: The number and overlap of the chimeric mRNAs in the sheep 
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Figure 4.23: ovhv2-miR-67 formed chimeras with sheep transcripts. 
ovhv2-miR-67 formed chimeras with delta like 1 (DLL1) and von Willebrand factor 
A domain-containing protein 5B2 (VWA5B2).  
Chimeric reads of DLL1 (A and D) and VWA5B2 (G). Barcodes, mRNA fragments, 
miRNAs and 3’ linkers are shown in blue, black, green and red respectively. miRNA 
target regions are shown in bold.  
Figure B and E (DLL1) and H (VWA5B2) show the results obtained from 
RNAhybrid software for the ovhv2-miR-67 target predication in the mRNA fragment 
of the chimeric reads. 
Figure C and F (DLL1) and I (VWA5B2) show results obtained from UNAfold 
software to fold chimeric reads to observe the miRNA-mRNA hybridized 
interactions.    
                    470                      500 
CACTAGCTGTGCTTCCGAGGTCGGGGTCACGACTCGCTCGCACCCCGGGGGUAUGUGCAGGACTG
GAATTCTCGGGTGCCA 
                       
 
 target 5'                               U            GAGG                   C 3' 
                              UGUGC      UCC           UCGGGGU     
                             ACGUG        GGG          GGCCCCA     
miRNA  3' CAGG             UAU                                         5‘ 
 
mfe: -23.3 kcal/mol 





target 5'      C    GGGGAGG        CCCG     A                 G 3' 
                       CC                 GCGC         AC  CCCGGGG     
                       GG                CGUG         UG  GGGCCCC     
miRNA  3' CA     A                        UA         G                 A 5‘ 
 
mfe: -30.4 kcal/mol 





target    5'    A      A     G      A                                   C 3' 
                        CC    G   GC     UG      CUGGGGU     
                        GG   C    UG    AU       GGCCCCA     
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 Validation of ovhv2-miRs targets identified in sheep embryo 4.3.3.4
fibroblasts, by CLASH 
Some of the mRNAs identified in the chimera analysis (section 4.3.3.3) may be 
potential targets of ovhv2-miRs and may play an important role in OvHV-2 infection 
in sheep. To validate those targets, dual luciferase reporter assays were carried out 
(Section 2.6). Only those mRNAs which showed an interaction with their respective 
ovhv2-miRs in the seed region (nucleotides 1-7 or 2-8) were considered the further 
investigation. Due to the time limits it was not possible to validate all the identified 
targets and only two mRNAs were selected for further analysis. Of these, DLL1 was 
chosen as it constituted the highest number of chimeras in all of the test samples 
(Section 4.3.3.3) and was also the top DEnGs in the single read datasets (4.3.2.7). In 
addition to DLL1, VWA5B2 which formed chimera with ovhv2-miR-67 was 
selected for validation.  
RNAhybrid analysis identified potential interactions between the miRNA seed region 
from position 1-7 and 2-8 with DLL1 and from position 1-7 with VWA5B2 (Figure 
4.23). The target sequences were located in the coding regions of the genes. 
Luciferase assays were performed using plasmid constructs containing target sites 
from DLL1 and VWA5B2 (as described in Sections 2.6 and 4.3.3.2). Luciferase 
constructs were created using custom oligonucleotides (Section 2.7). For DLL1 the 
region of mRNA used was from nucleotide 2620 to 2706 (ovis aries chromosome 8; 
exon 8: 90487092-90487006). Two target sites for ovh2-miR-67 were located in the 
region (2644-2650 and 2665-2671). The first 52 nucleotides of the mRNA region 
from 2620 to 2672 (chromosome 8; exon 8: 90487092-90487006) had perfect 
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sequence similarity to another region (chromosome 8; 90486767-90486715) which at 
the time of designing the oligonucleotides and performing the luciferase assays, was 
shown as a part of the exon.  Recent updates to the OarV3.1 annotation mapped that 
sequence as a part of the intron next to exon 8. Due to the presence of the sequence 
in the exon the primers were designed using that sequence (ovis aries chromosome 8; 
90486767-90486681) and was used for the validation of ovhv2-miR-67 targets in 
dual luciferase assays. Fortunately the ovhv2-miR-67 target sites were located in the 
first 52 nucleotides of the region which showed perfect sequence homology with the 
DLL1 mRNA sequence. Oligonucleotides were designed for VWA5B2 
corresponding to the region from 3291 to 3376 from the mRNA sequence 
(XM_004003830.1). The target site for the ovhv2-miR-67 was located from 
nucleotide 3333 to 3339.  
Luciferase assays and statistical analysis of results were carried out using 
successfully cloned constructs (LUC/DLL1 for DLL1 and LUC/VWA for VWA5B2) 
as described in Section 4.3.3.2.  
4.3.3.4.1 Validation of DLL1 as a predicted target of ovhv2-miR-67  
Introduction of the ovhv2-miR-67 at both 100 nM and 200 nM concentrations led to 
a significant down regulation (approximately 50% and 60%) in luciferase expression 
relative to the negative controls respectively, (LUC/DLL1+ovhv2-miR-67, 100 nM) 
p=0.001, (LUC/DLL1+ovhv2-miR-67,200 nM) p<0.001). In the absence of any 
miRNA LUC/DLL1 also showed significantly higher expression of luciferase than 
the control (LUC/DLL1, 100 nM) p<0.001 and LUC/DLL1, 200 nM) p<0.001 
(Figure 4.24 for 200 nM concentration result).  
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4.3.3.4.2 Validation of VWA5B2 as a predicted target of ovhv2-miR-67  
In the presence of the ovhv2-miR-67 at both (100 nM and 200 nM) concentrations no 
significant difference was observed in the luciferase expression relative to the 
negative controls (LUC/VWA+ovhv2-miR-67, 100 nM) p=1.0, (LUC/VWA+ovhv2-
miR-67,200 nM) p=0.42). LUC/VWA in the absence of any miRNA, showed no 
significant difference in expression of luciferase when compared with the control at 
100 nM concentration (LUC/VWA, 100 nM) p=0.05). However a significant higher 
expression of luciferase was observed compared to the negative control at 200 nM 
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Figure 4.24: Luciferase expression levels in BHK21 cells transfected with DLL1 
(LUC/DLL1) in the psiCHECK-2 plasmid in the presence/absence of target 
miRNA (ovhv2-miR-67) at 200 nM concentration. 
Data are represented as luciferase activity with the ***=p<0.001 relative to negative 
control (light grey) value at 200 nM concentration.  
 
 
Chapter 4           Identification and characterization of cellular targets of Ovhv2-miRs 
   230 
 
 
Figure 4.25: Luciferase expression levels in BHK21 cells transfected with 
VWA5B2 (LUC/VWA) in the psiCHECK-2 plasmid in the presence/absence of 
target miRNA (Ovhv2-miR-67) at 200 nM concentration. 
Data are represented as luciferase activity with the ***=p<0.001 relative to negative 
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 Discussion 4.4
In order to determine the potential role of ovhv2-miRs in MCF pathogenesis, it is 
necessary to identify their target mRNAs. There are a number of ways to identify 
miRNA targets; bioinformatic analysis using the seed region sequence of miRNA to 
identify the complementary sites in the mRNA sequence by alignment, microarrays 
which determine the difference in the abundance of transcripts in the samples 
with/without miRNA expression, and immunoprecipitation assays to pull-down the 
RISC-miRNA with targeted mRNA. CLASH is a relatively new technique and is a 
combination of pull-down/immuno-precipitation and bioinformatics. CLASH allows 
direct analysis of RNA-RNA interactions in the living cells and those interactions 
can be recorded using high throughput sequencing. Generally, CLASH provides a 
reliable alternative to existing experimental and bioinformatics methods. Because 
crosslinking is carried out in the living cells, the dynamic state of the RNA-RNA 
interactions can be probed as a function of physiological conditions (Kudla et al., 
2011). CLASH can also be used to identify miRNAs targets and their interactions 
with the targeted mRNAs. In this study CLASH was used to identify ovhv2-miRs 
targets within the transcripts of the bovine and sheep genomes.  
 
 CLASH identifies viral miRNA targets within LGL cell line BJ1035  4.4.1
The OvHV-2 infected LGL cell line BJ1035 expresses all the ovhv2-miRs and was 
used as a source to identify those miRs (Levy et al., 2012) and their targets. Due to 
the unavailability of appropriate control bovine cells, only BJ1035 cells were used in 
this study. BJ1035 cells are non-adherent cells and exhibit a doubling time of 7-8 
days under appropriate conditions (Swa et al., 2001) and for CLASH experiments a 
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large number of cells (Section 2.8.1) was required. Due to the long doubling time of 
cells, the multi-step nature of CLASH and the time required for high throughput 
sequencing, it was not possible to grow BJ1035 to a sufficient density in the 
available timeframe and so only one BJ1035 sample was characterised. This study 
provides a snap shot of the miRNA interactions with bovine mRNAs. The analysis of 
miRNA-mRNA chimeras (Section 4.3.3.1) has enabled the identification of potential 
bovine mRNA targets that may, with the further study provide insight into the 
pathology of MCF. The CLASH single read data, showed some differences from the 
RNA-seq data (for the abundance of ovhv2-miRs) presented by Levy (Levy PhD 
thesis, 2012). This might be due the differences in the experimental procedures 
between the studies in the construction of the cDNA libraries. CLASH required 
stringent purifications of tagged protein linked with the miRNA, mRNAs or miRNA-
mRNA chimera. Eight of the ovhv2-miRs validated by northern hybridization by 
Levy et al (Levy et al., 2012) also showed high abundance in the CLASH dataset 
(Table 4.2). In the CLASH data ovhv2-miR-217M was found (28300 reads) as the 
most abundant Ovhv2-miR whereas in the RNA-Seq data (Levy PhD thesis, 2012) 
ovhv2-miR-8 was found to be the most abundant (46048 reads) (Table 4.2). Thirty 
six of the 46 predicted ovhv2-miRs were present in CLASH data. Ten of the 
miRNAs which showed very low numbers in the RNA-Seq data were not present in 
CLASH data (Table 4.2). 
The single reads data obtained in the CLASH study had a high number of cellular 
mRNAs (Section 4.3.1.6). Due to the absence of an uninfected control sample it was 
not possible to compare if those mRNAs were targeted by ovhv2-miRs. To determine 
the mRNA bovine targets of ovhv2-miRs, the CLASH chimera data was used. 
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MicroRNAs can bind to a wide variety of targets; with both canonical and non-
canonical base pairing which indicates that miRNA targeting rules may be complex 
and flexible (Helwak et al., 2013). The analysis of chimeras found the presence of 
canonical (nucleotides 1-7 or 2-8) (approximately 37%) and non-canonical 
interactions (approximately 63%) between miRNAs and mRNAs. This data is in line 
with another CLASH related study (Helwak et al., 2013) where non-canonical seed 
interactions were approximately 1.7 fold more common than perfect base pairing. 
The targets or binding sites of miRNAs can be located in the 5’UTR, CDS or 
3’UTRs, with the majority of the target sites found within the CDS (Hafner et al., 
2010, Helwak et al., 2013). In this study approximately 60% of miRNA target sites 
were found to be located in the CDS of the mRNAs which is consistent with the 
previous studies (approximately 50% in Hafner et al., 2010 and 60% in Helwak et 
al., 2013)  
Among the ovhv2-miRs, ovhv2-miR-217M which was found as the most abundant 
miRNA in the single read dataset, was also found to form chimeras with the highest 
number of mRNAs (Section 4.3.3.1). Two of the mRNAs; cleavage stimulation 
factor subunit 3 (CSTF3) and U11/U12 small nuclear ribonuclearprotein 25 kDa 
protein (SNRNP25) were shown to have a canonical interaction in the seed region of 
ovhv2-miR-217M. The protein encoded by the CSTF3 gene is one of the three 
(CSTF1 and CSTF2) cleavage stimulation factors that combine to form a CSTF 
complex. This complex is involved in the polyadenylation and 3’end cleavage of pre-
mRNAs (Takagaki and Manley, 1994). CDC73, a tumor suppressor gene, is a 
component of the Paf1 complex (Paf1C) and is involved in 3’end formation of 
polyadenylated mRNAs (Penheiter et al., 2005). It has been reported that CDC73 is 
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physically associated with CSTF and the cleavage and polyadenylation specificity 
factor (CPSF) and regulates transcription processing. The CDC73-CSTF-CPSF 
complex connects Paf1C directly with RNA for 3’ end formation. CDC73 defects 
that predispose to tumor formation could result from alteration in the 3’mRNA 
processing or alteration in the chromatin structure or a combination of these events 
(Rozenblatt-Rosen et al., 2009). It is possible that ovhv2-miR-217M targets CSTF to 
inhibit or alter the 3’end formation of cellular mRNAs to shut off host translational 
machinery.  
The SNRNP25 gene encodes a 25KDa protein that is a component of the U12-type 
spliceosome, and is involved in the pre-mRNA splicing by removing U12-type 
introns (Konig et al., 2007, Will et al., 2004). Both of these mRNAs have functions 
related to pre-mRNA splicing and polyadenylation suggesting a possible role in 
transcription.  
Another miRNA ovhv2-miR-36 formed a chimera with U2 (Sections 4.3.1.6 and 
4.3.3.2, Figure 4.19). U2 a snRNA is a component of the major (U2-dependant) 
spliceosome complex, and is involved in pre-mRNA splicing by catalysing the 
removal of U2 type introns. In eukaryotes two of the spliceosomes; U2 and U12 
coexist however more than 99% of introns are the U2 type and require U2 dependent 
splicing events for mRNA maturation (Will and Luhrmann, 2011). ovhv2-miR217M 
and ovhv2-miR-36 both formed chimeras with the components of mRNA 
polyadenylation  (CSTF3) and splicing (SNRNP25 and U2), in this study. A number 
of studies have reported, reciprocal functional coupling between splicing and 3′ end 
processing of RNA (Kyburz et al., 2006, Dye and Proudfoot, 1999, Niwa et al., 
1990).  In addition, in vitro a functional coupling and dependence was observed, 
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defining terminal exon and polyA site cleavage in splicing the terminal intron (Rigo 
and Martinson, 2008). A defect in either process has also been shown to disrupt 
splicing and 3′ end formation as well as the linked process of transcriptional 
termination (Dye and Proudfoot, 1999).  
To confirm if the identified targets were real, experimental validation was required. 
Due to time constraints only one of the targets; U2 was chosen for target validation 
using dual luciferase assay (Section 4.3.3.2.1). The LUC/U2 construct contained an 
82 nucleotide long U2 fragment with an ovhv2-miR-36 target site. The data from 
luciferase assays showed that ovhv2-miR-36 mimic could effectively knockdown the 
translational activity of the luciferase gene and a significant ~20% down-regulation 
in the expression was observed (Figure: 4.21). These results indicate that ovhv2-miR 
may interfere with host pre-mRNA processing. Incomplete processing may lead to 
non-functional mRNA formation causing shut-off of host proteins expression. As 
herpesviruses express numerous intronless transcripts, this may give the transcripts a 
competitive advantage in accessing the cellular translation machinery. The herpes 
simplex virus (HSV) protein ICP27 mediates the inhibition of cellular splicing. Early 
in infection, ICP27 interacts with several splicing factors and affects their 
phosphorylation. This results in the blockage of the pre-spliceosome assembly, 
which in turn contributes to the shut-off of host protein synthesis because of 
incomplete cellular pre-mRNAs processing (Bryant et al., 2001, Hardy and Sandri-
Goldin, 1994). OvHV-2 and other related herpesviruses have a homologue of ICP27 
but no such effect has been reported. ORF57 of KSHV has been reported to have 
roles in viral mRNA biogenesis by acting as viral splicing factor to promote splicing 
of KSHV transcripts (Majerciak et al., 2008). KSHV achieves this by recruiting 
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hTREX (human transcription and export complex) onto viral intronless mRNAs 
thereby allowing access of the viral transcripts to the cellular mRNA export proteins 
(Boyne et al., 2010) which then export the viral RNA to the cytoplasm for translation 
and protein production. Moreover, preventing the expression of host proteins is also 
an effective way for the virus to counteract the antiviral response (Mohr et al., 2008). 
Although many viruses encode proteins that specifically inactivate host cell 
regulatory or defence system, the small size of viral genomes limits the utility of this 
approach. miRNA which are smaller in size could offer an attractive alternative way 
for viruses to turn off specific host genes. There is a possibility that ovhv2-miR-
217M and ovhv2-miR-36 inhibit cellular splicing to shutoff host genes by targeting 
CSTF3, SNRNP25 and U2 respectively. 
Genes which involved in other cellular processes also formed chimeras with ovhv2-
miRs. MCF2L, which is also called Rho specific guanine nucleotide exchange factor 
DBS (RhoGEFs), formed a chimera with ovhv2-miR-5. RhoGEFs catalyse the 
exchange of GDP to GTP on members of the Rho family of small GTPases 
(Whitehead et al., 1997). Rho GTPases are critically involved in a variety of vital 
cell functions such as cell proliferation, apoptosis, and gene expression and are 
considered to be the main regulators of the cell cytoskeleton. Increasing evidence 
indicates that many herpesviruses interact with cytoskeleton-regulating Rho GTPase 
signaling pathways during different phases of their replication cycle (Van den 
Broeke and Favoreel, 2011). Examples of these include Rho GTPase-mediated 
nuclear translocation of virus during entry to a host cell and Rho GTPase-mediated 
viral cell-to-cell spread during later stages of infection (Van den Broeke and 
Favoreel, 2011). Most Rho proteins exhibit biological activity only when these are in 
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the GTP-bound state and RhoGEFs are primarily thought to be Rho activators. The 
deregulated expression of RhoGEFs can cause tumorigenic growth and promotes the 
invasive potential of a variety of cell types and are often found associated with loss 
of contact inhibition, growth factor independence, anchorage-independent growth 
and tumorigenecity (Cheng et al., 2002, Whitehead et al., 1997).  
ovhv2-miR-5 also formed a chimera with ADAMTS1 (also referred as METH-1). 
This gene encodes a member of the ADAMTS (a disintigrin and metalloproteinase 
with thrombospondin motif) proteins, is involved in tissue repairs processes 
(Krampert et al., 2005), anti-angiogenic activity (Obika et al., 2012) and 
inflammation (Kuno et al., 1997).  Krampert showed ADAMTS1 may play a role in 
the wound-healing process, as it regulates keratinocyte differentiation as well as 
migration of fibroblasts and endothelial cells (Krampert et al., 2005).  
ovhv2-miR-8 formed chimeras with two bovine mRNAs; TM6SF1 and TBR-1. 
TM6SF1 is a transmembrane protein and found as a differentially expressed gene in 
a sub set of CD8+ T cells in a study related to multiple sclerosis (Fanchiang et al., 
2012). TM6SF1 was identified as a target of the related gamma herpesvirus KSHV 
encoded miRNA miR-K-12-11 and the human oncogenic miRNA has-miR-155 and 
in the presence of those miRs, significant inhibition of gene expression was observed 
using a luciferase reporter assay (Skalsky et al., 2007). To determine if TM6SF1 was 
also a real target of ovhv2-miR-8 a luciferase reporter assay was performed in this 
study (Section 4.3.3.2). The results indicated an increase in the luciferase expression 
of approximately 60 and 80% at 100 nM and 200 nM concentrations of miRNA 
mimics, as compared to the negative control respectively (Section 4.3.3.2.2). 
miRNAs generally induce translational repression by interacting with the target sites 
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located in mRNAs, however translational activations have also been reported (Lin et 
al., 2011a, Vasudevan et al., 2007, Vasudevan, 2012) (Section 1.5.3.4). Translational 
up-regulation by miRNAs could be achieved in two ways; activation by direct action 
of miRNA /miRNPs or by the relief of repression where the action of a repressive 
miRNA is abrogated (Vasudevan, 2012). miR-206 binds the 3’UTR and upregulates 
translation of KLF4 mRNA in quiescent cell lines (Lin et al., 2011a). The liver 
specific miR-122 stimulates translation of HCV RNA through direct binding to two 
target sites in the virus 5’UTR (Henke et al., 2008). miR-346 interacts with the 
5’UTR of RIP140 and up-regulates translation in mouse brain tissue and p19 cells 
independent of AGO2 (Tsai et al., 2009). Binding of miR-125b to the 3’UTR of κB-
Ras2 mRNA and miR-466I to interleukin (IL)-10 mRNA mediates increased mRNA 
stability in human macrophages (Ma et al., 2010, Murphy et al., 2010).  Further 
investigation is required to confirm if the translational activation was due to ovhv2-
miR-8 interaction with TM6SF1. Experimentally a reporter assay using a miR-8 
target site knockout construct could confirm if the translation activation was due to 
an interaction between miR-8 and TM6SF1 interactions. It is also possible that the 
negative control caused a non-specific effect on the knockdown experiments. 
Changing or adding more negative controls can also provide a better insight into the 
results. 
TBR-1, which formed a chimera with ovhv2-miR-8, is a member of a conserved 
family of genes that share a common DNA-binding domain, the T-box. T-box genes 
encode transcription factors involved in the early cell fate decisions for 
differentiation and organogenesis (Wilson and Conlon, 2002).  
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CA12, which formed chimera with ovhv2-miR-39, belongs to the carbonic 
anhydrases (CAs) family.  CA is a large family of zinc metalloenzymes that 
catalyzes the reversible hydration of carbon dioxide. CAs participate in a variety of 
biological processes, including respiration, calcification, acid-base balance, bone 
resorption, and the formation of aqueous humor, cerebrospinal fluid, saliva, and 
gastric acid. This gene product is a type I membrane protein that is highly expressed 
in normal tissues (GeneCards®). CA12 is also found to be induced by hypoxia in 
various tumor cells, and promotes cell survival and growth in an acidic environment 
through pH maintenance. Silencing of CA12 and another CA (CA9) caused a 
dramatic decrease in the rate of tumor growth and might act as potential candidates 
for anticancer treatments (Chiche et al., 2009). The function of this gene does not 
support MCF pathology. However, the OvHV-2 immortalized LGL cell line BJ1035 
used in this study, is a mixed population of cells with respect to the virus life cycle; 
the majority of the cells are latently infected, but a small proportion express early and 
late virus genes (Rosbottom et al., 2002, Thonur et al., 2006). It is also possible that 
ovhv2-miRs may also be differentially expressed in the proportion of cells in culture 
in which the virus is latent.   
Other mRNAs forming chimeric interactions were; LAMB2 (ovhv2-miR-67) a 
laminin protein belonging to a family of extracellular matrix glycoproteins, involved 
in cell adhesion, differentiation, migration, signalling and metastasis (Aumailley and 
Krieg, 1996). CPNE2 (ovhv2-miR-7), a calcium-dependent membrane-binding 
protein that may regulate molecular events at the interface of the cell membrane and 
cytoplasm (Perestenko et al., 2010) and THSD1 (ovhv2-miR-54) which contains a 
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type 1 thrombospondin domain found in a number of proteins involved in the 
complement pathway, as well as in extracellular matrix proteins (GeneCards®).  
There were also a number of cellular mRNAs forming non-canonical chimeras with 
ovhv2-miRs (section 4.3.3.1). The interactions between miRNA and their targets are 
usually mediated by the seed region, which is a 6-8 nucleotide long fragment of 
miRNA at the 5’end and forms a Watson and Crick pairing with the target mRNA 
(Bartel, 2009). However non-canonical miRNA-mRNA interactions (interactions in 
the regions other than the miRNA 5’end) are also reported. Shin et al reported the 
presence of centered sites that have 11-12 contiguous Watson Crick pairs to miRNA 
nucleotides 4-15. Testing the perfect 11-mer matches using luciferase reporter assay 
starting at miRNA positions 3, 4, and 5 were each significantly associated with 
repression (Shin et al., 2010). Another study on the mapping of the human miRNA 
interactome by CLASH identified frequent non-canonical interactions. miR-92a was 
tested for experimental validation of the non-canonical interactions. Luciferase 
constructs with miR-92a seed region or non-seed region targets showed significant 
increase in expression on depletion of miR-92a (Helwak et al., 2013).   
Some of the mRNAs identified in this study which showed non-canonical 
interactions with the ovhv2-miRs, have functions that could influence the control of 
cellular processes.  ATRN (ovhv2-miR35) (also referred to DPPIV) is a normal 
serum glycoprotein which is rapidly expressed on the surface of activated T-cells in 
the initial stages of T-cell proliferation and can up-regulate antigen specific T cell 
responses (Duke-Cohan et al., 1998). ATRN positive CD4+ T cells exhibit a 
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memory phenotype, induce immunoglobulin synthesis in B cells and activate MHC-
restricted cytotoxic T cells (Boonacker and Van Noorden, 2003).  
FHOD1 (ovhv2-miR-39) interacts with Rac1 GTPases and mediates rearrangements 
of the actin cytoskeleton that might play a role in transcription regulation (Gasteier et 
al., 2003). ABR (ovhv2-miR-53) functions as a GTPases activating protein for Rac 
and CDC42 and promotes exchange of GDP to GTP (Cho et al., 2007). Rac is a 
subfamily of GTPases and is involved in the regulation of a diverse array of cellular 
events including cell growth, cytoskeleton reorganization and activation of protein 
kinase (Ridley, 2006).  
MAP3K2 (ovhv2-miR-53) (also referred to MEKK2) is a member of the 
serine/threonine protein kinase family. This kinase preferentially activates other 
kinases involved in the MAP kinase signaling pathway. This kinase has been shown 
to directly phosphorylate and activate Ikappa B kinases, and thus plays a role in the 
NF-kappa B signaling pathway. This kinase has also been found to bind and activate 
protein kinase C-related kinase 2, which suggests its involvement in a regulated 
signaling process (GeneCards). MAP3K2 enhanced the lytic replication of a related 
gamma herpesvirus; MHV68, when overexpressed (Li et al., 2010).  
ATP6V1B1 (ovhv2-miR-217M) is a multi-subunit enzyme and a component of a V-
ATPase complex. ATP6V1B1 is associated with an ATP-dependent proton pump 
and mainly functions as an acidifier in the internal environment of endomembrane 
systems such as lysozymes and endosomes (Ohta et al., 1996). V-ATPases have 
diverse roles in normal physiological processes including endocytosis, pH 
homeostasis and membrane trafficking (Forgac, 2007).  Acidification of intracellular 
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compartments has also been shown to be required for efficient MHC class II 
presentation (Benaroch et al., 1995) suggesting a role in adaptive immune system. 
Expression of ATP6V1B1 increases in various cancer cells and inhibitor of this 
protein inhibit the growth of various cells and inducing apoptosis (Manabe et al., 
1993, Morimura et al., 2008). Acidic endosomal compartments also have been 
shown to involve in the entry of some of the enveloped viruses in to the cells 
(Gruenberg and van der Goot, 2006). Pavelin et al found that ATP6V0C, a 
component of the V-ATPase complex, is an essential factor for HCMV replication. 
ATP6V0C was also targeted by HCMV encoded miRNA US25-1. Knockdown of 
ATP6V0C resulted in striking inhibition of virus replication and during growth curve 
analysis almost no infectious virus was detected (Pavelin et al., 2013). They also 
suggested that blocking of a component of V-ATPase complex, required for efficient 
replication, might represent a mechanism of establishing or maintaining viral latency 
(Pavelin et al., 2013).  MCF is characterized by cellular proliferation and targeting of 
MAP3K2 and ATP6V1B1 by ovhv2-miRs would be expected to cause an inhibitory 
effect on cellular growth. It is possible that targeting these mRNAs might help virus 
in evading the immune system or as discussed earlier that it is possibly due to the 
presence of cells in the BJ1035 cell line, which support latency. 
PDCL3 (ovhv2-miR-57) (also known as VIAF) is an inhibitor of apoptosis (IAP) 
interacting factor that functions in caspase activation during apoptosis and co-
regulates the apoptotic pathway (Wilkinson et al., 2004).  MLL5 (ovhv2-miR-53) 
has a regulatory role in the different stages of cell cycle. Ectopically over expressed 
MLL5 caused G1/S phase arrest (Deng et al., 2004) whereas siRNA mediated knock 
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down of MLL5 arrested cell cycle at both G1/S and G2/M phases (Cheng et al., 
2011).  
MAGI3 (ovhv2-miR63) is involved in various cellular and signalling processes. It 
interacts with tumor suppressor PTEN for enhanced regulation of AKT/PKB kinase. 
It serves to position the PTEN to specific sub-cellular locations that are involved 
with the regulation of cell proliferation and survival (Wu et al., 2000b). Down-
regulating PTEN can lead to cell proliferation, hypertrophy, and a lowered cellular 
response to stress (Yang et al., 2009). PTEN is also frequently deleted or mutated in 
various cancers to promote tumorigenesis. A cellular miRNA, miR-216a also targets 
PTEN. ovhv2-miR-217M has seed sequence homology with cellular miR-216a 
(Figure 4.5A) and it is possible that PTEN is also a target of ovhv2-miR-217M. To 
test if these mRNAs are functional targets of ovhv2-miRs and if ovhv2-miR-217M is 
a functional homologue of cellular miR-216a, experimental validation of those 
targets is required and this work is ongoing in the lab. 
Chimera data analysis of BJ1035 sample therefore identified a number of cellular 
mRNAs which are involved in important biological processes such as transcription, 
cell cycle regulation, signal transduction and apoptosis. It is possible that these genes 
are involved in one or more features of cellular dysregulation in MCF. It is also 
possible that targeting of these genes by ovhv2-miRs could influence OvHV-2 
persistence in the host cells. To determine how these genes are involved in MCF 
pathogenesis and in virus lytic or latent lifecycle, further investigation is required.  
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 CLASH identifies viral and cellular miRNA targets within sheep   4.4.2
embryo fibroblasts 
To investigate ovhv2-miRs targets in the sheep transcripts, SEF were used, in the 
CLASH experiments.  SEF were used due to two reasons; first, unavailability of 
OvHV-2 infected or uninfected sheep lymphocyte cell lines and second, double 
transductions were required which needed long antibiotic selection periods and it 
diminished the possibility of growing primary sheep lymphocytes in cultures. SEF 
were doubly transduced with lentiviruses expressing tagged Ago2 and ovhv2-miRs 
from Cluster-3 (Section 4.3.2.2).  
The majority of ovhv2-miRs are encoded from the regions of the genome which 
contain no predicted protein coding ORFs (Figure 1.5). The majority of the miRNAs 
are localized in three clusters on the negative sense strand; Cluster-1 is located at the 
left-hand end of the genome, 5’ of Ov2, the other two (Cluster-2 and Cluster-3) are in 
the 9.3 kb non-coding region between ORF11 and ORF17/17.5. Cluster-2 and 
Cluster-3 encode for 27 and 3 ovhv2-miRs respectively and are approximately 4.3Kb 
apart from each other (Figure 1.5) (Levy PhD thesis, 2012). In other gamma 
herpesviruses clustering of miRNAs in the regions which do not encode any ORF, 
was also observed (Cai et al., 2006a, Marshall et al., 2007, Samols et al., 2005). 
Cluster-2 and Cluster-3 were analysed for the expression of ovhv2-miRs by RT-
qPCR. Expression of all three of the ovhv2-miRs (7, 67 and 8) located on Cluster-3 
were found comparable to the positive control and that cluster was used for the 
CLASH experiments (Section 4.3.2.2-4.3.2.4). Illumina Solexa sequencing results of 
cDNA libraries from three replicates each of the test (SEF-Cluster-3) and control 
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(SEF-Empty) samples were analysed (4.3.2.5). The total read counts were variable 
between samples (Table 4.5). The protocol for performing CLASH was the same for 
each sample however difference in the abundance of the reads was observed (Table 
4.5). One possible reason for this difference is that, the lysates for test and control 
samples were collected from cells with different passage number. SEF might behave 
differently at different passage numbers. Slight variation in the salt levels, during the 
experiment may also lead to differences in the total reads at the sequencing stage.  
Ovhv2-miR-67 was found as the most abundant among the three ovhv2-miRs. 
Ovhv2-miR-8 and ovhv2-miR-7 were two of the highly abundant miRs validated by 
northern blot anlaysis (Levy PhD thesis) but were observed to be less abundant in 
this dataset. CLASH experimental results are based on the 
immunoprecipitated/pulled down RISC-miRNA-mRA complexes whereas RNA-seq 
results provide a broad picture of RNAs in the cells, obtained from total RNA 
extracted from the cells.  
To identify the targets of the three ovhv2-miRs in ovine transcripts, there were three 
datasets available from the test and control samples; chimeras dataset, CLASH single 
reads dataset and microarray dataset.  
Like the chimeras obtained in the BJ1035 dataset (Section 4.3.3.1), canonical and 
non-canonical interactions were also found between miRNA and sheep mRNAs. 
Canonical interactions ranged between 47-63% in test samples (Section 4.4.3). 
Among the three ovhv2-miRs, miR-67 formed most of the chimeras with sheep 
mRNAs fragments. Some of the mRNAs forming canonical interaction with ovhv2-
miRs, have functions which might be essential for cellular processes and be involved 
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in OvHV-2 pathology in sheep and were important to discuss. Due to time 
constraints only two of the chimeric mRNAs (DLL1 and VWA5B2) were selected 
for functional validation.  
Fragments of DLL1 mRNA were found to form the highest number of chimeras.  
ovhv2-miR-67 was shown to interact with DLL1 in all these chimeras (Table 4.15). 
Among the CLASH identified DEnGs, DLL1 was also found as the highest 
significant gene (Table 4.7). DLL1 is a part of the Notch signaling pathway and is a 
ligand for Notch receptors. Notch signaling regulates differentiation of lymphocytes 
and blocks the differentiation of progenitor cells into the B-cell lineage while 
promoting the emergence of a population of cells with the characteristics of a T-
cell/NK-cell precursor (Jaleco et al., 2001). Notch signaling is involved in various 
cellular processes including regulation of cell fates and cell number via effect on 
proliferation and survival, depending on dose, times and context of Notch signals 
(Maillard et al., 2005). Inactivation of Notch causes a complete block in the T-cell 
development at an early stage, before expression of T-cell lineage markers (Radtke et 
al., 1999). Activation of the Notch receptor by binding of its ligands (e.g DLL1, 
Jagged, or Serrate) leads to proteolytic cleavage of the receptor at the inner side of 
the membrane. The Notch intracellular domain (NIC) is then translocated to the 
nucleus, where it activates genes by interacting with the RBP-JK protein (Radtke and 
Raj, 2003). RBP-JK acts as a transcription repressor when not bound to NIC and a 
transcription activator of Notch target genes, when bound to NIC (Zimber-Strobl and 
Strobl, 2001). In the related gamma herpesviruses; EBV and KSHV virus 
transactivator proteins also interact with RBP-JK (Chang et al., 2005, Hayward, 
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2004) . EBNA2 of EBV can activate the cellular antiapoptotic bfl-1 gene (Pegman et 
al., 2006). Recombinant KSHV with deleted RBP-JK binding sites within the RTA 
promoter showed increased viral latency and a decreased capability for lytic 
replication in HEK 293 cells (Lu et al., 2012). EBNA2 and RTA can act as viral 
homologues of activated Notch receptors (Hayward, 2004). Activation of Notch 
signalling increases tumor cell proliferation and also maintains the cancer stem cell 
pool (Capaccione and Pine, 2013). Cellular miRNAs also have been shown to target 
Notch signalling at different levels. Tumor suppressor miRs; miR-1 and miR-34a 
negatively regulate DLL-1 protein levels in embryonic stem cells and down-regulate 
protein expression of Notch receptors in glioma and pancreatic cancer cells, 
respectively (Wang et al., 2010).   
Validation of DLL1 as a real target of ovhv2-miR-67, was carried out using a dual 
luciferase assay (4.3.3.4.1). The detail of the fragment used is shown in Section 
4.3.3.4. Luciferase assays showed a significant decrease in the expression of 
luciferase genes when the DLL1 constructs were treated with ovhv2-miR-67 
concentrations. OvHV-2 does not cause lymphoproliferation or cytotoxicity in sheep 
and targeting of DLL1 by ovhv2-miR-67 might stop Notch signalling thereby 
stopping lymphocyte cell differentiation and maintaining viral latency. Further 
investigations of DLL1 as a viral target, are being carried out by Katie Nightingale. 
Preliminary analysis using luciferase assays showed constructs with both DLL1 
predicted target sites mutated showed abrogation in the inhibition of luciferase 
expression compared to that of the parent construct (Katie Nightingale personal 
communication). 
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Another mRNA, VWA5B2 which formed a chimera with ovhv2-miR-67, was 
validated by luciferase reporter assay. VWA5B2 belongs to the von Willebrand 
factor (vWF) domain A containing proteins. Proteins that contain type A domains 
also participate in numerous biological events such as hemostasis, cell adhesion, 
migration, homing, pattern formation, and signal transduction and interact with a 
large array of ligands (Colombatti et al., 1993). vWF proteins are also involved in 
pathological processes including cell proliferation, angiogenesis, inflammation and 
tumor cell survival. The mitogenic effect of vWF proteins is also involved in the 
prompt and robust up-regulation of multiple genes associated with growth factor 
stimulation (Lenting et al., 2012). Targeting of VWA5B2 by ovhv2-miR-67 might 
inhibit excessive inflammation and cell proliferation produced in response to OvHV-
2 infection. To determine if the VWA5B2 is a potential target of ovhv2-miR-67 
luciferase analysis was carried out. The results showed no significant difference in 
the luciferase expression compared to that of the control, at 100 nM or 200 nM 
concentrations of ovhv2-miR-67 mimic (Section 4.4.4.2). There is a possibility that it 
is not a real target but in the absence of any further investigation, at this stage it is not 
possible to comment further.  
KLHL2 (also referred as Mayven), was found to form chimeras with ovhv2-miR-7 in 
all the test samples (Table 4.15). The KLHL2 target site for ovhv2-miR-7 was 
located in the 3’UTR of the mRNA and the interaction between seed region and 
target site was canonical. KLHL2 is involved in the maintenance of the cytoskeleton. 
KLHL2 is also abundantly expressed in certain cancers. It activates c-Jun expression 
and cyclin-D1 promoter activity and promotes transcription. KLHL1 causes cell 
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cycle progression from G1 to S phase in cancer cells and overexpression of KLHL2 
may promote tumor growth through c-Jun and cyclin D1 (Bu et al., 2005). KLHL2 
was found in all the test samples and it is a possibility that it is a target of ovhv2-
miR-7. 
TRIM27 (also known as RFP transforming protein) (formed a chimera with ovhv2-
miR-8 in the T1 sample) is highly expressed in various cancer cells. It can function 
as a transcriptional activator and repressor. TRIM27 inhibits the transcriptional 
activation of genes bound by tumor suppressor protein RB (Hatakeyama et al., 
2011). On the other hand TRIM27 along with RET tyrosine kinase, a proto-oncogene 
increases the catalytic activity of RET which results in subsequent cell proliferation 
and tumorigenesis (Kato et al., 2000, Tezel et al., 2009).  
FGF19 (formed a chimera with ovhv2-miR-67 in the T1 sample) when bound with 
its cognate receptor FGFR4 can initiate multiple signaling cascades. FGF19-FGFR4 
play important roles in development and tissue repair by regulating cell proliferation, 
migration, chemotaxis, differentiation, morphogenesis, and angiogenesis. 
Dysregulation of this signaling system appears to be important for tumor 
development and progression (Desnoyers et al., 2008). The ectopic expression of 
FGF19 in transgenic mice led to tumor formation in the liver (Nicholes et al., 2002). 
Inhibiting the interaction of FGF19-FGFR4 can inhibit MAPK signalling and lowers 
the tumor growth significantly (Desnoyers et al., 2008).   
MARK4 (formed chimera with ovhv2-miR-67 in T3 sample) protein is associated 
with the centrosome throughout mitosis and may be involved in cell cycle control. 
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Expression of this gene is a potential marker for cancer (Drewes et al., 1997, 
Trinczek et al., 2004).  
CRK (formed a chimera with ovhv2-miR-67 in the T3 sample) is an adaptor protein 
and can mediate intracellular signalling related to cell motility and proliferation. 
CRK transmit signals from various tyrosine-phosphorylated proteins, including 
components of focal adhesion, growth factor receptors and signalling proteins by 
binding to them via its SH2 domain (Feller, 2001). In addition to its physiological 
functions, CRK contributes to the malignant conversion and progression of tumor 
cells. Overexpression of CRL has been detected in many types of human cancer cells 
(Rodrigues et al., 2005, Watanabe et al., 2009). PAK7 (formed a chimera with 
ovhv2-miR-67 in the T3 sample) is a p21 activated protein kinase that is known to be 
the effector of GTPases Rac and CDC42.  
PAK7 can activate different pathways including c-Jun N-terminal and cell survival 
signalling pathway (Cotteret and Chernoff, 2006, Dan et al., 2002). In addition, 
PAK7 can inhibit the induction of apoptosis by localizing to mitochondria and 
phosphorylating the proapoptotic protein BAD thus blocking BAD translocation to 
mitochondria (Cotteret et al., 2003). A combined inhibition of PAK7, MAP3K7 and 
CK2a kinases increase apoptosis in most cancer cell lines, in vitro (Giroux et al., 
2009). The genes shown above have the functions related to cell proliferation and 
survival, apoptosis, cell cycle, migration, signal transduction, tumour development 
and progression and conversion to malignancy. Targeting of these transcripts by 
ovhv2-miRs may help OvHV-2 to establish and maintain latency in sheep cells.  
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Analysis of the CLASH single read and microarray datasets also identified many 
DEnGs and GEG which may be important for different cellular processes and viral 
persistence in the host cell. Microarray was carried out to support and validate the 
CLASH single read results and to determine if there were any common sets of gene 
present in both datasets (4.3.2.8, 4.3.2.9).  Those genes were identified from both 
datasets at a 5% false discovery rate (FDR). FDR is an expected proportion of false 
positives among the declared significant results (Benjamini and Hochberg, 2000), In 
the CLASH dataset only five genes and in microarray dataset no gene could pass the 
5% FDR threshold.  To provide greater insight, the analysis was extended to include 
the sets beyond those that met the 5% FDR criterion for two reason; Firstly, to not 
miss genes which could be biologically relevant and secondly, to identify genes 
which could be followed up in future studies. From the CLASH dataset genes with a 
p-value<0.05 were selected for DEnGs and in the microarray dataset genes with a 
fold change > +1.5 or < -1.5 and p<0.01 were selected as DEG.  
GLI2 is a transcription factor and was found to have target sites for ovhv2-miR-7, 67 
and 8 (Table 4.9) GLI2 is involved in the sonic hedgehog (SHH) signaling pathway. 
SHH signalling has been shown to regulate a wide range of developmental processes 
as well as to contribute to lymphoid cell development and differentiation. Mutation 
of this system has been linked to many cancers, including basal-cell carcinoma 
(Benson et al., 2004). GLI2 is suspected to be the primary activator of SHH 
signaling. Overexpression of GLI2 appears to be sufficient to generate and maintain 
the malignant process in some cancers. Active forms of GLI2 translocate to the 
nucleus, to induce expression of target genes such as GLI1, Ptc, Bcl-2, Bcl-XL and 
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cyclinD (encoding cell cycle regulators) (Kolterud and Toftgård, 2008, Muller et al., 
2008). In human keratinocytes GLI2 activation up-regulates a number of genes 
involved in cell cycle progression. GLI2 is able to induce G1–S phase progression in 
contact-inhibited keratinocytes which may drive tumour development (Regl et al., 
2004). Notch signalling and SHH signalling may also be specific targets for anti-
cancer drugs (Muller et al., 2008).   
EPAS1 (also referred to hypoxia-inducible factor 2 alpha (HIF2 a)) is a transcription 
factor and is one of the highly expressed DEnGs in CLASH.  EPAS1 has target sites 
for ovhv2-miR-7, -67 and -8 (Table 4.9). EPAS1 has high homology with hypoxia-
inducible factor 1 α (HIF1 α) and it is reported to be involved in regulation of 
vascular endothelial growth factor (VEGF) transcription and in induction of oxygen 
related genes in response to hypoxia. EPAS1 is abundantly expressed in highly 
vascularized organs and was found to be involved in angiogenesis of different cell 
carcinomas (Maxwell, 2005, Takeda et al., 2004, Tian et al., 1997, Xia et al., 2001). 
Imtiyaz et al reported that mice lacking HIF 2a displayed a marked inability to 
mount an inflammatory response (Imtiyaz et al., 2010). Increased levels of HIF 2a 
can also upregulate the KSHV RTA promoter which results in production of RTA 
and lytic KSHV activation (Haque et al., 2003).  
Some of the DEnGs identified in CLASH were found to have functions related to 
transcriptional repression. HIC1 (containing target sites for ovhv2-miR-7, -67 and -8 
(Table 4.8) is an epigenetically regulated transcriptional repressor that cooperates 
with p53 to suppress cancer. The loss of HIC1 function promotes tumorigenesis via 
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activation of the stress-controlling protein SIRT1 and attenuates p53 function (Chen 
et al., 2005).  
ZBTB7C has target sites for ovhv2-miR-7, -67 and -8 (Table 4.8) (also known as 
KR-POK) and is a zinc finger and BTB domain containing gene and might have a 
role in tumor suppression. ZBTB7C has been shown to regulate cell cycle and 
proliferation through the regulation of CDKN1A, a gene member of the p53 
pathway. CDKN1A encodes the protein p21, which is a negative regulator of the cell 
cycle (Kim et al., 2013, Yoon et al., 2014). Targeting tumor suppressor genes might 
cause an increase in cell proliferation which is usually not observed in OvHV-2 
lately infected sheep and may play a role in early infection. 
TPT1, a translationally controlled tumor protein (TCTP), is a multifunctional protein, 
which is highly regulated during adaptation of cells to alterations in physiological 
conditions, such as growth induction, tumorigenesis, stress and apoptosis (Bommer 
et al., 2010). TPT1 was identified as a DEnGs in the CLASH dataset with a negative 
fold change indicating that the number of reads for the mRNA was higher in control 
samples than that of test samples. It is difficult to speculate why TPT1 expression is 
higher in the control samples. It has been reported that the levels of TPT1 decreases 
under stress conditions (Bommer et al., 2010, Li et al., 2013b).  It is also possible 
that due to the inhibitory effect of ovhv2-miRs, cells undergo stress in test samples. 
It is possible that down-regulation of the expression of one transcript due to the 
interaction of ovhv2-miRs leads to the down-regulation of TPT1 in the test samples 
and this effect was not observed in control samples.  
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Two of the microarray-identified DEG were SEMA3A and SEMA3D which are 
classified as class-3 semaphorins and both have target sites for ovhv2-miR-7, -67 and 
-8 (Table 4.9).  IPA analysis showed involvement of these genes in the semaphorin 
signalling pathway. Another semaphorin, SEMA5B, was found as a target of ovhv2-
miR-67 in the T1 sample in the chimeras’ dataset analysis (Table 4.14). Semaphorins 
are secreted, transmembrane proteins, defined by cysteine-rich semaphorin protein 
domains, that have important roles in a variety of tissues (Yazdani and Terman, 
2006). Plexin are primary receptors for semaphorins and receptor ligand association 
leads to a cascade of events controlling cell adhesion, invasion, axon guidance, 
migration, angiogenesis, organogenesis and immune response. Some of the members 
of semaphoring including SEMA3A are also called as immune semaphorins and 
involve in immune cell interactions and immune cell trafficking during physiological 
and pathological immune responses (Takamatsu et al., 2010). Semaphorin signaling 
is deregulated in multiple cancers. Depending on the receptor complex and 
intracellular signal transducers, semaphorins can either promote tumorigenesis or 
inhibit it (Rehman and Tamagnone, 2013, Yazdani and Terman, 2006, Zhou et al., 
2008). OvHV-2 also encodes a homologue of semaphorin gene; Ov3 (Hart et al., 
2007). AlHV-1   A3 (AHV Sema) also has significant homology to the semaphorin  
gene (SEMA7A) which is a membrane-bound signalling protein found on activated 
lymphocytes (Ensser and Fleckenstein, 1995). So far, no precise role has been 
described for Ov3 and AHV Sema and these might be used to mimic certain 
semaphorin effects so as to evade the host immune response. RNAhybrid analysis 
showed the presence of target sites in the Ov3 transcript for ovhv2-miRs-7, -67 and -
8. The interaction of ovhv2-miR-8 with the target site in Ov3 was canonical 
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(nucleotide 2-8) with perfect base pairing. It is possible that OvHV-2 regulate the 
expression of semaphorin using ovhv2-miRs to regulate cellular processes important 
for viral persistence.  
One of the microarray identified DEG, PDE1A (containing target sites for ovhv2-
miR-7, -67 and -8) is a cyclic nucleotide phosphodiesterase (PDE). PDE1A plays 
role in many signal transduction pathways and acts as one of the key regulators of 
physiological processes by catalysing the hydrolysis of cyclic Adenosine mono 
phosphate (cAMP). Canonical pathway analysis showed PDE1A was involved in 
three pathways; cAMP mediated signalling, G-protein coupled receptor signalling 
and Protein kinase A signalling. Crosstalk of these pathways is involved in many cell 
functions; G-protein coupled receptor signalling is involved in activation of cAMP as 
well as in cell proliferation, survival and motility, tumour induced angiogenesis and 
tumour matastasis (Dorsam and Gutkind, 2007). Protein kinase A (PKA) signalling is 
also dependent on cAMP for activation and is involved in phosphorylation of a large 
number of cellular proteins. By inhibiting PDE1A activity, the cAMP rises and 
causes an activation of PKA (Berridge, 2012, Houslay and Milligan, 1997).  
The most down-regulated DEG in the microarray dataset, FTH1 has target sites for 
ovhv2-miR-8 (Table 4.9) was found to be the part of the NRF2 (Nuclear factor like 
2)-mediated oxidative stress response pathway. Under oxidative stress NRF2 
activates and binds to the antioxidant response element (ARE) in promoters of target 
genes involved in iron homeostasis and heme metabolism, such as FTH1 (Campbell 
et al., 2013).  FTH1 and other ferritin heavy chain subunits are also involved in 
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different biological events such as cell differentiation and pathologic states such as 
cancer (Di Sanzo et al., 2011).  
Other microarray identified DEG include; VLDLR (containing target sites for ovhv2-
miR-67 and -8) which is a member of a family of cell surface proteins involved in 
receptor-mediated endocytosis of specific ligands (D'Arcangelo et al., 1999). ITGA8 
(containing target sites for ovhv2-miR-7, -67 and -8) which  belongs to a class of 
integrins and play roles in cell to cell and cell to  extracellular matrix interactions 
(Schnapp et al., 1995). 
ENPP2 (has target sites for ovhv2-miR-7, -67 and -8) which is also refered to 
autotaxin (ATX) is a secreted enzyme with both phosphodiesterase and 
phospholipase activity. ENPP2 can generate higher levels of lysophosphatidic acid 
(LPA) in different cancers. ENPP2 stimulates the motility of tumor cells and has 
angiogenic properties, and its expression is up-regulated in several kinds of 
carcinomas (Houben and Moolenaar, 2011, Wu et al., 2014). Specific down-
regulation of ENPP2 reduces cell growth and viability.  Baumforth et al reported that 
EBV infection of Hodgkin lymphoma (HL) cells leads to the induction of autotaxin 
which results in an increased generation of LPA and enhances the proliferation and 
survival of HL cells (Baumforth et al., 2005).  
Taken as a whole these results indicate that many of the genes identified in three 
datasets (chimeras, DEnGs from CLASH single read and DEG from microarray) are 
involved in regulation of biological processes related to transcription, cell growth 
and proliferation, differentiation, angiogenesis, immune evasion and tumour related 
biological processes. It is a real possibility that some of these genes are true targets 
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of ovhv2-miRs. By targeting those genes OvHV-2 might fulfil the goal of remaining 
latent in the sheep cells. OvHV-2 also needs the host cell for longer to complete its 
lifecycle which can be achieved by helping the cell to survive longer and evade the 
immune system, by targeting the genes which can promote replication. 
In this study CLASH was successfully used to identify OvHV-2 encoded miRNAs 
targets in bovine and ovine transcripts. A large number of transcripts were found as 
potential targets. The proteins of those transcripts have potential functions which 
hypothetically and theoretically relate to the involvement of those proteins in MCF 
pathology and virus-host interactions. However, there is no experimental evidence to 
prove their involvement and further investigations are required.  In this study four of 
the CLASH identified potential targets were experimentally validated. One of the 
bovine targets; U2 and one of the sheep target DLL1 were successfully validated by 
luciferase assays. Due to time constraints it was not possible to further validate those 
using knockout/mutagenic experiments. Further investigation of DLL1 is being 
carried out, in the lab which has also shown it to be a potential target of ovhv2-miR-
67. Some of the CLASH identified bovine or sheep genes in this study, might be 
involved in regulation of MCF pathology in bovine and sheep but before hypotheses 
about ovhv2-miRs regulation can be made, functional analysis is required, and that 
work is continuing. 
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MCF occurs as a result of infection of susceptible hosts such as cattle or deer through 
contact with an asymptomatic carrier species, e.g sheep, that acts as a virus reservoir. 
Infection of susceptible species by OvHV-2, the causative agent of sheep-associated 
MCF, results in a fatal lymphoproliferative disease that involves marked T cell 
hyperplasia with infiltration of infected T cells, described as LGLs, which are virus 
genome positive. It has been proposed that MCF lesion development occurs not due 
to virus cytopathology but due to non-antigen specific, unrestricted NK like activity 
of virus infected LGLs (Cook and Splitter, 1988).  In cattle and sheep, all virus 
infected lymphocytes express CD2 and variably express CD4 and CD8 (Meier-
Trummer et al., 2010). Thus, in both cattle and sheep similar set of cells are infected 
by the virus but only in cattle does dysregulation of the T cells lead to development 
of the characteristic MCF lesions.  
Analysis of the genome of OvHV-2 has shown that it encodes 35 miRNAs (Levy et 
al., 2012, Nightingale et al., 2014). It has been proposed that these ovhv2-miRs 
might interact differently with bovine and ovine genes resulting in a different disease 
outcome in the two closely related species. This project was designed to identify and 
functionally validate the targets for ovhv2-miRs in virus, cattle and sheep transcripts.   
Using Blastn, a number of viral targets were predicted for eight, northern blot 
validated ovhv2-miRs (Levy PhD thesis, 2012).  Six of the viral genes were 
identified as having potential targets for viral miRNAs in their 5’ and 3’ UTR. Based 
on homology with other herpesviruses, the proteins encoded by these ORFs would be 
expected to play a functional role in virus latency, replication, cell cycle regulation or 
reactivation from latency, were selected for study (Section 3.2). Three of the ORFs, 
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ORF20 (cell cycle control), ORF50 (reactivation) and ORF73 (viral latency), were 
shown to be regulated by ovhv2-miRs. To further investigate the regulation of these 
OvHV-2 ORFs by the ovhv2-miRs, a RT-qPCR assay was developed for the ORF20, 
ORF50 and ORF73 transcripts. The results show that following transfection with the 
relevant miRNA mimic a significant reduction in the levels of ORF50 transcripts 
could be observed, within the BJ1035 LGL cell-line (Riaz et al., 2014). Utilizing the 
same approach, a smaller but non-significant decrease in ORF20 mRNA levels was 
found, however no decrease was observed in the level of the ORF73 transcript (Riaz 
et al., 2014). A number of possible factors may address why the transfection of the 
BJ1035 cell-line with the mimics targeting either ORF20 or ORF73 did not 
reproduce the result observed in vitro using the luciferase- reporter gene system 
(Section 3.3).  Firstly, BJ1035 are not a homogeneous population, so the significant 
variation in transcript expression between biological replicates (Dr I.Dry, Personal 
Communication) could overwhelm any subtle effect. Additional concerns that may 
also have impacted the results include the transfection efficiency of the BJ1035 cells 
or the concentration of miRNA mimics used.  
In this study, the targets of eight validated ovhv2-miRs were analysed. It is worth to 
analyse remaining 25 miRNAs, using the similar approach may reveal more targets 
for future studies. The transfection of LGLs as an in vitro system has its limitations. 
Further work needs to be carried out to see if it can be improved as an in vitro 
biological assay for miRNA function. However it is a valuable tool in the arsenal of 
OvHV-2 virologists. 
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To identify bovine and ovine targets which formed chimeras with ovhv2-miRs, a 
new and highly sensitive approach, CLASH was used.  
The BJ1035 cell line expresses all of the 35 ovhv2-miRs (Levy et al., 2012, 
Nightingale et al., 2014). The CLASH approach provided a snapshot of mRNAs 
targeted by ovhv2-miRs. The cellular RNAs which formed chimeras, were shown to 
be involved in biological pathways such as pre-mRNA splicing, cell cycle and 
immune system regulation (Section 4.5.1).  
U2, a component of major spliceosome complex was found as a target of ovhv2-
miR-36 and successfully validated using a luciferase reporter gene assay (4.3.3.2.2). 
Other components of the spliceosomal complex (CSTF3 and SNRNP25) were also 
found as predicted targets. The targeting of components of spliceosomal complex 
could indicate a viral strategy to interfere in pre-mRNA processing and hence shut 
off host protein expression or alter splicing to reduce the expression of specific 
transcript variants in the natural host. Herpesviruses have been shown to either 
interact with host cell pre-mRNA splicing (in HSV-1) or promote their own 
intronless mRNA splicing (in KSHV) (Bryant et al., 2001, Majerciak et al., 2008). 
Further investigation including luciferase assays or RT-qPCR assay using miRNA 
mimics to observe reduction in the levels of the luciferase or targeted transcripts 
respectively is necessary to understand the role of these targets in virus biology and 
pathology.  
Recent miRNA target recognition studies have found many functional targets which 
interact with their targeting miRNAs in regions of the miRNAs other than seed 
region (Helwak et al., 2013, Shin et al., 2010). In this study, I predict that miR-217M 
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interacts with ATP6V1B1 non-canonically. ATP6V1B1 is a component of V-
ATPase complex and mainly functions as an acidifier in internal membrane system 
such as lysozymes and endosomes (Ohta et al., 1996). V-ATPases also play 
important roles in other cellular processes including endocytosis, membrane 
trafficking, apoptosis and the immune system (Benaroch et al., 1995, Morimura et 
al., 2008). In HCMV, another component of the V-ATPase complex; ATP6V0C was 
recently shown to be a target of a HCMV encoded miRNA US25-1. Subsequent 
investigation showed that ATP6V0C was an essential factor in HCMV replication 
and control of the expression of ATP6V0C by this via viral-encoded miRNA might 
be important in establishing or maintaining viral latency (Pavelin et al., 2013). 
Unlike BJ1035 cells, sheep embryo fibroblasts do not express ovhv2-miRs and so a 
lentivirus expressing three of the ovhv2-miRs (miR-7, miR-67, miR-8) was 
constructed and used. Three datasets were analysed for the identification of the 
targets; Chimeras obtained from test samples using CLASH, differentially enriched 
genes (DEnGs) obtained from test and control samples using CLASH and 
differentially expressed genes (DEG) obtained from the test and control samples 
using microarray. The CLASH and the microarray comparison did not identify any 
common genes (Section 4.3.2.10) possibly because CLASH involves the enrichment 
of genes targeted by miRNAs while microarray involves changes in the overall 
expression of genes, affected directly and indirectly by the targeting of the miRNAs. 
A number of genes were identified in the CLASH and microarray datasets. The 
identified genes are associated functionally in the regulation of transcription, cell 
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proliferation and survival, cell cycle, differentiation, apoptosis and immune evasion 
(Section 4.4.2).  
DLL1, a part of the Notch signalling pathway, was found to be a target of miR-67 
(Section 4.3.3.4.1). DLL1 is a ligand for Notch receptors and binding of these 
receptors to DLL1 activates Notch. The Notch signalling pathway plays a critical 
role in the regulation of the differentiation of lymphocytes. Notch signalling blocks 
the differentiation of progenitor cells into B-cell lineage and promotes the emergence 
of T-cells/NK cells precursors (Jaleco et al., 2001). OvHV-2 causes a 
lymphoproliferation or cytotoxicity in cattle but not in sheep. It is possible that miR-
67 targets DLL1 in sheep cells and might inhibit the Notch signalling thereby 
stopping lymphocyte differentiation and maintaining viral latency. Work currently 
ongoing in the lab is focused on investigating whether the regulation of DLL1 by 
ovhv2-miRs differs between susceptible species and the natural host.   
Three semaphorins; SEMA3A, SEMA3D and SEMA5B were identified as putative 
ovine targets in this study. Semaphorins are secreted, transmembrane proteins that 
have important roles in a variety of cell processes such as cell adhesion, cell 
migration. SEMA3A is among the semaphorins that are also called immune 
semaphorins due to their roles in immune cell interaction and movement during 
physiological and pathological immune responses (Takamatsu et al., 2010).  OvHV-2 
and AlHV-1 both encodes genes, Ov3 and A3 respectively which have significant 
homology with semaphorins (Ensser and Fleckenstein, 1995, Hart et al., 2007). No 
precise role of the viral semaphorins has been described yet. One possibility is that 
these viral semaphorin homologues might mimic certain functions of the cellular 
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semaphorins that are required for viral persistence.  The encoding of a cellular 
homologue would thus enable the virus to use ovhv2-miRs to regulate the expression 
of the cellular semaphorins thereby inhibiting any anti-viral functions that they may 
have, without impacting the viruses own long-term persistence.  
In summary, we have shown that ovhv2-miRs have targets within viral and host 
transcripts. Viral targets of ovhv2-miRs are involved in both in maintaining viral 
latency and potentially in reactivating the virus from latency. Our analysis also 
showed that a number of sheep and cattle genes, are targets of ovhv2-miRs. Due to 
time constraints it was not possible to validate all of the genes identified in the 
CLASH experiments. No common genes were found between the datasets of the 
susceptible and natural hosts, which may indicate that ovhv2-miRs might play 
different roles in susceptible and natural hosts. Further investigation on the role of 
ovhv2-miRs in the regulation of genes in susceptible and host species may increase 
our understanding towards the different disease outcomes and in the long-term may 
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Appendix-1: Recipes  
LB Broth   5 g yeast extract 
  10g peptone from casein 
  10g sodium chloride 
  12g agar-agar 
``  up to 1 L water. 
 
Phosphate-buffered saline (PBS) (pH7.4) 8g NaCl 
  0.2g KCl 
  1.44g Na2H2PO4 
  0.24g KH2PO4 
  Up to 1 L water  
 
1 x TAE Buffer  40mM TRIS -acetate 
  1mM EDTA (pH 8.0) 
 
Semi Dry Transfer Buffer  3g TRIS base 
  11.3g glycine 
  100 ml methanol 
  Up to 1L water 
 
1 x TBS Buffer  100mM TRIS base  
  0.9 % NaCl (v/v) 
  pH 7.5 
 
Appendix-1             Recipes 
   266 
 
1 x TBST Buffer  100mM TRIS base  
  0.9 % NaCl (v/v) 
  0.1 % Tween 20 
  pH 7.5 
0.1M Sodium Phosphate Buffer   2.62g NaH2PO4 
  14.42gm Na2HPO4 
  Up to 1 L water 
  pH 7.4 
 
3M Ammonium Sulfate  39.6g (NH4)2SO4  
Dissolved in 100 ml 0.1M sodium 
phosphate buffer  
 
PBS+ 0.5% Triton X-100  0.5% (W/v) Triton X-100 in 100 ml of 
PBS 
 
0.1M Glycin HCl   7.5g Glycin 
  Up to 1 L water 
  HCl to adjust pH 2.5 
 
100mM Triethylamine  168µl of Triethylamine 
  11.156ml water 
 
PBS/0.02% Sodium azide  0.1g sodium azide 
  500 ml PBS 
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CLASH Lysis Buffer  2.5ml 1M TRIS (pH 7.5) 
  3ml 5M NaCl 
  5ml 10% NP-40 
  0.5ml 1mM EDTA 
  10 ml 50% glycerol 
  25µl 2-mercaptoethanol (added fresh) 
  Up to 50 ml water 
 
5 x PNK buffer  62.5ml 1M TRIS-HCl (pH 7.5) 
  
  1.19g MgCL2  
  62.5ml 10% NP-40 
  12.5ml 5M NaCl 
  5mM 2 Mercaptoethanol (added fresh) 
  Up to 250 ml water 
 
1 x PNK5 buffer   10 ml 5 x PNK buffer (without 
2Mercaptoethanol) 
  5mM 2 Mercaptoethanol (added fresh) 
  Up to 40 ml water 
 
1 x PNK10 buffer   10 ml 5 x PNK buffer (without 
2Mercaptoethanol) 
  10mM 2 Mercaptoethanol (added fresh) 
  Up to 40 ml water 
 
Ni-EB 200 buffer  0.5 ml 1M TRIS-HCl (pH7.8) 
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0.1 ml 5M NaCl 
  2ml 1M Imidazole 
  0.1ml 10% NP-40 
  5mM 2Mercaptoethanol (added fresh) 
  Up to 10 ml water 
 
HS-IgG-WB buffer  2.5ml 1M TRIS-HCl (pH 7.5) 
8ml 5M NaCl 
1ml 0.5M MgCl2 
  2.5ml 10% NP-40 
  2.5ml glycerol 
  5mM 2Mercaptoethanol (added fresh) 
  Up to 50 ml water 
 
LS-IgG-WB buffer  2.5ml 1M TRIS-HCl (pH 7.5) 
3ml 5M NaCl 
0.5ml 0.5M MgCl2 
  2.5ml 10% NP-40 
  2.5ml glycerol 
  5mM 2Mercaptoethanol (added fresh) 
  Up to 50 ml water 
 
Ni-WB-I buffer  2.5ml 1M TRIS-HCl (pH7.8) 
3ml 5M NaCl 
  0.5ml 1M Imidazole 
  28.66g Guanidine-HCl 
Appendix-1             Recipes 
   269 
 
  0.5ml 10% NP-40 
  5mM 2Mercaptoethanol (added fresh) 
  Up to 50 ml water 
 
Ni-WB-II buffer  2.5ml 1M TRIS-HCl (pH7.8) 
3ml 5M NaCl 
  0.5ml 1M Imidazole 
  0.5ml 10% NP-40 
  5mM 2Mercaptoethanol (added fresh) 
  Up to 50 ml water 
 
Proteinase K mix:    2.5 ml 1M Tris-HCl  
   0.5ml 50mM NaCl      
0.5 ml 10mM imidazole   
0.5 ml 0.1% NP-40   
  
5 ml 1% SDS     
0.5 ml 5mM EDTA   
  5mM 2Mercaptoethanol (added fresh) 
  Up to 50 ml water 
 
2 x Protein Sample buffer  0.9 ml 10%SDS 
  0.45 ml 100% Glycerol 
  0.27 ml 1M Tris-HCl pH 6.8 
  0.05 g Bromophenol blue 
  0.25 ml 2-Mercaptoethanol 
  Up to 2ml water 
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1 x Protein Sample buffer  0.5 ml of 2 x Protein sample buffer 
  0.5 ml water 
10% Protein resolving gel  1.65 ml 30% acrylamide/0.8%bis 
  1.25 ml 1.5M Tris-HCl pH 8.7 
  50 µl 10% SDS 
  50 µl 10% Ammonium persulfate 
  5 µl TEMED 
  2.01 ml water 
 
Stacking gel  500 µl 30% acrylamide/0.8%bis 
  625 µl 1M Tris-HCl pH 6.8 
  50 µl 10% SDS 
  25 µl 10% Ammonium persulfate 
5 µl TEMED 
  3.12 ml water 
 
10 x SDS Running buffer  30.2 g Tris-base 
  180g Glycine 
  10g SDS 
  Up to 1L water 
 
1 x Protein Transfer buffer  2.47g Tris-base 
  11.54g Glycine 
  200 ml Methanol 
  Up to 1L water     
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1M Sodium Phosphate buffer  142g Na2HPO4 
  up to 1L water 




Annealing buffer 10X  1 ml 1M Tris (pH 7.6) 
  500 µl 1M MgCl2 
  500 µl 5M NaCl 
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Appendix-3 Primers, miRNA mimics, Linkers and barcode sequences  
PCR Primers  Sequence 
LUC/3’-Ov2-Forward  
5`-AACTCGAGGAGATGTGAGTTAAACCC- 3’ 
              XhoI  
LUC/3’-Ov2-Reverse 
5’-AAGCGGCCGCGGTAAAAGGCATGTAGTG-3’ 
              NotI  
LUC/3’-20-Forward 
5`-AACTCGAGACAACATAGTCCAGGCAAACA-3’ 
              XhoI 
LUC/3’-20-Reverse 
5`-AAGCGGCCGCCACCCCTGGCTGGACTAT-3’ 
              NotI 
LUC/3’-36-Forward 
5`-AACTCGAGCCTGGAGCAGACCATAAC -3’ 
              XhoI  
LUC/3’-36-Reverse 
5’-AAGCGGCCGCGTCTTGGGAAAATCAGCAG-3’ 
              NotI  
LUC/3’-49-Forward 
5’-AACTCGAGCAAACGGCAAAGCAGCTT-3’ 
             XhoI 
LUC/3’-49-Reverse 
5’-AAGCGGCCGCACATTCAGGGCAGGTTAC-3’ 
              NotI 
LUC/3’-50-Forward 
5’-AACTCGAGCTCCTCAGGGTTTCAGT-3’ 
             XhoI 
LUC/3’-50-Reverse 
5’-AAGCGGCCGCAGGGGGTTAAAGTGCTC-3’ 
              NotI 
LUC/3’-73-Forward 
5`-AACTCGAGGATACAAGCTAAGTACTGC-3` 
              XhoI  
LUC/3’-73-Reverse 
5`-AAGCGGCCGCTACAGAAGCACACAGTATC-3` 
              NotI 
LUC/5’-20-Forward 
5’-AACTCGAGCTGTCGCACACAACCCATC-3’ 
              XhoI  
LUC/5’-20-Reverse 
5’-AAAGATCTGGCCTCCAACTCTCCCTCTC- 3’ 
              BglII 
LUC/5’-73- Forward 
5’-AACTCGAGCTTACTCCCTTTACTCTGG-3’ 
              XhoI  
LUC/5’-73-Reverse 
5’-AATTCGAA TTTGTAGCTTTACTGCCTG-3’ 
              HindIII  
Cluster-2-Forward 
5’-AAGTCGACGACTCCAAAGAATGAATCACGC-3’ 
                SalI 
Cluster-2-Reverse 
5’-AAGTCGACCAGCTTTACGTGTGGCGGTC-3’ 
                SalI 
Cluster-3-Forward 
5’-AA CTCGAG GGTCATGACTCAGTTTGTT-3’ 
             XhoI 
Cluster-3-Reverse 
5’-AATCTAGACTGAAGTTCTTTGTTTGTGTC-3’ 
                XbaI 
Sequencing primers  
TOPO Forward 5’-GTAAAACGACGGGCCAG-3’ 
TOPO Reverse 5’-CAGGAAAACAGCTATGAC-3’ 
psiCHECK Forward 5'-TGCTGAAGAACGAGCAGTAA-3' 
psiCHECK Reverse 5'-CGAGGTCCGAAGACTCATTT-3' 
pGL4-Primer Forward 5’-CTAGCAAAATAGGCTGTCCC-3’ 
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Mutagenic primers  
LUC/3’-50-M-Forward 
5’-CCCAGAAATGTGACAT GGCGCGCC CTTTTTTACTTGTGGTTTG-3’ 
                                                        AscI 
LUC/3’-50-M-Reverse 
5’-CAAACCACAAGTAAAAAAG GGCGCGCC ATGTCACATTTCTGGG-3 
                                                                AscI 
LUC/5’-20-M-Forward 
5’-CACTGTTGTCCTCCTCGTTTAAACTTGGGCACGTCGTAGTCG-3’ 
                                                       PmeI 
LUC/5’-20-M-Reverse 
5’-CGACTACGACGTGCCCAAGTTTAAACGAGGAGGACAACAGTG-3’ 
                                                            PmeI 
LUC/5’-73-M1-Forward 
5’CCCGACATCCCGGGACGTTTAAACGCAGCCGTCTGAGCCTTTTC 3’  
                                                     PmeI                          
LUC/5’-73-M1-Reverse 
5’GAAAAGGCTCAGACGGCTGCGTTTAAACGTCCCGGGATGTCGGG 3’     
                                                                PmeI 
LUC/5’-73-M2-Forward  
5’-CCTGAGCCTGCAGCCGTGTTTAAACTTTCTAAAAATTATGCCTTC-3’ 
                                                         PmeI                                             
LUC/5’-73-M2--Reverse 
5’-GAAGGCATAATTTTTAGAAAGTTTAAACACGGCTGCAGGCTCAGG-3’  








                                                      SbfI                                      PmeI 



































((NotI and XhoI) 
5’GCGGCCGCGGACAGGTGAAGCGAGAAGGGGCAGAGCTGACCTTACTT
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CLASH linkers and 
primers 
 
3’Linker (miRCat linker-33) AppTGGAATTCTCGGGTGCCAAG/ddC/ 
5’Linker 
invddT-ACACrGrArCrGrCrUrCrUrUrCrCr GrArUrCrUrXrXrXrXrXrArGrC (where X 









PCR primers  
miRcat-33 primer 5’-CCTTGGCACCCGAGAATT-3’ 
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